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ABSTRACT 
BRET DAVID WALLACE: Alleviating Cancer Drug Toxicity Through Targeted Inhibition 
of a Bacterial Enzyme and Exploring the Structural and Functional Properties of the 
Xenobiotic Nuclear Receptor PXR 
(Under the direction of Matthew R. Redinbo) 
Although symbiotic GI bacteria are essential to human health, in some cases these 
organisms contribute to undesirable side effects during the treatment of disease. For example, 
the anticancer drug CPT-11 is employed against a range of human malignancies; however, its 
efficacy is severely limited by diarrhea generated by the reactivation of a glucuronidated 
drug metabolite in the gastrointestinal tract.  The enzymes responsible for this dose-limiting 
side effect are bacterial β-glucuronidases in our symbiotic intestinal microflora.  We sought 
to selectively eliminate this GI-specific drug reactivation. We identified potent and novel 
bacterial β-glucuronidase inhibitors through high-throughput screening. Hits exhibit nM-
level in vitro inhibition against E. coli β-glucuronidase and no effect on a mammalian β-
glucuronidase. We further elucidated the crystal structure of E. coli β-glucuronidase both 
alone and in complexes with novel, potent inhibitors.  Crystal structures established that 
selectivity was conferred through a loop unique to bacterial β-glucuronidases. Oral 
administration of novel inhibitors in mice proved successful in alleviating CPT-11 induced 
toxicity.  As such, drugs may be utilized to disrupt deleterious bacterial enzymatic activity in 
the human GI. 
The nuclear receptor PXR plays a key role in human biology and xenobiotic 
metabolism. This ligand-regulated transcription factor responds to a variety of chemically
unique ligands, including many endogenous compounds and clinical drugs.  In addition, PXR 
regulates the expression of a critical set of protective gene products involved in xenobiotic 
and endobiotic metabolism. The structural basis of the PXR ligand binding domain’s 
remarkable and unique promiscuity has only recently come to light. An understanding of the 
PXR/RXRα complex through structural and functional studies is ever more important with 
the recently elucidated structure of the PPARγ/RXRα full-length complex and protein-DNA 
interactions.  We show here the crystal structure of the PXR/RXRα LBD complex, revealing 
a heterotetrameric complex, unique to this particular nuclear receptor complex.  In addition, 
we present, to our knowledge, the first of experimental methods for the expression, 
purification, and complex formation for the full-length PXR.1 and RXRα complex. 
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CHAPTER 1. 
The Metabolism of Chemotherapeutic Camptothecins and Role of Symbiotic Bacteria 
 
INTRODUCTION 
 Camptothecin (Figure 1.1.A), a plant alkaloid derived from the Chinese Camptotheca 
acuminata tree, was added to the NCI natural products screening set in 1966.  It showed 
strong antineoplastic activity but poor bioavailability and toxic side effects. Camptothecin is 
a planar, five-ring compound with a pyridone group in the D-ring, and both a lactone and 
chiral S-hydroxyl group in the E-ring (Figure 1.1.B) (1). After thirty years of modifying the 
camptothecin scaffold, two derivatives emerged and are now approved for clinical use (2). 
Topotecan (Hycamptin®; GlaxoSmithKline) is currently employed to treat solid ovarian, lung 
and brain tumors (2) and contains hydroxyl and ethyldimethylamino groups on the A-ring. 
The prodrug CPT-11 (also called Irinotecan; Figure 1.1.B, and Camptosar®; Pfizer) contains 
and ethyl group on its B-ring, and a carbamate-linked dipiperidino moiety on its A-ring that 
significantly increases bioavailability in mammals (2). The camptothecins have been 
employed in combination with other chemotherapeutics to treat solid malignancies, although 
they have recently been utilized for treatment of solid lung and brain tumors, along with 
refractory forms of leukemia and lymphoma (3). The dipiperidino group is removed from the 
CPT-11 prodrug in vivo to produce the drug’s active metabolite, SN-38 (4).  
Camptothecins Selectively Target Human Topoisomerase I 
The sole target of the camptothecins is human topoisomerase I (5). This enzyme 
relieves superhelical tension throughout the genome and is essential for DNA metabolism, 
including DNA replication, transcription and homologous recombination (6). Topoisomerase 
I breaks one strand in duplex DNA, forming a covalent 3’-phosphotyrosine linkage, and 
guides the relaxation of DNA supercoils (7, 8).  It then reseals the single-strand DNA break 
and releases a relaxed duplex DNA molecule. The camptothecins bind to the covalent 
topoisomerase I-DNA complex and prevent the religation of the broken single DNA strand, 
effectively trapping the 91 kDa protein on the DNA (5) (Figure 1.2.A).  The now 
immobilized macromolecule acts to obstruct the progression of DNA replication and 
transcription complexes, causing double-strand DNA breaks and apoptosis (3).  Because 
many cancer cells are growing rapidly, the camptothecins impact neoplastic cells more 
significantly than normal human tissues.  Structural studies have shown that the 
camptothecins stack into the duplex DNA, replacing the base pair adjacent to the covalent 
phosphotyrosine linkage (9, 10) (Figure 1.2.B).  Furthermore, the drug can only bind to the 
enzyme-substrate complex after DNA nicking has occurred.  Religation of the nicked DNA 
strand is prevented by increasing the distance between the 5’-hydroxyl and the 3’-
phosphotyrosine linkage to >11 Å (9, 10).  Structural analysis reveals the role of the key 
moieties in the camptothecin line of drugs, most notably the S-hydroxyl, lactone, and 
pyridone groups. 
 
CPT-11 
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Metabolism and Associated Toxicity 
 CPT-11 efficacy is severely limited by delayed diarrhea that accompanies treatment 
(11).  While the earlier onset of a cholinergic syndrome that generates diarrhea within hours 
can be successfully treated with atropine, the diarrhea that appears ~2-4 days later is 
significantly more debilitating and difficult to control (12). The average incidence of severe 
diarrhea in patients treated with CPT-11 is ~30-40%, of which 10% required hospitalization 
(13-17). Updated formulations of CPT-11 and newer camptothecin analogs have not solved 
the toxicity problems associated either with glucuronidation or other side effects (18, 19). It 
is not clear that reabsorption of SN-38 from the GI plays a significant role in anti-tumor 
efficacy. Recirculation of SN-38 from intestinal reabsorption would be expected to result in 
second or multiple peaks in blood over time, which are not observed (11, 20-23). Local 
absorption directly to colon tumors may occur, but, to date, intestinal SN-38 concentrations 
have been associated with toxicity not efficacy (24).   
CPT-11 undergoes a complex cycle of activation and metabolism that directly 
contributes to drug-induced diarrhea (Figure 1.3.A) (12).  CPT-11 administered by 
intravenous injection can traffic throughout the body, but concentrates in the liver where it is 
activated to SN-38 is by the human liver carboxylesterase hCE1 (Figure 1.3.B). The SN-38 
generated in the liver is eliminated from the body via glucuronidation to SN-38G by the 
phase II drug metabolizing UDP-glucuronosyltransferase (UGT) enzymes (25) (Figure 
1.3.B). SN-38G is excreted from the liver via the bile duct and into the GI.  Once in the 
intestines, however, SN-38G serves as a substrate for bacterial β-glucuronidase enzymes in 
the intestinal flora that remove the glucuronide moiety and produce the active SN-38 
(Figures 1.3.A-B) (26). SN-38 in the intestinal lumen produced in this manner contributes to 
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epithelial cell death and the severe diarrhea that limits CPT-11 efficacy.  This effect has been 
partially reversed in rats using the relatively weak (IC50=90 μM) β-glucuronidase inhibitor 
saccharic acid 1,4-lactone (27).  
 
Treatment Options to Alleviate Severe Toxicity 
 While broad-spectrum antibiotics have been used to eliminate enteric bacteria from 
the GI tract prior to CPT-11 treatment (28), this approach has several drawbacks.  First, 
intestinal flora play essential roles in carbohydrate metabolism, vitamin production, and the 
processing of bile acids, sterols and xenobiotics (29, 30).  Thus, the partial or complete 
removal of GI bacteria is non-ideal for patients already challenged by neoplastic growths and 
chemotherapy.  Second, it is well established that the elimination of the symbiotic GI flora 
from even healthy patients significantly increases the chances of infections by pathogenic 
bacteria, including enterohemorrhagic Escherichia coli and Clostridium difficile (31-37) 
Third, bacterial antibiotic resistance is a human health crisis, and the unnecessary use of 
antimicrobials is a significant contributor to this problem (32).   
 
β-GLUCURONIDASE 
 
Background 
 The metabolic significance of the human microbiome is becoming more widely 
understood (38).  Indeed there are a large number of enzymes, particularly sugar hydrolases, 
produced by the symbiotic bacteria that play a dramatic role in the metabolism of a variety of 
compounds, both xenobiotics and endobiotics (39).  Of these, β-glucuronidase is a key player, 
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as the process of detoxification in the liver employs the UGTs conjugating many xenobiotics 
to a glucuronide form (40).  These now glucuronidated metabolites are passed through the 
bile duct into the intestine.  The glucuronides can then be hydrolyzed by these β-
glucuronidase enzymes of almost any bacteria present in the gut, releasing the aglycone form 
of the conjugated xenobiotics, which can then be reabsorbed and may be recycled through 
the liver and back into the gut. 
β-glucuronidases are found in prokaryotes and eukaryotes, and remove glucuronic 
acid sugar moieties via hydrolysis from various endogenous and xenobiotic compounds (41-
43). Human β-glucuronidase processes chondroitin sulfate and dermatan sulfate, and is 
thought to play a role in the onset and progression of rheumatoid arthritis (41, 44). The loss 
of β-glucuronidase via germ-line mutations causes Sly syndrome, a devastating human 
condition associated with macrocephaly, spinal deformities and mental retardation (45). β- 
glucuronidases are ubiquitous in bacteria, and their catalytic action is exploited in 
commonly-used water purity tests, in which the conversion of the β-glucuronidase 4-
methylumbelliferyl glucuronide (4-MUG) to 4-methylumbelliferone (4-MU) is monitored to 
detect bacterial contamination (46-50). 
 
Enzymatic Mechanism of β-Glucuronidase 
β-glucuronidase is part of a sequence-related family of β-glycosidases in which the 
enzymes hydrolyze substrates with net retention of anomeric configuration via a double 
displacement mechanism involving the action of two carboxylic acid residues (51-53).  
Furthermore, it is suggested that prior to the formation of the covalent glycosyl-enzyme 
intermediate, the transition state appears to have an oxo-carbenium ion (54, 55).  The 
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proposed mechanism for the E. coli β-glucuronidase is shown with a generic glucuronide-
linked substrate (Figure 1.4.A).  The catalytic residues, Glu413 and Glu504 were determined 
through sequence alignment versus the human β-glucuronidase (Figure 1.4.B) and act as the 
acid/base catalyst and nucleophile, respectively.  It is suggested that substrate specificity is 
imparted through the surrounding active site loop residues (56, 57).  The information 
provided from the structural characterization of the mechanism would allow a better 
understanding of how to inhibit this enzyme, either through the formation of a trapped 
covalent intermediate or by competition due to an increased affinity for the active site 
derived from interactions with the catalytic residues and the surrounding active site loop. 
 
Alleviation of Toxicity by Inhibiting β-Glucuronidase Activity 
 As detailed in Figure 1.3.B, SN-38G, generated in the liver by UGTs, is reactivated 
to the toxic metabolite SN-38 by bacterial β-glucuronidases.  By specifically targeting the 
bacterial β-glucuronidases in the gut, it is possible to prevent SN-38G conversion to SN-38.  
Previous studies from the literature suggest that relatively weak inhibitors of β-glucuronidase 
have been reported (Ki values of 25 μM to 2 mM) (58); however, no potent and/or selective 
inhibitors of the bacterial enzymes have been presented.   
With limited successes in the targeted inhibition of GI bacterial β-glucuronidases 
using a variety of approaches, or broad-spectrum elimination of all enteric microflora, we 
sought to discover novel, potent compounds that not only effectively disrupt glucuronidase 
activity, but are also selective for the bacterial enzyme without affecting the human β-
glucuronidase. 
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Crystallization of a Bacterial β-Glucuronidase 
While the crystal structure of human β-glucuronidase was reported in 1996 (59), no 
structure of a bacterial β-glucuronidase has been presented.  To better understand how the 
bacterial β-glucuronidase enzyme functions, we pursued the crystal structure of the E. coli 
glucuronidase enzyme.  This would allow for a detailed comparison between the bacterial 
and mammalian versions of the enzyme to better prepare a highly selective inhibitor which 
targets bacterial glucuronidase enzymes while leaving the mammalian enzyme unaffected. 
 
FIGURE LEGENDS 
 
Figure 1.1 (A) Camptothecin scaffold with each ring labeled and key functional groups 
labeled. Camptothecin is a planar, five-ring compound with a pyridone group 
in the D-ring, and both a lactone and chiral S-hydroxyl grou pin the E-ring. 
(B) The two chemotherapeutic compounds derived from camptothecin, the 
pro-drug CPT-11 (left) and Topotecan (right).  Adding polar moieties in the 
A- and B-rings of the scaffold yielded these two analogues, with improved 
pharmacokinetic properties. 
 
Figure 1.2 (A) Overall structure of the human DNA Topoisomerase I bound with trapped 
camptothecine and duplex DNA (PDB ID, 1T8I). (B) An active site view of 
the trapped ternary complex.  This shows key residues forming interactions 
with the now trapped camptothecin molecule, including the phosphorylated-
Tyr 723. 
 
Figure 1.3 (A) Schematic view of the metabolic pathway of CPT-11 after intravenous 
injection into the body, including route to tumor and through the GI tract.  
Activation to SN-38 and further glucuronidated to SN-38G occurs in the liver.  
All three compounds can be shuttled to the GI tract through the bile duct, 
where reactivation can occur causing toxicity. (B) Mechanism of SN-38 
conversion in the liver by UGTs to SN-38G and reactivation to SN-38 in the 
intestine by β-glucuronidases.  Structures of both the UGT and the β-
glucuronidase have both been solved in the Redinbo Lab. 
 
Figure 1.4 (A) Proposed enzymatic mechanism of E. coli β-glucuronidase with a generic 
glucuronide-linked substrate.  This mechanism is similar to the human β-
glucuronidase mechanism as well as other sugar hydrolyzing enzymes, 
including β-galactosidase and lysozyme. (B) Full sequence alignment of E. 
coli versus human β-glucuronidase, with the secondary structure of the 
bacterial enzyme shown above the sequence alignment.  The catalytic residues, 
E413 and E504, are starred.  The overall sequence identity between these two 
species’ enzymes is ~45%. 
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Figure 1.1 (A) Camptothecin scaffold with each ring labeled and key functional 
groups labeled. (B)  The two chemotherapeutic compounds derived from 
camptothecin, the pro-drug CPT-11 and Topotecan. 
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Figure 1.2 (A) Overall structure of human DNA Topoisomerase I bound with 
trapped camptothecin and duplex DNA (PDB ID 1T8I). (B) Active site 
view of the trapped ternary complex, showing key residues and the 
camptothecin molecule. 
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Figure 1.3 (A) Schematic view of the metabolic pathway of CPT-11 after I.V. 
injection into the body, including route to tumor and through the GI tract. 
(B) Mechanism of SN-38 conversion in the liver by UGTs to SN-38G and 
reactivation to SN-38 in the intestine by β-glucuronidases. 
 
11 
 
Figure 1.4 (A) Enzymatic mechanism of E. coli β-glucuronidase with a generic 
glucuronide linked substrate.  (B) Full sequence alignment of E. coli 
versus human β-glucuronidase, with secondary structure shown and 
catalytic residues starred. 
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CHAPTER 2. 
Expression, Purification, and Inhibition Studies of E. coli β-Glucuronidase 
 
INTRODUCTION 
 Genomic DNA from E. coli was acquired from American Type Culture Collection for 
the amplification of the β-glucuronidase gene.  This chapter outlines the experimental 
methods used to amplify and clone the gene, express and purify the full-length β-
glucuronidase protein, and utilize the purified protein for high-throughput screening and in-
house inhibition studies.  Specifically outlined is the process for optimized protein expression 
to produce protein for discovery of novel compounds to disrupt the glucuronidase activity.  
In addition, details will be included for each in-house assay used to characterize and inhibit 
the enzymatic activity in vitro as well as in cell-based assays.  Further outlined will be β-
glucuronidase knock-out studies.  In order to properly assess the characteristics of the novel 
compounds, a variety of secondary assays were performed.  This chapter will provide 
information on anaerobic cell-based assays performed as well as survivability assays for both 
bacterial and mammalian cell lines.  To determine specificity of the inhibitors for the 
bacterial enzymes versus the mammalian version of the enzyme in vitro assays were 
conducting used a mammalian β-glucuronidase. 
 
 
 
CLONING AND EXPRESSION OF β-GLUCURONIDASE 
 
Cloning of E. coli β-Glucuronidase 
 A previous graduate student of the Redinbo Laboratory, Dr. Jillian Orans, acquired 
the genomic DNA of β-glucuronidase from E. coli in order to amplify the appropriate gene.  
PCR amplification was performed using primers that incorporated the NdeI and NotI 
restriction sites, respectively, which were used for cloning into the pET-28a vector 
(Novagen).  The gene was only amplified successfully using the Platinum® Taq DNA 
Polymerase (Invitrogen).  The PCR reaction contained 10X PCR buffer minus Mg2+, dNTPs, 
MgCl2, as well as the Platinum® Taq DNA Polymerase. 
 The full-length gene was successfully amplified and cloned into the pET-28a vector, 
with multiple undesirable mutations.  Using site-directed mutagenesis, these mutations were 
successfully corrected.  The full-length gene was cloned such that an N-terminal 6x 
Histidine-tag will be fused to the recombinant protein during expression to facilitate 
purification. 
 
Expression and Purification of Escherichia coli β-Glucuronidase 
E. coli BL21-DE3 competent cells were transformed with the expression plasmid and 
grown in the presence of kanamycin (25 μg/ml) in Luria-Broth (LB) medium with vigorous 
shaking at 37 °C until an OD600 of 0.6 was attained. The expression was induced with the 
addition of 0.3 mM isopropyl-1-thio-D-galactopyranoside (IPTG) and further incubated at 
37 °C for 4 hrs. Cells were collected by centrifugation at 4500xg for 20 min at 4 °C in a 
Sorvall (model RC-3B) swinging bucket centrifuge. Cell pellets were resuspended in Buffer 
19 
 
A (20 mM Potassium Phosphate, pH 7.4, 25 mM Imidazole, 500 mM NaCl), along with 
phenylmethylsulfonyl fluoride (PMSF) (2 μL/mL from 100 mM stock) and 0.05 μL/mL of 
protease inhibitors containing 1 mg/mL of aprotinin and leupeptin. Resuspended cells were 
sonicated and centrifuged at 14,500xg for 30 min in a Sorvall (model RC-5B) centrifuge to 
clarify the lysate. The cell lysate was flowed over a pre-formed Ni-NTA His-Trap (GE 
Healthcare) gravity column and washed with Buffer A. The Ni-bound protein was eluted 
with Buffer B (20 mM Potassium Phosphate, pH 7.4, 500 mM Imidazole, 500 mM NaCl). 
Collected fractions were then tested for initial purity by SDS-PAGE. Relatively pure (~85%) 
fractions were combined and loaded into the Äktaxpress FPLC system (Amersham 
Biosciences) and passed over a HiLoad™ 16/60 Superdex™ 200 gel filtration column. The 
protein was eluted (Figure 2.1.A) into 20 mM HEPES, pH 7.4, and 50 mM NaCl for 
crystallization and activity assays. Two milliliter fractions were collected based on highest 
ultraviolet absorbance at 280 nm. Fractions were analyzed by SDS-PAGE (which indicated 
>95% purity, Figure 2.1.B), combined, and concentrated to 10 mg/mL for long-term storage 
at -80 °C. 
 
β-Glucuronidase Activity Assays 
 There are a number of well-characterized enzymatic activity assays to detect 
glucuronidase activity (1, 2).  As previously described in CHAPTER 1, the enzymatic 
properties of β-glucuronidase are utilized to detect bacteria in water samples, in which the 
conversion of the β-glucuronidase substrate 4-methylumbelliferyl glucuronide (4-MUG) to 4-
methylumberlliferone (4-MU) is detected by fluorescence (3-7).  Utilizing the properties of 
4-MU, Dr. Kimberly Lane (previously a post-doctoral research associate in the Redinbo 
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laboratory) developed an in vitro assay to detect the presence of 4-MU by fluorescence 
(Figure 2.2.A).  
 Additional absorbance based enzymatic assays were employed to further characterize 
glucuronidase activity.  Phenolphthalein glucuronide (PheG) and p-nitrophenyl glucuronide 
(PNPG) have been previously used to detect the presence of β-glucuronidases (2, 8, 9).  
These assays were the main method to not only assess enzymatic activity, but additionally to 
measure the efficiency of inhibition by several compounds.  These two substrates have a 
detection wavelength of 540 nm (PheG) and 410 nm (PNPG) (Figure 2.2.B); this eliminated 
the possibility for any background absorbance or fluorescence from any inhibitor compounds 
used in assays to create false positive or negative effects to the absorbance readouts. 
 
High-Throughput Screening for Inhibitor Discovery 
 Purified protein was sent to collaborators at the Biomanufacturing Research Institute 
and Technology Enterprise (BRITE) at North Carolina Central University (NCCU; Durham, 
NC) to screen multiple compound libraries for potential inhibitors.  Using a colorimetric 
readout of the 4-MUG assay described above, high-throughput screens were performed with 
two libraries of chemical compounds, which included 350,000 compounds from Biogen and 
250,000 compounds from Asinex (Figure 2.3).  The inhibition assays exhibited robust 
characteristics, with a screening Z’-factor of 0.84 (10). The hit rate was 1% for the 100 
compounds that produced 90% inhibition or better, exhibited good Hill coefficients and R2 
values for inhibition curves of 0.99 or better.  Nine compounds representative of the chemical 
diversity of the hits were chosen for further investigation (Figure 2.4). 
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In vitro Inhibition of β-Glucuronidase 
 In vitro assays were conducted at 50 μL total volume in 96-well, clear bottom assay 
plates (Costar). Reactions consisted of the following: ten microliters Assay Buffer (5 μL of 
5% DMSO, and 5 μL of 500 mM HEPES, pH 7.4), 30 μL substrate (various concentrations), 
5 μL of an inhibitor solution (various concentrations), and 5 μL of 5 nM enzyme. Substrates 
used consisted of p-nitrophenyl glucuronide (PNPG) and phenolphthalein glucuronide 
(PheG) and were acquired from Sigma. The presence of the hydrolysis product of each, p-
nitrophenol (PNP) and phenolphthalein (8), was measured by absorbance at 410 nm or 540 
nm, respectively. Reactions were allowed to proceed for 6 hours at 37 °C and were quenched 
with 100 μL of 0.2 M sodium carbonate. Absorbance was measured using a PHERAstar Plus 
microplate reader (BMG Labtech). Data acquired was analyzed using Microsoft Excel and 
Sigmaplot 11.0.  
 The nine representative compounds chosen from the high-throughput screening 
results (Figure 2.4) were all more potent than a previously known weak inhibitor, glucaro-δ-
lactam, in vitro (Table 2.1, Figure 2.5.B).  Figure 2.5.A shows a typical graph of the 
increase in inhibition of the β-glucuronidase activity with an increase of inhibitor 
concentration. In vitro, six of the nine inhibitors exhibited nanomolar-level IC50 values, and 
the other three had values of less than 2 μM.  Compound i (Figure 2.4) proved to be the 
strongest inhibitor, with an IC50 value of 1.2 ± 0.50 nM (Table 2.1).   
 Four (a, b, d, f, Figure 2.4) of the nine inhibitors (renamed Inhibitors 1-4, Figure 
2.6) exhibited highly similar chemical structure, and were chosen for further assessment 
through kinetic studies and crystallization trials (detailed in CHAPTER 3).  Kinetic assays 
were carried out in a similar manner as previously stated, however, to capture the initial 
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velocity of the reaction, data points were collected every 2 min for 1 h. As outlined in Table 
2.2, these four inhibitors are more potent than GDL and exhibit nanomolar Ki values.  To 
determine the type of inhibition these 4 compounds exhibit, kcat/Km values were calculated 
for each inhibitor and compared to the WT enzyme’s kcat/Km.  As these values were 
consistent with and without inhibitor, it was determined that these four inhibitors were 
uncompetitive (11). 
In collaboration with Dr. Sridhar Mani of Albert Einstein College of Medicine, 
studies were conducted to show the conversion of SN-38G to SN-38 using purified E. coli β-
glucuronidase (Figure 2.7). SN-38G was a generous gift from ENZON Pharmaceuticals, 
Bridgewater, NJ. The SN-38G enzymatic reactions were conducted in a phosphate buffered 
saline (PBS) buffer, pH 7.4, with 10 μM SN-38G, and with and without purified β-
glucuronidase at 0.5 μM. Enzyme and substrate were incubated at 37 °C for 1 min and 1 h. 
After the incubation period, the reaction mixture was acidified (HCl) and 10 μL of the 
reaction mixture was used to quantify SN-38/SN-38G concentrations. Concentrations were 
determined by a high-performance liquid chromatography (Phenomenex C 18- Jupiter [250 x 
4.6, 5 μm]) assay with fluorescence detection using excitation and emission wavelengths of 
368 and 515 nm, respectively. The zero enzyme control with SN-38G showed no conversion 
to SN-38. The mobile phase (20 mM ammonium acetate, pH 3.5, mobile phase A) and 100% 
acetonitrile containing 1% tetrahydrofuran (mobile phase B) was delivered at a flow rate of 
0.5 mL/min. The mobile phase was filtered and degassed before use, and was freshly 
prepared for each run. The calibration curves (R2=0.9998) were determined using a 
concentration range from 1 ng to 1 μg of SN-38G and SN-38. The LLQ was 1 ng/mL. 
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Cell-based Inhibition of β-Glucuronidase 
E. coli HB101 cells, transformed with the pET-28a vector containing the β-
glucuronidase gene, were grown to an OD600 of 0.6 in LB medium. The cells were then used 
in in vivo assays to assess the glucuronidase activity and efficacy of the inhibitors. This assay 
was performed in a similar manner to the in vitro assay: ten microliters of substrate, 1 μL of 
inhibitor solution, and 40 μL of cells. Again, after 6 h of incubation at 37 °C, the reaction 
was quenched with 100 μL of 0.2 M sodium carbonate. A β-glucuronidase gene (GUS) 
knockout cell-line (GMS407) was purchased from CGSC at Yale University. Absorbance 
was measured at the appropriate wavelength, either 410 nm or 540 nm. Cell survivability in 
the presence of the four inhibitors was assessed by plating a 10-5 dilution of 200 μL of 
saturated cells after incubation with 100 μM of each inhibitor for 6 hours. In addition, 1 mM 
of each hydrolysis product, 10 nM tetracycline (negative control), and 2% DMSO (maximum 
concentration of DMSO when 100 μM inhibitor is added) were also tested for inhibitor 
effects on cell growth. Plated cells were allowed to incubate at 37 °C overnight, and colonies 
were counted to quantify the viability of the cells. 
Cell-based assays in living E. coli cells were also conducted on each of the nine 
compounds; EC50 values are presented Table 2.1.  The potency of inhibition improved in 
cells relative to in vitro for compounds a, b, d, e, and g (Figure 2.4); however, compounds f 
and h showed no improvement, and compound c was ineffective.  The efficacy of compound 
i remained strong in cells, with an EC50 value of 3.6 ± 1.8 nM.  To assess the validity of these 
results, cell survival was tested in the presence of 100 μM of each of the nine inhibitors, as 
well as 1 mM of the hydrolysis products, PNP and Phe.  The nine compounds exhibited no 
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effect on cell survival (Figure 2.8). Thus, potent inhibition of β-glucuronidase activity was 
achieved in E. coli cells grown under aerobic conditions. 
The β-glucuronidase knock-out cell-based assays showed that there was no 
background glucuronidase activity in the absence of the enzyme (Figure 2.9), even with the 
addition of IPTG.  Furthermore, when these knockout cells were transformed with the 
pET28a plasmid containing the β-glucuronidase gene, there is a regeneration of the 
glucuronidase activity, with and without the addition of IPTG.  The presence of enzymatic 
activity without IPTG addition may also suggest that there is leaky expression for these 
controls. 
 
Inhibition of Anaerobic Bacterial Glucuronidase Activity 
Because over 99% of the bacterial species present in the GI tract are obligate 
anaerobes (12), we next tested E. coli cells grown under anaerobic conditions, as well as 
other relevant anaerobic bacterial species (13).  For the anaerobic cell lines used, two types 
of growth medium and agar plates were prepared: de Man, Rogosa, Sharpe (MRS) 
medium/agar was used for Lactobacillus reuteri and Bifidobacterium infantis, and brain/heart 
infusion (BHI) medium/agar for Bacteroides vulgatus and Clostridium ramosum. Anaerobic 
cell lines were graciously provided by the Sartor Lab at the University of North Carolina at 
Chapel Hill. MRS agar plates were prepared by combining MRS and agar powder, as well as 
0.1 g L-cysteine. BHI plates were produced in a similar manner with the addition of 0.2 mL 
each of 5 mg/mL hemin and 0.1% resazurin.  
Prior to streaking, plates were pre-equilibrated in an oxygen-free environment created 
in an anaerobic chamber and using the BD BBL™ GasPak™ Plus Anaerobic System 
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Envelopes. One day before an assay was conducted, 5 mL overnight cultures, using the 
appropriate medium, were grown with no antibiotics as they did not contain inherent 
resistance. Assay plates were prepared similar to the E. coli cell studies, and the reaction was 
allowed to progress in the anaerobic chamber for 6 h. Absorbance data was collected after the 
reaction was quenched and analyzed.  
The cell-based inhibition assays using anaerobic E. coli yielded similar results to 
those of the aerobic conditions using Inhibitors 1-4 (Figure 2.10.A).  Furthermore, in-cell 
assays using the obligate anaerobes B. vulgatus and C. ramosum also demonstrated inhibitor 
efficacy (Figure 2.10.B).  We also tested L. reuteri and B. infantis, which do not contain the 
β-glucuronidase gene (14, 15), and found no evidence of enzyme activity or inhibitor impact 
on assay signal (Figure 2.10.C).  As such, these cell lines are effective negative controls.  
Taken together with the in vitro and cell-based data outlined above, these results confirm that 
we have demonstrated that Inhibitors 1-4 are potent disruptors of  β-glucuronidase activity 
that are effective in living aerobic and anaerobic bacterial cells lines but do not impact 
microbial cell survival. 
 
MAMMALIAN VERSUS BACTERIAL β-GLUCURONIDASE 
 
Impact on Mammalian Cells and Enzymes 
 Bovine liver β-glucuronidase was acquired in lyophilized form from Sigma. The 
protein was dissolved and the assay was conducted as previously published, using PNPG as 
the primary substrate for enzyme activity detection (8). The reaction mixture contained 1 μM 
bovine liver β -glucuronidase and 1 mM PNPG substrate. Inhibitors 1-4 (Figure 2.6) were 
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tested for an effect on mammalian β-glucuronidase activity by adding a concentration range 
of 0 to 100 μM to the reaction mixture. The reaction was allowed to proceed for 6 h and then 
quenched with 0.2 M sodium carbonate. Absorbance was measured at the appropriate 
wavelength, and the data analyzed using Microsoft Excel and SigmaPlot 11.0.  
The four compounds were tested for cytotoxicity in mammalian cells. CMT93 murine 
colon cancer cells, CaCO-2 human colon cancer cells, and HCT116 human colon cancer cells 
were grown and cultured in DMEM medium until confluent and adherent. Cells were 
counted and the appropriate dilutions were made to achieve a 50,000 cell count per reaction. 
Each cell line was aliquoted onto a 96-well assay plate and allowed to incubate at 37 °C in 
media for 16 h prior to treatment with inhibitors. After incubation, 1 μL of each inhibitor, to 
achieve a final concentration of 100 μM, were added to the cells and further incubated for 24, 
48, and 72 h. Using the CellQuanti-Blue™ Cell Viability Assay Kit (BioAssay Systems), 10 
μL of the CellQuanti-Blue™ Reagent was added to each reaction and incubated at 37 °C for 
2 h. After incubation with the reagent, fluorescence was measured with excitation at 544 nm 
and emission at 590 nm.  
The specificity of the four compounds for bacterial β-glucuronidase relative to a 
mammalian enzyme orthologue was tested by conducting in vitro assays using bovine liver 
β-glucuronidase.  In comparing the effect of Inhibitor 1 against the E. coli enzyme and the 
bovine liver β-glucuronidase, it can be seen that the activity of the bacterial enzyme 
decreases significantly with increasing inhibitor concentration; however, the mammalian 
enzyme is not affected (Figure 2.11.A).  With a concentration range of 0 to 100 μM for each 
of the nine inhibitors, no effect was observed on the activity of this mammalian β-
glucuronidase (Figure 2.11.B).  Thus, the representative inhibitors characterized from the 
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high-throughput screening results exhibit no impact on the viability of a human intestinal 
epithelial cell line, and appear selective in their disruption of only bacterial β-glucuronidase 
activity.   
Finally, the effects of these inhibitors on human intestinal cells were examined.  
CMT93 murine colon cancer cells, CaCO-2 human colon cancer cells, and HCT116 human 
colonic epithelial cells (16) were treated with each of the nine inhibitors, and cell viability 
was assayed.  The results show that the novel β-glucuronidase inhibitors characterized have 
no effect on human epithelial cell survival (Figure 2.12).   
 
E. coli β-Glucuronidase Loop Mutant 
 Sequence alignments using CLUSTALW (17) of the E. coli β-glucuronidase with 
other bacterial enzymes show a unique 17 residue section that is not found in similar 
sequence alignments with mammalian versions of the enzyme (Figure 2.13).  As previously 
described in this chapter, these novel inhibitors are selective towards the bacterial enzyme, 
being ineffective against a mammalian β-glucuronidase in vitro (Figure 2.11).  It was 
hypothesized that this loop region present in the bacterial version of the enzyme, yet absent 
in the mammalian enzyme, confers selectivity of these inhibitors. 
 To test this hypothesis a bacterial β-glucuronidase loop mutant was created.  Utilizing 
PCR, amino acids 360-376 were removed using the following primers:  Forward, 5’-
CTGCTGTCGGCTTTAACCTCGAAGAGGCAGTCAACGGGGA-3’; Reverse, 5’-
TCCCCGTTGACTGCCTCTTCGAGGTTAAAGCCGACAGCAG-3’.  Since the forward 
and reverse primers were long, the PCR protocol involved two separate reactions.  Each 
reaction contained only one primer, to allow for the primer to properly anneal to the template 
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instead of the complementary primer.  After 10 rounds of amplification, reactions from each 
primer were combined and allowed to continue for another 30 rounds.   
 Expression and purification and the ΔLoop β-glucuronidase was performed in a 
similar manner as the WT enzyme. The stability and purity of the ΔLoop mutant was the 
same as for the WT enzyme. 
 
Loop Mutant Inhibition Assays 
 Inhibition assays were performed to assess the importance of amino acids 360-376 in 
inhibitor binding and efficacy.  As previously described in this chapter, inhibition assays 
were performed using the ΔLoop mutant in place of the WT enzyme.  Detailed in Figure 
2.14, the ΔLoop mutant’s activity was unaffected by inhibitors 1-4 at 100 μM.   
The loss of potency against the ΔLoop mutant suggests that residues 360-376 play a 
critical role in inhibitor efficacy.  As will be described in the following CHAPTER 3, this in 
vitro biochemical data showing lose of efficacy is supported by structural evidence found in 
the inhibitor-bound β-glucuronidase structure. 
 
Table 2.1 Calculated IC50 and EC50 values for the inhibitors a-i (Figure 2.4) 
chosen from the high-throughput screen from in-house assays using the 
substrates PNPG and PheG. N.E.= Not Effective. 
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Table 2.2 Detailed inhibition characteristics for known inhibitor Glucaro-δ-lactam 
and novel Inhibitors 1-4 including IC50, EC50 and Ki, kcat/Km values.  
These novel inhibitors prove to be far more potent than Glucaro-δ-lactam.  
Furthermore, the constant kcat/Km values for Inhibitors 1-4 suggest that 
these are uncompetitive inhibitors.
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FIGURE LEGENDS 
 
Figure 2.1 (A) UV Chromatogram of E. coli β-glucuronidase from an S200 gel filtration 
purification showing a peak at ~62.2 mL, representing a homotetramer state of 
the enzyme. (B) SDS-PAGE gel analysis after a Nickel column purification, 
which was followed by gel filtration purification.  S200 fractions were 
determined to be >95% pure and were combined, concentrated and used for 
crystallization or activity assays. 
 
Figure 2.2 (A) Preliminary β-glucuronidase enzymatic assay using the substrate 4-MUG, 
which upon hydrolysis yields the fluorescent product 4-MU.  Data collection 
was performed on a BMG Pherastar, with excitation at 365 nm, and emission 
detected at 450 nm. (B) Schemes of the secondary enzymatic assays used in-
house to further characterize β-glucuronidases and novel inhibitor compounds 
utilizing PNPG and PheG.  Both assay products were detected by absorbance, 
410 nm for PNPG, and 540 nm for PheG. 
 
Figure 2.3 Example of the colorimetric output, using the 4-MUG assay (Figure 2.2.A), 
from the high-throughput screening conducted at NCCU-BRITE.  Blue 
represents no inhibition of the enzyme, and red represents max inhibition. 
 
Figure 2.4 Nine inhibitors from the high-throughput screen which exhibited nanomolar to 
low micromolar IC50 values against E. coli β-glucuronidase.  These nine 
inhibitors were purchased to do further testing in-house using our secondary 
validation assays (Figure 2.2.B) and in-cell studies. 
 
Figure 2.5 (A) Example of an inhibitor dose-response curve showing increasing enzyme 
inhibition with increasing inhibitor concentration. This graph in particular 
details the inhibition of β-glucuronidase using inhibitor a (Figure 2.4; for 
inhibitor 1 from Figure 2.6). (B) In vitro and cell-based inhibition assay using 
the known β-glucuronidase inhibitor glucaro-δ-lactam showing only weak 
efficacy in vitro and no effect in vivo.  Prior to studies done in the Redinbo 
Lab, this was one of the most effective at inhibiting β-glucuronidase activity, 
but still proved unsuccessful at alleviating toxicity from CPT-11 dosing. 
 
Figure 2.6 Four inhibitors chosen from the original 9 (renamed from Figure 2.4) for 
further characterization in kinetic studies and crystallization trials.  These four 
were picked from the original 9 due to similar molecular structure as well as 
having a range of IC50 values, from low nanomolar to low micromolar. 
 
Figure 2.7 HPLC analysis showing hydrolysis of SN-38G to SN-38 by purified E. coli β-
glucuronidase.  Purified enzyme was produced in the Redinbo Lab and sent to 
Einstein Medical College to perform the SN-38G to SN-38 assay by Dr. 
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Sridhar Mani’s Lab.  This data shows that after 1 min, a small portion of the 
SN-38G has already been converted to SN-38.  After 1 hour, all of the SN-
38G has been hydrolyzed to by the enzyme to form the SN-38. 
 
Figure 2.8 Bar graph representation showing the growth of CFUs after incubation with a 
variety of compounds including the nine inhibitors (Figure 2.4), which have 
little to no effect on cell growth. The 2% DMSO control shows a slight 
reduction in colony growth, which is most likely the cause for any reduction 
in CFUs produced in the presence of any of the nine inhibitors, as they were 
dissolved in DMSO. 
 
Figure 2.9 Bar graph representing the β-glucuronidase knockout (ΔβG) studies show no 
background glucuronidase activity; however, after reintroduction of the E. coli 
β-glucuronidase gene in the pET-28a plasmid, enzyme activity is restored.  
The ΔβG cells were transformed with the pET-28a plasmid containing the 
enzyme, and compared to the HB101 cells, used for cell-based enzymatic 
assays.  Both showed enzymatic activity with and without IPTG induction.  
Activity detected without IPTG most likely indicates leaky expression of the 
β-glucuronidase enzyme. 
 
Figure 2.10 (A) Cell-based inhibition assays comparing E. coli bacteria in aerobic and 
anaerobic environments using inhibitors 1-4 (Figure 2.6). This bar graph 
shows that these inhibitors are effective at disrupting activity in both oxygen-
rich and oxygen-free environments. (B) Inhibitors 1-4 are successful at 
disrupting β-glucuronidase from other anaerobic bacteria found in the human 
GI tract.  B. vulgatus and C. ramosum cell lines were tested to determine the 
effectiveness of these inhibitors against the β-glucuronidase enzymes 
expressed by these species. (C) A negative control using L. reuteri and B. 
infantis (both β-glucuronidase deficient) shows no background signal from the 
four inhibitors or enzyme activity in the absence of these inhibitors. 
 
Figure 2.11 (A) Bar graph depicting the potent inhibition of purified E. coli β-
glucuronidase and no significant effect on the mammalian bovine liver 
enzyme using inhibitor 1. At increasing inhibitor concentrations of inhibitor 1, 
there is no drop off of activity of the mammalian enzyme, where as there is 
clear disruption of activity of the bacterial enzyme. (B) Dose response graph 
showing that inhibitors 1-4 are ineffective at halting mammalian β-
glucuronidase through a range of concentrations. 
 
Figure 2.12 Human cell lines HCT116, CaCO-2 and the murine CMT93 were incubated 
with inhibitors 1-4 to assess toxicity of each compound, and as detailed in the 
24 to 72 hour time points there is little to no effect on survivability.  HCT116 
and CaCO-2 cell lines are both human carcinoma cell lines, and the CMT93 
line are murine carcinoma cells.  Triton X-100 was used as a negative control 
to disrupt the cell membrane and rupture the cells showing complete death of 
each cell line. 
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Figure 2.13 (Top) A portion of the sequence alignment of E. coli β-glucuronidase with 
various mammalian β-glucuronidases highlighting the unique 17 residues that 
are absent from the mammalian enzyme. This loop region, present in the E. 
coli gene is critical for inhibitor binding. (Bottom) Alignment of the E. coli 
enzyme with other bacterial species’ version of the enzyme reveal that each 
has a “bacterial loop”.  This further supports the theory that this loop region is 
a potential reason for the selectivity of these inhibitors for the bacterial 
enzymes. 
 
Figure 2.14 Comparing the results of inhibition assays using the WT E. coli β-
glucuronidase and the ΔLoop (Δ360-376) enzyme reveals that these 
compounds have lost their ability to target and disrupt the enzyme.  The 
ΔLoop mutant of the E. coli enzyme is now more closely related to the 
mammalian version of this enzyme, and as such inhibitors 1-4 can no longer 
bind to the target. This is further discussed with structural support in the 
following CHAPTER 3. 
 
Figure 2.1 (A) Chromatogram of E. coli β-glucuronidase from gel filtration 
purification showing a peak at 62.2 mL, representing a tetramer.  (B) 
SDS-PAGE gel of β-glucuronidase from a Nickel column purification, 
which was followed by gel filtration purification. 
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Figure 2.2 (A) Preliminary β-glucuronidase enzymatic assay using the substrate 4-
MUG, which upon hydrolysis yields the fluorescent product 4-MU. (B) 
Schemes of the secondary enzymatic assays used in-house to further 
characterize β-glucuronidases and novel inhibitor compounds utilizing 
PNPG and PheG. 
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Figure 2.3 Example of the colorimetric output, using the 4-MUG assay (Figure 
2.2.A), from the high-throughput screening conducted at NCCU-BRITE. 
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Figure 2.4 Nine inhibitors from the high-throughput screen which exhibited 
nanomolar to low micromolar IC50 values against E. coli β-glucuronidase. 
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Figure 2.5 (A) Example of an inhibitor dose response curve showing increasing 
enzyme inhibition with increasing inhibitor concentration. (B) In vitro 
and cell-based inhibition assay using the known β-glucuronidase inhibitor 
glucaro-δ-lactam showing only weak efficacy in vitro and no effect in vivo. 
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Figure 2.6 Four inhibitors chosen from the original 9 (renamed from Figure 2.4) for 
further characterization in kinetic studies and crystallization trials. 
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Figure 2.7 HPLC analysis showing hydrolysis of SN-38G to SN-38 by purified E. coli 
β-glucuronidase. 
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Figure 2.8 Bar graph representation showing the growth of CFUs after incubation 
with a variety of compounds including the nine inhibitors (Figure 2.4), 
which have little to no effect on cell growth. 
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Figure 2.9 Bar graph representing the β-glucuronidase knockout (ΔβG) studies show 
no background glucuronidase activity; however, after reintroduction of 
the E. coli β-glucuronidase gene, activity is restored. 
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Figure 2.10 (A) Cell-based inhibition assays comparing E. coli bacteria in aerobic and 
anaerobic environments using inhibitors 1-4. (B) Inhibitors 1-4 are 
successful at disrupting β-glucuronidase from other anaerobic bacteria 
found in the human GI tract. (C) A negative control using L. reuteri and 
B. infantis (β-glucuronidase deficient) shows no background signal from 
the four inhibitors. 
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Figure 2.11 (A) Bar graph depicting the potent inhibition of purified E. coli β-
glucuronidase and no significant effect on the mammalian bovine liver 
enzyme using Inhibitor 1.  (B) Dose response graph showing that 
inhibitors 1-4 are ineffective at halting mammalian β-glucuronidase 
through a range of concentrations. 
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Figure 2.12 Human cell lines HCT116, CaCO-2 and the murine CMT93 were 
incubated with inhibitors 1-4 to assess toxicity of each compound, and as 
detailed in the 24 to 72 h time points there is little to no effect on survival. 
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 Figure 2.13 (Top) A portion of the sequence alignment of E. coli β-glucuronidase with 
various mammalian β-glucuronidases highlighting the unique 17 residues 
that are absent from the mammalian enzyme.  (Bottom)  Alignment of the  
E. coli enzyme with other bacterial species’ version of the enzyme reveal 
that each has a “bacterial loop”. *Candidate β-glucuronidase. 
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Figure 2.14 Comparing the results of inhibition assays using the WT E. coli β-
glucuronidase and the ΔLoop enzyme reveals that these compounds have 
lost their ability to target and disrupt the enzyme. 
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CHAPTER 3. 
Crystallization of E. coli β-Glucuronidase and Structural Analysis 
 
INTRODUCTION 
 Although the crystal structure of the human β-glucuronidase was solved previously, 
we sought to crystallize the bacterial version of the enzyme to inspect for critical differences 
in the active site region, as well as the surrounding residues to better understand how the 
enzyme operates mechanistically.  Furthermore, the elucidation of the crystal structure would 
allow for an in-depth understanding of why our novel inhibitors proved to be effective at 
disrupting the bacterial enzyme’s activity while not inhibiting the mammalian β-
glucuronidase (see CHAPTER 2). 
 After successfully purifying the E. coli β-glucuronidase enzyme, commercial crystal 
screens were used to identify potential crystallization hits.  These were optimized to produce 
diffraction quality crystals, from which native data was acquired.  Even though the human 
and E. coli enzyme share a high sequence identity (~45%), phasing from molecular 
replacement was unsuccessful.  As such we produced selenomethionine-substituted E. coli β-
glucuronidase to acquire experimental phasing to solve the bacterial structure. 
 We sought to co-crystallize the enzyme in the presence of a number of our novel 
inhibitors to understand where and how they bind and disrupt the enzymatic activity.  
Detailed analysis of the bacterial crystal structures solved revealed the importance of the 
unique loop region present only in the bacterial enzyme to the binding of the novel inhibitor 
compounds. 
 
CRYSTALLIZATION OF E. COLI β-GLUCURONIDASE 
 
Expression and Purification of Selenomethionine Substituted β-Glucuronidase 
 To express selenomethionine-substituted enzyme, E. coli B834 competent cells were 
transformed with pET-28a containing the β-glucuronidase gene (CHAPTER 2). B834 cells 
are derived from a methionine auxotroph strain; they are unable to produce their own 
methionine and therefore cannot incorporate the residue into the nascent protein chain 
without supplemented methionine in the growth media. A 100 mL overnight culture grown 
from a single colony in LB was centrifuged at 40,000 g for 15 min, and the pellet was 
washed twice with 50 mL of ddH2O. This step is critical for removal of any residual 
methionine from the media used in the overnight culture. The washed pellet was resuspended 
in 1 mL ddH2O. The cells were then ready for inoculation. To produce the selenomethionine 
protein, cells were grown in SeMet Medium Base minimal media and SelenoMet Nutrient 
Mix (Athena Enzyme Systems, Baltimore, MD). The medium base (21.6 g) was added to 1 L 
of ddH2O and autoclaved. After cooling, 5.1 g of nutrient mix was dissolved in 50 mL 
ddH2O; this solution was sterilely filtered into the medium base. After adding antibiotics 
(Kanamycin) and supplementing the media with 50 mg selenomethionine, the 1 mL sample 
of washed and resuspended overnight culture was added. The cells were grown at 37 °C until 
an OD600 of 0.6 was reached and then were induced with 0.3 mM IPTG. The temperature 
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was lowered to 15 °C and the cultures were grown overnight with shaking. Purification was 
performed as for the wild-type enzyme detailed in CHAPTER 2, with the addition of 1 mM 
tris(2-carboxyethyl)phosphine (TCEP) to prevent oxidation of the selenium substituted 
methionines. 
 
Crystallization of β-Glucuronidase and Data Collection 
The native β-glucuronidase has been previously crystallized by Dr. Kimberly Lane 
after purification on a Nickel column with a step elution; however, attempts to reproduce 
these results proved unsuccessful.  Renewed attempts to crystallize the apo-protein have been 
successful with a new purification protocol, detailed in CHAPTER 2. 
Initial crystal trials were performed using commercially available reagent screens 
from Qiagen.  An initial hit, containing 20% PEG3350 and 0.2 magnesium acetate from the 
PEGs I Crystal Screen, yielded a single needle cluster (Figure 3.1.A), from which additional 
optimization experiments were derived. Optimized crystals of E. coli β-glucuronidase were 
obtained at 2 mg/mL protein in 15% PEG3350, 0.2 M magnesium acetate, and 0.02% sodium 
azide at 16 °C. Crystals first appeared after 5 days, and grew to a final size of approximately 
100x100x50 μm3, and are shown in Figure 3.1.B. Crystals were cryo-protected with 
perfluoropolyether vacuum pump oil (Sigma) and flash cooled in liquid nitrogen. Diffraction 
data were collected on the 22-BM beam line at SER-CAT (Advanced Photon Source, 
Argonne National Laboratory). At least 210° of diffraction images were collected to ensure a 
complete data set was collected.  Data was indexed and scaled using HKL2000 (1) and X-
GEN (2). The crystals exhibited the space group C2, and the asymmetric unit contained two 
monomers according to a Matthew’s coefficient calculation (3). Selenomethionine-
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substituted crystals grew in a similar fashion to the native protein crystals.  It general, 
however, the SeMet crystals appeared to grow more efficiently and with higher quantity of 
crystals produced.  SeMet crystals were also sent for X-ray data collected for future phasing 
studies.  These data were collected to 2.9 Å and processed similarly.  
 
Phasing and Structure Solution 
Initial attempts of molecular replacement using the previously solved human β-
glucuronidase structure (4) proved fruitless, as the model bias proved to be too severe to 
properly build and refine the E. coli structure.  As such, the SeMet-substituted enzyme was 
crystallized and data collected at the peak wavelength of the Selenium scan (Figure 3.2). The 
PHENIX software suite (AutoSol) was utilized to locate heavy atom sites and to trace a 
portion of the model (5). An initial model was built by hand in Coot using the SAD data and 
later used with Phaser for molecular replacement with a native data set and the inhibitor 
bound structures (6, 7). The structure was refined using simulated annealing and torsion 
angle refinement with the maximum likelihood function target in CNS, and monitored using 
both the crystallographic R and cross-validating R-free statistics (8, 9). Ramachandran 
outliers were in loops with poor density relative to other regions of the model, and none 
existed within 20 Å of the enzyme’s active site. Data collection and refinement statistics are 
presented in Table 3.1. The software suite PHENIX was used for anisotropic B-factor and 
TLS refinement (5). The model was manually adjusted using Coot and 2Fo-Fc and Fo-Fc 
electron density maps (6).  
 
Co-crystallization of β-Glucuronidase with Inhibitor Compounds 
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 Prior to crystallization studies with our novel inhibitor compounds, co-crystallization 
experiments of the bacterial enzyme with previously known β-glucuronidase inhibitors were 
executed.  Before discovery of inhibitors 1-4, glucaro-δ-lactam was one of the most potent 
compounds capable of disrupting β-glucuronidase activity (10).  Purified E. coli β-
glucuronidase was incubated at 2 mg/mL with 1, 5, and 10 mM glucaro-δ-lactam for 4 h 
prior to crystal tray setup.  Crystals of the enzyme in the presence of glucaro-δ-lactam grew 
in similar conditions as with the apo-enzyme crystals.  The software program PRODRG (11) 
was used to generate the model and geometry definition files for glucaro-δ-lactam, and was 
placed and manually refined using Coot (6).  Computational refinements were performed 
using PHENIX (5), similar to the apo-structure.  X-ray data collection and refinement 
statistics of the glucaro-δ-lactam bound enzyme crystal structure is detailed in Table 3.1. 
To better understand how the novel inhibitor compounds (detailed in CHAPTER 2) 
bind to β-glucuronidase and the location of the binding site, co-crystallization studies were 
performed to elucidate the inhibitor-bound crystal structure of E. coli β-glucuronidase.  The 
crystallization trials were carried out in a similar manner as for the apo-protein, with the 
exception of a pre-incubation period of the protein solution and inhibitor solution.  Inhibitors 
1-4 were incubated with 2 mg/mL enzyme on ice for 4 h at various concentrations, including 
1, 5, and 10 mM.  These concentrations were all in excess of the protein concentration to 
insure binding of the compound.  The crystallization condition was the same as for the apo-
protein.  Prior to tray setup, the protein/inhibitor solution was centrifuged at 13,000xg for 10 
min.  This step was necessary as the inhibitor compounds were poorly soluble in anything 
other than DMSO, causing much of the inhibitor to precipitate out of solution during the 
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incubation.  The centrifugation separated the solid inhibitor from the soluble fraction; this 
was critical to prevent inhibitor salt crystals from forming during the crystallization trials. 
 Enzyme incubated with inhibitors 2 and 3 grew crystals more efficiently than 
incubations with inhibitors 1 and 4.  In addition, these inhibitor-bound crystals grew more 
slowly than apo-protein crystals.   Crystals were cryo-protected in a similar fashion to the 
apo-crystals.  X-ray data collection and data reduction was also performed similarly.  These 
co-crystals also exhibited the same C2 space group and similar cell constants (Table 3.1).  
Using the previously solved apo-structure, Phaser (7) was used to generated phases from 
molecular replacement. The software program PRODRG (11) was used to generate a model 
and geometry definition file for the inhibitor compounds.  For inhibitors 2 and 3, the model 
files were easily placed into positive Fo-Fc density in Coot (6) and refined using PHENIX 
(5) as with the apo-structure. 
  
STRUCTURAL ANALYSIS OF E. COLI β-GLUCURONIDASE 
 
Apo-Structure of β-Glucuronidase 
The asymmetric unit in the native and SeMet-substituted crystal structures contains 
two monomers, each composed of 597 ordered residues (Figure 3.3.A). Two residues at the 
C-terminus of the enzyme, K602 and Q603, lacked electron density, as did a disordered loop 
region from 363-369; as such, these regions were not placed in the final model.  The N-
terminal domain of E. coli β-glucuronidase (residues 1-180) contains 12 β-strands and two 
short α-helices, which resembles the sugar binding domain of family 2 glycosyl hydrolases 
(12). The C-terminal domain (274-603) forms an αβ-barrel (12) composed of 8 short β-
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strands and 9 α-helices, and contains the active site residues E413 and E504. The region 
between the N- and C-terminal domains, composed of residues 181-273, exhibits a 7-
stranded immunoglobin-like β-sandwich domain consistent with other family 2 glycosyl 
hydrolases (12, 13).  Crystallographic symmetry generates the tetramer (modeled in PyMOL 
(14)) expected to be the native form of the enzyme, as observed previously for human β-
glucuronidase (4) and by gel filtration chromatography for the E. coli enzyme (Figure 3.3.B 
and Figure 2.1.A). 
Superimposing the E. coli β-glucuronidase structure on that of the human enzyme (4) 
reveals an overall 1.4 Å root mean square deviation (r.m.s.d.) over 565 equivalent Cα 
positions (Figure 3.4.A).  The E. coli enzyme contains one loop of ~17 residues in length not 
found in the human orthologue (shown in the sequence alignment in Figure 1.4.B and more 
in-depth in Figure 2.13). In contrast, the human enzyme contains structural elements not 
observed in the bacterial enzyme including two loops approximately 9-11 residues longer 
than the equivalent E. coli regions.  In spite of these differences, the active sites of the 
bacterial and human enzymes superimpose well.  Furthermore, only two residues within 5 Å 
of the catalytic glutamic acid residues, L361 of the E. coli structure and V410 of the human 
structure, are not conserved between the two sequences.  This observation highlights the 
expected conservation in mechanism across these β-glucuronidases.  Additional analysis 
using DALI (15) shows that the E. coli β-glucuronidase is similar to many other sugar-
hydrolyzing enzymes (Table 3.2).  Structural alignments using the native β-glucuronidase 
structure revealed over 886 similar structures (Z-scores between 48-10). A subset is 
presented in Table 3.2. 
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Inhibitor-Bound β-Glucuronidase 
 The 2.4 Å resolution, glucaro-δ-lactam (GDL)-bound structure reveals a single clear 
binding mode of the inhibitor within the β-glucuronidase active site (Figure 3.5.A).  GDL 
forms direct contacts with four amino acids (D163, R562, K568, Y472, H330) and one of the 
catalytic residues (E413), and is located 2.8 Å from the second catalytic residue, E504 
(Figure 3.5.B).  The inhibitor-bound structure shares 1.2 Å r.m.s.d. over 597 equivalent Cα 
atoms when superimposed on the 2.5 Å resolution structure of the native, unliganded enzyme.  
The most significant difference (shifts in backbone position ≥ 2.8 Å) between the two 
structures occurs adjacent to the catalytic site (Figure 3.6.A-B).  The entrance to the active 
site in the native structure is occluded by the 466-476 loop that contains tyrosines 468, 469 
and 472, such that this loop would clash sterically with the observed position of the GDL 
inhibitor (Figure 3.6.A).  In the inhibitor-bound structure, this loop has shifted in position to 
relocate these aromatic residues 7-14 Å away and allow GDL binding (Figures 3.6.A-B).  
Upon this shift, the opening of the active site increases in area from 10.9 Å2 (unliganded) to 
20.8 Å2 (inhibitor-bound) (Figure 3.7), and allows Y472 to form a direct contact with the 
GDL molecule (Figure 3.5.B).  Thus, a conformational change is critical to inhibitor binding 
to the E. coli β-glucuronidase active site. 
 E. coli β-glucuronidase was successfully co-crystallized with inhibitor 2 (2.3 Å) and 3 
(2.4 Å).  Both inhibitors are positioned in the same area just outside of the enzyme’s active 
site with the ethoxy groups extending to within 3.3 Å of the catalytic residue E413, and also 
using a 5-amino acid stretch as its binding interface (Figure 3.8.A).  One of the most notable 
binding interactions is with an F365 found in an adjacent monomer in the biologically 
relevant tetramer (Figure 3.8.B).  Additional interactions formed between the enzyme and 
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inhibitors include mainly hydrophobic interfaces encompassing each inhibitor, with the 
exception of hydrogen bonding between the ethoxy group and E413 for both inhibitors, and 
H162 for inhibitor 2 (Figure 3.9).   
Similar to the GDL-bound structure, tyrosines 468, 469, and 472 are shifted when 
compared to the native structure, opening up the cavity surrounding the active site.  Even 
though inhibitors 2 and 3 do not bind in the active site, the conformational change of these 
tyrosines suggests that there is a bound and unbound state of the enzyme, and the inhibitors 
lock the enzyme in the bound state.  Furthermore, the 360-376 loop, which was originally 
disordered in the native and GDL-bound structure, becomes ordered in the presence of both 
inhibitors 2 and 3 and was able to be built into electron density.  As inhibitors 2 and 3 utilize 
the 360-376 loop region as a binding surface and key residue interactions are formed between 
these inhibitors and the loop region within the same monomer as well as an adjacent 
monomer, we find that this bacterial loop is critical for inhibitor binding. 
 
Crystal Structure Reveals Evidence for Bacterial Specificity 
 The elucidated co-crystal structures of the inhibitor 2- and 3-bound β-glucuronidase 
shows that these compounds utilize the 360-376 loop region as a binding surface.  
Structurally, this section of the enzyme appears to be critical for inhibitor binding.  Adding to 
the structural data, sequence alignments (Figure 2.13) and loop deletion mutant assays 
(Figure 2.14), it is demonstrated that this bacterial loop is vital to the binding, potency, as 
well as the selective properties of these inhibitors towards the bacterial enzyme. 
 A structural alignment of the loop region of the E. coli enzyme versus the human 
crystal structure reveals the dramatic difference in this area of the two enzymes (Figure 3.10).  
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To assess the validity of the bacterial loop as a critical factor for inhibitor binding and 
selectivity, the Human Microbiome Project (16) database was accessed (June 29, 2010) to 
search for similar loop regions in other bacterial species known to inhabit the human GI tract.  
Using the E. coli β-glucuronidase amino acid sequence to search the GI bacterial sequence 
database, it was found that 43% of the bacterial species contained a β-glucuronidase gene or 
candidate enzyme (Figure 3.11).  Of those species’ enzymes, 98% had at least half of the 
loop region (N-terminal half).  Ninety-one percent of these had similar key residues in the 
loop region similar to L361 and F365 in the E. coli structure. Bacterial species that were 
determined to have the conserved bacterial loop are listed in Table 3.3. 
able 3.1 Data collection, phasing, and refinement statistics for E. coli β-
glucuronidase crystal structures. 
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Table 3.2 Structural alignment results from DALI using the native E. coli β-
glucuronidase structure showing a sample of similar structures from a 
total of 886 identified structures. 
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Table 3.3 List of GI bacterial species, identified from the Human Microbiome 
Project Database, found to contain a β-glucuronidase with the bacterial 
loop and key residues to interact with inhibitors 2 and 3.
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Table 3.3 (continued) 
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FIGURE LEGENDS 
 
Figure 3.1 (A) Initial crystal hit from the PEGs I suite, containing 20% (w/v) PEG 3350 
and 0.2 M magnesium acetate. This hit was a single needle cluster, and 
optimization grids were performed around this condition. (B) After refining 
the original hit by optimizing precipitant concentration, and drop ratio, single, 
well-ordered crystal growth was achieved.  Similar crystal growth was seen 
for the SeMet protein as well as for the co-crystals in the presence of 
inhibitors. 
 
Figure 3.2 Energy (kEV, x-axis) scan of SeMet-substituted β-glucuronidase crystals 
showing the electron count (y-axis) and anomalous scattering from the 
selenium ions.  Data was collected at the “peak”, where selenium has the 
highest absorption.  The peak data was used to calculated experimental phases 
to solve the E. coli structure. 
 
Figure 3.3 (A) Asymmetric unit of E. coli β-glucuronidase, colored by chain, is 
composed of 2 monomers. The structure is composed of the N-terminal β-
sandwich region found in the family 2 of glycosyl hydrolases as well as the C-
terminal α/β-barrel, which contains the active site. (B) Biological unit (as 
evidenced by gel filtration, Figure 2.1.A) of E. coli β-glucuronidase, 
generated in PyMol, is shown here as a homotetramer. Each monomer is 
colored by chain. 
 
Figure 3.4 Front and side view of the E. coli β-glucuronidase monomer overlaid with a 
monomer from the human β-glucuronidase structure (PDB ID 1BHG).  An 
overall comparison of the two structures shows highly conserved secondary 
structural features, with exceptions including loop regions on the surface of 
the protein and hovering over the active site. 
 
Figure 3.5 (A) Stereo view of the GDL-bound β-glucuronidase structure’s active site 
showing key residues surrounding the GDL molecule. The electron density 
map shown is a simulated annealing omit map, contoured at 1.5σ.  The map 
shows clear and tight density surrounding the GDL molecule as well as the 
surround residues forming interactions with the ligand. (B) Diagram showing 
residues that make interactions with the GDL molecule in the β-glucuronidase 
active site. These interactions consist of hydrogen-bonding and electrostatic 
interactions with the distances of each interactions shown. 
 
Figure 3.6 (A) Surface representation of the unbound (magenta, with GDL overlaid) and 
GDL-bound (blue) active site detailing opening of the active site to allow for 
binding.  It is also evidenced in the top picture the steric clashing that would 
form between the protein’s active site and the ligand if the region did not 
expand. (B) GDL-bound (blue) and native (magenta) overlay showing the 
conformational change of 3 tyrosines to accommodate the GDL.  Also 
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indicated are the distances that each tyrosine (Y468, Y469, and Y472) rotates 
away from the active site, expanding the region to allow for ligand binding. 
 
Figure 3.7 Compared to the native (magenta, GDL overlaid) structure, the active site 
opening of the GDL-bound (blue) structure nearly doubles in area to allow for 
substrate binding.  The method of active site area calculation is detailed here. 
 
Figure 3.8 (A) Active site of β-glucuronidase with inhibitors 2 and 3 overlaid, showing 
proximal residues.  Both crystal structures depict these inhibitors as binding in 
a similar position, lying on the labeled “bacterial loop” region, colored in red. 
Catalytic residues are boxed in, and other surround residues are shown and 
labeled. (B) Inhibitors were found to stack cooperatively between monomers 
in the tetramer.  The F365 from an adjacent monomer forms ring-stacking 
interactions with the planar rings of inhibitors 2 and 3, and vice versa. This 
interaction likely contributes the potency in disrupting glucuronidase activity. 
 
Figure 3.9 Key interactions between residues and inhibitors 2 and 3 found in the crystal 
structure. The majority of interactions made between the enzyme’s surround 
residues and these inhibitors are hydrophobic, many of which are formed 
between the inhibitor and the bacterial loop residues. Additional hydrogen 
bonding interactions are found between the enzyme’s catalytic residues E413 
and the ethoxy-chain’s hydroxyl group, which is inserted into the actual active 
site upon binding. Also shown is the F365 interaction made with an adjacent 
monomer.  
 
Figure 3.10 The 360-376 loop of the E. coli β-glucuronidase forms direct contact with the 
bound inhibitor 2; this loop is absent from the human structure.  Show in grey 
is the human β-glucuronidase structure (PDB ID 1BHG), which lacks any 
structural elements in this loop region.  This prevents our inhibitors from 
binding to the mammalian enzyme and disrupting activity. 
 
Figure 3.11 Flowchart detailing the results of the β-glucuronidase search of the Human 
Microbiome Project Database. ‡ Search conducted on June 29, 2010.  This 
diagram shows that nearly half of the sequenced GI bacterial species contain 
glucuronidase activity, with a majority (98%) containing a loop region similar 
to that of the E. coli enzyme. Ninety-one percent of these species have 
residues which have the potential to form critical hydrophobic interactions 
with the inhibitors. 
 
 
 
Figure 3.1 (A) Initial crystal hit from the PEGs I suite, containing 20% (w/v) PEG 
3350 and 0.2 M magnesium acetate. (B) After refining the original hit by 
optimizing precipitant concentration and drop ratio, single, well-ordered 
crystal growth was achieved. 
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Figure 3.2 Energy (kEV, x-axis) scan of SeMet-substituted β-glucuronidase crystals 
showing the electron count (y-axis) and anomalous scattering from the 
selenium.
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Figure 3.3 (A) Asymmetric unit of E. coli β-glucuronidase, colored by chain, is 
composed of 2 monomers. (B) Biological unit of E. coli β-glucuronidase, 
generated in PyMOL, is shown here as a homotetramer. 
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Figure 3.4 Front and side view of the E. coli β-glucuronidase monomer overlaid with 
a monomer from the human β-glucuronidase structure (PDB ID 1BHG). 
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Figure 3.5 (A) Stereo view of the GDL-bound β-glucuronidase structure’s active site 
showing key residues surrounding the GDL molecule. (B) Diagram 
showing residues that make interactions with the GDL molecule in the β-
glucuronidase active site. 
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Figure 3.6 (A) Surface representation of the unbound (magenta, with GDL overlaid) 
and GDL-bound (blue) active site detailing opening of active site to allow 
for binding. (B) GDL-bound (blue) and native (magenta) overlay showing 
the conformational change of 3 tyrosines to accommodate the GDL. 
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Figure 3.7 Compared to the native (magenta, GDL overlaid) structure, the active 
site opening of the GDL-bound (blue) structure nearly doubles in area to 
allow for substrate binding. 
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Figure 3.8 (A) Active site of β-glucuronidase with inhibitors 2 and 3 overlaid, 
showing proximal residues. (B) Inhibitors were found to stack 
cooperatively between monomers in the tetramer. 
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Figure 3.9 Key interactions between residues and inhibitors 2 and 3 found in the 
crystal structure. 
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Figure 3.10 The 360-376 loop of the E. coli β-glucuronidase forms direct contact with 
the bound inhibitor 2; this loop is absent from the human structure. 
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Figure 3.11 Flowchart detailing the results of the β-glucuronidase search of the 
Human Microbiome Project Database. ‡ Search conducted on June 29, 
2010. 
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CHAPTER 4. 
Additional Studies on β-Glucuronidase and Future Directions 
 
INTRODUCTION 
 It has successfully been demonstrated in previous chapters that the novel compounds 
1-4 (Figure 2.6) are potent inhibitors of E. coli β-glucuronidase in vitro, in cell-based assays, 
and in preliminary mice studies (1).  However, E. coli is only one of many bacterial species 
that inhabit the human GI tract (2-4); as such it is necessary to examine additional bacterial 
β-glucuronidases.  We acquired the genomic DNA of Bacteroides fragilis and Streptococcus 
agalactiae from ATCC and the DNA for Clostridium perfringens str. 13 from Dr. Bruce 
McClane from the University of Pittsburgh. We cloned, expressed, and purified the β-
glucuronidase from each of these species to test the efficacy of our inhibitors in kinetic 
assays and for crystallization trials. 
 Previous literature has also shown that β-glucuronidases are involved in ulcer 
formation caused by the use of NonSteroidal Anti-Inflammatory Drugs (NSAIDs).  This 
iatrogenic disease is manifested as ulceration and bleeding of the mucosa, inflammation, and 
even perforation (5-7). With the advent of novel diagnostic tools including video capsule 
endoscopy, it has become increasingly clear that not only the stomach, but also the small 
intestine is a major target of NSAID-associated toxicity (8-10). Indeed, approximately two-
thirds of both long-term (> 3 months) and short-term (~ 1 week) NSAID users exhibited mild 
or more severe forms of drug-induced lesions in the small intestine (11, 12). In addition, 
many unexplained GI lesions in “control subjects” were found to be attributable to non-
prescription use of NSAIDs (13). Despite this high incidence of the disease, there are 
currently no approved therapies to prevent or treat NSAID enteropathy.  
The conjugates of these NSAIDs are enzymatically cleaved by β-glucuronidases, and the 
aglycone is reabsorbed (14, 15).  We sought to target a mechanism that would provide 
effective protection against NSAID enteropathy upstream of these primary and secondary 
events by limiting the initial exposure of the intestinal mucosa to the drug. This novel 
strategy is based on a characteristic pharmacokinetic feature of diclofenac (DCF) and other 
carboxylic acid-containing NSAIDs. A portion of the hepatic diclofenac pool is conjugated 
with glucuronic acid to form a water-soluble 1-β-O-acyl glucuronide. This acyl glucuronide 
(AG) is readily excreted across the hepatocanalicular membrane via Mrp2 into the biliary 
tree (14) and delivered to more distal sites, i.e., the jejunum and ileum (16). During this 
transport, a portion of the AG is converted to iso-glucuronides by spontaneous acyl migration 
of the aglycone along the sugar ring (17). Diclofenac AG (but not the iso-glucuronides) can 
be cleaved by bacterial β-glucuronidase in the lumen of the small bowel. The released DCF is 
then taken up by enterocytes and undergoes enterohepatic circulation, thus re-exposing the 
mucosa repeatedly. We hypothesized that the intraluminal release of the parent drug by 
bacterial β-glucuronidase could be a key factor in the initiation of NSAID enteropathy; hence, 
highly selective inhibition of bacterial β-glucuronidase would protect against intestinal injury. 
Dr. Urs Boelsterli from the University of Connecticut contacted our lab to begin a 
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collaboration to alleviate the ulcer formation by utilizing our compounds to disrupt 
enzymatic activity without altering the gut flora. 
 Additional studies are necessary to fully understand how our novel inhibitors affect 
enzymes that are related to β-glucuronidase.  To do this, many of the related enzymes can be 
purchased in lyophilized form from commercial retailers, as well as the detectable substrates.  
Furthermore, more rounds of high-throughput screening can be performed to discover more 
compounds that are potent at disrupting β-glucuronidase activity.  These compounds should 
undergo the same rigorous secondary validation and characterization in-house, and should 
also be used for co-crystallization studies to determine if they utilize the same bacterial loop 
as our inhibitors 1-4 or if they bind in another unique portion of the enzyme. 
 
β-GLUCURONIDASE ENZYMES FROM ADDITIONAL GUT BACTERIA 
 
Cloning, Expression, and Purification of Novel Gut Bacterial β-Glucuronidases 
 The β-glucuronidase genes from the B. fragilis, S. agalactiae, and C. perfringens 
were PCR amplified using the following primers, respectively: B. fragilis, Forward, 5’-
TACTTCCAATCCAATGCGATGAAAAAACTTTTAGCAGC-3’; Reverse, 5’-
TTATCCACTTCCAATGCGCTATTATTTTATTTTCTCAAAAATAGC-3’; S. agalactiae, 
Forward, 5’-TACTTCCAATCCAATGCGATGTTATATCCATTATTGAC-3’; Reverse, 5’-
TTATCCACTTCCAATGCGCTACTATTTTACACTATTTTTTTTATTATG-3’; C. 
perfringens, Forward, 5’-
TACTTCCAATCCAATGCGATGTTATATCCAATAATTACAGAATCAAG-3’, Reverse, 
5’-TTATCCACTTCCAATGCGCTATTATTTTTTGTATCCAAATTCCG-3’.  The B. 
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fragilis and C. perfringens gene was inserted into the MBP-LIC pMCSG vector and the S. 
agalactiae was put into the HIS-LIC pMCSG vector (both vectors acquire from the Sondek 
Lab, UNC-CH).   
 All three genes were expressed in a similar manner.  E. coli BL21 (DE3) AI cells 
were transformed with the vectors described above, LB media was inoculated with the 
transformed cells and allowed to shake at 37 °C until the OD600 was ~0.6.  The temperature 
was turned down to 17 °C, induced with 0.3 mM IPTG, and allowed to grow overnight.  
Cells were spun down and stored as previously described for the E. coli β-glucuronidase. Cell 
pellets were resuspended in Buffer A (25 mM HEPES, pH 7.4, 50 mM imidazole, 500 mM 
NaCl, 5% glycerol, and 0.5 mM TCEP), along with a protease inhibitor tablet (18) for each 
50 mL of lysis buffer. Resuspended cells were sonicated and centrifuged at 14,500xg for 30 
min in a Sorvall (model RC-5B) centrifuge to clarify the lysate. The cell lysate was flowed 
over a Ni-NTA His-Trap (GE Healthcare) column and washed with Buffer A. The Nickel-
bound protein was eluted with Buffer B (25 mM HEPES, pH 7.4, 250 mM imidazole, 500 
mM NaCl, 5% glycerol, and 0.5 mM TCEP). Collected fractions were then tested for initial 
purity by SDS-PAGE. For the MBP-fused C. perfringens β-glucuronidase, TEV protease was 
added to the protein and allowed to incubate and cleave the MBP tag for ~8 h prior to gel 
filtration purification. Relatively pure (~85%) fractions were combined and loaded into the 
Äktaxpress FPLC system (Amersham Biosciences) and passed over a HiLoad™ 16/60 
Superdex™ 200 gel filtration column. The protein was eluted into 20 mM HEPES, pH 7.4, 
100 mM NaCl, 5% glycerol, and 0.5 mM TCEP for crystallization and activity assays. Two 
milliliter fractions were collected based on highest ultraviolet absorbance at 280 nm. 
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Fractions were analyzed by SDS-PAGE (which indicated >95% purity, Figure 4.1), 
combined, and concentrated to ~10 mg/mL for long-term storage at -80 °C. 
 
Crystallization of New β-Glucuronidase Enzymes 
 The S. agalactiae and C. perfringens β-glucuronidase proteins were initially screened 
using the commericially available Qiagen PEGs I suite at 15, 10, and 5 mg/mL at 16 °C.  The 
initial hit for the S. agalactiae β-glucuronidase was 20% PEG3350 and 0.2 M KSCN (Figure 
4.2.A).  The C. perfringens β-glucuronidase was first crystallized in 30% PEG400 and 0.1 M 
MES pH 6.5 (Figure 4.2.B).  These initial conditions were optimized by varying the 
precipitant concentration, salt concentration or pH. 
 
Crystal Structure of Streptococcus agalactiae β-Glucuronidase 
The optimized S. agalactiae β-glucuronidase crystal conditions (Figure 4.3) resulted 
in two different crystal structures showing multiple conformations of the predicted bacterial 
loop region (see Figure 3.10).  Diffraction data was collected at APS using the GM/CA-CAT 
beamline, HKL-2000 (19) was used for data reduction, and Phaser (20) for molecular 
replacement using the native E. coli β-glucuronidase structure.  The two crystal structures 
solved of the S. agalactiae β-glucuronidase are shown in Figure 4.4.A.  The overall 
structures of the S. agalactiae β-glucuronidase are relatively unchanged when compared to 
the E. coli β-glucuronidase structures, with exceptions in the β-sheet region of the 
immunoglobin-like domain.  Calculated r.m.s.d. for the S. agalactiae and E. coli structure is 
1.58 Å over all atoms aligned (Figure 4.4.B). Although the N-terminal domains of the two 
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enzymes are highly conserved, the high r.m.s.d. is most likely indicative of the differences in 
the C-terminal β-sandwich domain. 
The bacterial loops of the S. agalactiae β-glucuronidase structures are in two different 
conformations, one for each structure (Figure 4.5.A).  When compared to the bacterial loop 
of the E. coli structures of the S. agalactiae β-glucuronidase structures we see that it is in a 
similar position as the native structure (Figure 4.5.B).  Although the entire loop was not able 
to be built as the majority was disordered, it is predicted to follow the same path as the E. 
coli structure.  Co-crystallization experiments will be conducted to crystallize the SABG 
enzyme with one of the 4 inhibitors discussed in CHAPTER 2 to see if the bacterial loop of 
the S. agalactiae enzyme becomes ordered and acts as the binding interface for these 
inhibitors as it is for the E. coli enzyme. 
 
ALLEVIATION OF ULCER FORMATION BY NSAID TOXICITY 
 
Diclofenac-Acyl-Glucuronide is a β-Glucuronidase Substrate 
 Expression and purification of E. coli β-glucuronidase was conducted as previously 
described (21). Diclofenac-acyl-glucuronide (DCF-AG) assays were performed at 50 μL total 
volume in 96-well assay plates (Costar). Reactions consisted of the following: twenty-five 
microliters Assay Buffer (2% DMSO, 100 mM NaCl, and 100 mM HEPES, pH 6.8), 15 μL 
substrate (DCF-AG, various concentrations), 5 μL of Inh-1 solution (various concentrations), 
and 5 μL of 5 nM enzyme.  Each reaction was quenched with trichloroacetic acid (TCA) to a 
final concentration of 10% TCA.  Samples were centrifuged at 13,000xg for 10 min to pellet 
the precipitate prior to sample detection. HPLC-UV detection of the DCF product was 
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carried out in a similar protocol as previously reported (22) using a Phenomenex Luna 5 μm 
C18 (23) reverse-phased HPLC column.  The AUC for the peak corresponding to the product 
DCF was calculated for each inhibitor concentration.  
 
Inhibitor 1 Disrupts β-Glucuronidase Conversion of DCF-AG to DCF 
To test the hypothesis that inhibitor 1 would prevent the enzymatic hydrolysis of 
luminal DCF-AG (Figure 4.6.A) by enteric bacterial β-glucuronidase, we first determined 
whether DCF-AG was a substrate for bacterial β-glucuronidase in vitro. Purified E. coli β-
glucuronidase converted DCF-AG (various concentrations) to its aglycone in vitro (Figure 
4.6.B). To assess the inhibition characteristics of inhibitor 1, we added increasing 
concentrations of the inhibitor to the incubation system containing 4 mM DCF-AG. Inhibitor 
1 decreased the release of free DCF in a concentration-dependent manner resulting in >90% 
inhibition at 100 μM inhibitor (Figure 4.6.B). The IC50 was calculated to be ~164 + 11 nM 
(n = 3 independent experiments). Previous studies had revealed that the inhibition of bacterial 
β-glucuronidase by inhibitor 1 exhibits uncompetitive characteristics (1). These data 
demonstrate that bacterial β-glucuronidase is involved in the hydrolytic cleavage of DCF-AG, 
and, secondly, that inhibitor 1 inhibits this reaction with a high potency in the low nanomolar 
range.  
 
FUTURE DIRECTIONS 
 
Effect of Inhibitors on Related Enzymes 
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 β-Glucuronidase is in the family 2 of glycosyl hydrolases, all of which use a 
conserved mechanism of enzymatic cleavage (24-27).  Additional enzymes outside of this 
family, such as β-galactosidase, β-mannosidase, and β-glucosidase, also utilize an acid/base 
and a nucleophile to hydrolyze a variety of sugar-linked metabolites and compounds (28-31).  
Each of these enzymes contains the generic α/β-barrel and has an overall similar structure to 
E. coli β-glucuronidase (see Table 3.2).  With these similarities, it is crucial to determine if 
our novel inhibitors affect the enzymatic activity of these other sugar hydrolyzing enzymes.  
Many of these enzymes can be purchased from commercial retailers, as well as the substrates 
that can be used to detect activity via fluorescence- or absorbance-based detection. 
 
Additional High-Throughput Screening 
 The original high-throughput screening of two libraries at NCCU-BRITE institute 
yielded many hits that have been further characterized in-house through activity assays and 
crystallization studies.  However, additional screening of other compound libraries could 
yield a number of other hits.  The newly developed Center for Integrative Chemical Biology 
and Drug Discovery at UNC contains a number of widely used chemical compound libraries 
that could be used to further screen for additional β-glucuronidase inhibitors.  Newly 
discovered compounds should be characterized in a similar way as inhibitors 1-4 of these 
previous studies. 
 
FIGURE LEGENDS 
 
Figure 4.1 SDS-PAGE gels of purified S. agalactiae β-glucuronidase, C. perfringens β-
glucuronidase, and B. fragilis β-glucuronidase.  Each protein was first purified 
by IMAC, followed by S200 gel filtration.  Both the S. agalactiae and C. 
perfringens enzyme achieved >95% purity.  The B. fragilis β-glucuronidase 
was determined to be >80% pure, however, other bands found on the gel were 
believed to be degraded protein. 
 
Figure 4.2 (A) Initial crystal hit of S. agalactiae β-glucuronidase.  This condition was 
composed to 20% (w/v) PEG3350 and 0.2 M potassium thiocyanate as well as 
10-15 mg/mL protein. (B) Initial crystal hit of C. perfringens β-glucuronidase.  
These crystals were grown in the presence of 30% (w/v) PEG400 and 0.1 M 
MES pH 6.5 and 10-15 mg/mL protein. 
 
Figure 4.3 Optimized crystals of the S. agalactiae β-glucuronidase. A grid optimization 
screen was prepared by varying the precipitant (PEG3350) and salt (potassium 
thiocyanate) concentration, as well as testing a range of protein to crystallant 
drop ratios to achieve well formed crystals. 
 
Figure 4.4 (A) Overall structures of the two solved versions of S. agalactiae β-
glucuronidase. One structure was determined in the space group I222 (left), 
with a 2.6 Å data limit, and one monomer in the ASU.  The other crystal 
structure was solved in the space group P21212, at 2.3 Å, with 2 monomers in 
the ASU. (B) Monomer overlay of the E. coli structure and the S. agalactiae 
structure. The secondary structure of these two structures proved relatively 
similar with an overall r.m.s.d of 1.58 Å over all atoms.  Deviations were 
mostly localized in the N-terminal region (β-sandwich domain) of each 
protein. 
 
Figure 4.5 (A) Structural overlay of the two S. agalactiae structures, focusing on the 
proposed loop region of each structure, showing both conformations. The I222 
loop region swings further out into the solvent region, and actually crosses 
paths with a symmetry mate in the crystal packing.  The P21212 loop is 
positioned much closer to the active site opening.  These two conformations 
suggest that this loop is mobile, and upon ligand binding, most likely adopts 
the position seen in the P21212 structure. (B) Overlay of the two S. agalactiae 
and inhibitor 2-bound E. coli β-glucuronidase structures, focusing on the 
bacterial loop region.  Although the loops in the S. agalactiae proved to be 
disordered in the structures, they appear to follow the same path as the E. coli 
loop, most notably that of the P21212 structure. 
 
Figure 4.6 (A) DCF-AG conversion to DCF catalyzed by bacterial β-glucuronidases; 
using inhibitor 1 prevents this reaction. Ideally, inhibitor 1 will prevent the 
88 
 
89 
 
hydrolysis of the glucuronidated-DCF to form DCF, which would prevent 
formation of ulcers. (B) HPLC results of the in vitro assay using DCF-AG as a 
substrate, as well as inhibitor 1 to disrupt enzyme activity.  The bar graph 
represents a dose-response of DCF formation, resulting from DCF-AG 
hydrolysis by β-glucuronidase, with increasing inhibitor 1 concentrations.  
DCF formation is severely disrupted with increasing amounts of the inhibitor, 
with a calculated IC50 of ~164 + 11 nM. 
 
 
 
 
 
Figure 4.1 SDS-PAGE gels of S200 gel purified S. agalactiae β-glucuronidase, C. 
perfringens β-glucuronidase, and B. fragilis β-glucuronidase. 
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Figure 4.2 (A) Initial crystal hit of S. agalactiae β-glucuronidase. (B) Initial crystal 
hit of C. perfringens β-glucuronidase. 
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Figure 4.3 Optimized crystals of the S. agalactiae β-glucuronidase. 
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Figure 4.4 (A) Overall structures of the two solved versions of S. agalactiae β-
glucuronidase. (B) Monomer overlay of the E. coli structure and the S. 
agalactiae structure. 
 
 
93 
 
Figure 4.5 (A) Structural overlay of the two S. agalactiae structures, focusing on the 
proposed loop region of each structure, showing both conformations. (B) 
Overlay of the two S. agalactiae and the inhibitor 2-bound E. coli β-
glucuronidase structures, focusing on the bacterial loop region.
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Figure 4.6 (A) DCF-AG conversion to DCF catalyzed by bacterial β-glucuronidases; 
using inhibitor 1 prevents this reaction. (B) HPLC results of the in vitro 
assay using DCF-AG as a substrate (DCF formation detected as μV*min), 
as well as inhibitor 1 to disrupt enzyme activity. 
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CHAPTER 5. 
Background on Xenobiotic Nuclear Receptors and Formation of the PXR.1/RXRα 
Complex 
 
INTRODUCTION 
 A vast array of enzymes are responsible for the biotransformation and metabolism of 
xenobiotics compounds in the human body.  The metabolism of xenobiotics occurs by three 
different methods, classified as Phase I, Phase II, or Phase III (1-5).  Phase I metabolism 
includes oxidation, reduction, hydrolysis, and hydration (6). Phase II involves conjugation of 
the xenobiotics by hydrophilic compounds to increase water solubility to facilitate excretion 
and removal from the body (6).  Phase III uses membrane-bound drug pumps that serve to 
inactivate and clear chemical compounds (5).   
 In the liver, the heme-containing family of enzymes known as cytochrome P450’s are 
mono-oxygenases involved in endobiotic and xenobiotics clearance.  Furthermore, they 
prepare xenobiotic compounds to be shuttled to the Phase II mechanism of metabolism (6). 
This system is utilized for the metabolism of not only xenobiotics compounds (drugs and 
other foreign compounds), but also of endogenous chemicals such as steroids, bile acids, 
hormones, and fatty acids (5, 7).  There are 57 known P450s expressed in the human genome, 
 
and of these, 15 are found to be involved in xenobiotic metabolism, including carcinogens, 
food additives, pollutants, pesticides, and other chemicals (7).  However, it has been noted 
that in the absence of such xeno- or endobiotic compounds, the basal expression of the P450 
family is quite low.  Furthermore, in the presence of these substrates, their expression is 
greatly elevated (8, 9).   
 These drug metabolizing enzymes are critically involved in clinically significant 
drug-drug interactions, and the mechanism of these interactions are derived from the drug-
induced increase in expression of the P450 enzymes.  As such, other drugs that are 
metabolized by the now induced protein will have altered characteristics, possibly resulting 
in adverse or negative effects.  This upregulation of the P450 class of enzymes is mediated 
by a group of proteins known as orphan nuclear receptors.  These orphan nuclear receptors 
are related to nuclear hormone receptors, but are distinguished in that there are no previously 
identified physiological ligands (5).  
 Over the last several years, it has come to light that two closely related nuclear 
receptors, the pregnane x receptor (PXR) and the constitutive androstane receptor (CAR), are 
xenobiotic sensors that regulate the induction of the drug clearance pathways involving the 
P450 family of enzymes.  CHAPTER 5 and 6 will focus on the orphan nuclear receptor PXR. 
 
THE ORPHAN NUCLEAR RECEPTOR PXR 
 The nuclear pregnane x receptor (PXR; NR1I2, also referred to as SXR and PAR (10-
12) is a member of the nuclear receptor subfamily 1, group I, member 2 sub-section of 
ligand-dependent transcriptional factors.  It is a key regulator for genes involved in 
xenobiotic and endobiotic metabolism, originally characterized as critical in the role or 
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detecting endogenous pregnanes (13).  Since then, it has subsequently been classified as a 
central xenobiotic sensor that responds to a number of pharmaceutically relevant compounds 
and drugs.   
 PXR is expressed predominantly in the liver, with the second most prevalent being 
the GI tract.  It is activated by a wide range of structurally unique ligands that are known to 
induce the upregulation of cytochrome P450 (CYP450) genes relevant to drug metabolism.  
A few of these compounds include phenobarbital, rifampicin, dexamethasone, hyperforin, 
and a number of other ligands (Table 5.1) (12-14).  Several Phase I drug metabolism genes 
are induced through PXR activation including the CYP450s, carboxylesterases, and 
dehydrogenases (13-21). In addition, PXR has been shown to also control Phase II drug 
metabolizing genes such as those that encode the UDP-glucuronosyltransferases and 
glutathione-S-transferases (22-26), and furthermore, is known to regulate the Phase III drug 
efflux pumps multidrug resistance protein 1 and multidrug resistance protein 2 (18, 27, 28). 
 In addition to xenobiotic-induced activation, PXR regulation is also derived from 
endogenous ligands, including pregnanes, bile acids, hormones, and vitamins (11, 13).  These 
endobiotic ligands control the induction of a number of genes involved in bile acid 
metabolism and transport, cholesterol homeostasis, and protection from toxic endobiotics. 
 
PXR Ligand and Coregulator Binding 
 PXRs from a variety of species are all known to be promiscuous and can bind a wide-
reaching set of xenobiotic and endobiotic compounds.  These compounds vary in chemical 
make-up, molecular weight, and overall size in the 3-dimensional space.  Ligand binding 
assays performed using scintillation binding assays (29) show that PXR is activated by the 
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direct binding of compounds within its flexible ligand-binding cavity.  A few PXR agonists, 
shown in Table 5.1, include the cholesterol drug SR12813, the antibiotic, rifampicin, as well 
as the active agent of St. John’s wort, hyperforin.  These ligands clearly differ in shape, size, 
and chemical functional groups.  The promiscuity of PXR’s ligand binding has proven to be 
unique to this nuclear receptor (10), and X-ray crystallographic studies (19, 30, 31) reveal a 
novel insert in the ligand binding domain (LBD) as well as a highly malleable ligand binding 
pocket, offering detailed insight into the promiscuous nature of PXR. 
 PXR was found to interact with SRC-1 (nuclear receptor coactivator 1) (13), a 
member of the p160 family of coactivators that bind in a ligand-dependent fashion to various 
nuclear receptors utilizing a Leu-X-X-Leu-Leu repeat (X=any amino acid) (32). Ligand 
binding induces a conformational change of the activation function 2 (AF-2) region of the C-
terminus of the LBD creating an appropriate binding cleft for the SRC-1 peptide to bind (30, 
31).  There are a number of other coactivators of the p160 family and the p300 family known 
to bind to PXR (33, 34), as well as a variety of corepressors found to bind to PXR, the impact 
of which has yet to be determined (18). 
 
PXR-LBD Crystal Structures 
 Several crystal structures of the LBD of PXR have been elucidated in the unliganded 
as well as the liganded-state.  These complexes include PXR bound with SR12813, 
Rifampicin, Hyperforin, as well as PNU-142721 (19, 30, 31, 35).  In addition to various 
ligands co-crystallized with the LBD, structures have been determined in the presence and 
absence of the SRC-1 peptide. 
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 Detailed structural analyses of the many PXR LBD crystal structures have been 
published a number of times (19, 30, 31, 36).  The overall fold of the PXR LBD consists of a 
three-layered α-helical sandwich that enclosed a large conformable ligand binding pocket 
(Figure 5.1.A).  Five-stranded antiparallel β-sheets lie adjacent to the ligand binding pocket.  
These β-sheets are particularly unique to PXR, as many nuclear receptors only contain 2-3 
stranded β-sheets (36).  In addition, this particular secondary structural element leads to the 
formation of a unique PXR homodimer, seen in nearly every PXR LBD structure (Figure 
5.1.B). 
 It is evident when comparing the SR12813-bound and the rifampicin-bound PXR 
LBD structures how this unique nuclear receptor is able to accommodate such a variety of 
ligands (Figure 5.2.A).  An overlay of these structures shows that three regions of the LBD 
become disordered to create the space necessary to facilitate binding of rifampicin.  These 
regions include residues 229-235, 309-321, and 192-210 (Figure 5.2.B). 
 Six amino acids are shown to consistently be involved in protein-ligand interactions 
in human PXR LBD-liganded structures: Ser247, Gln285, His407, Met243, Trp299, Phe420.  
With the variety of co-crystal structures of PXR elucidated, a number of other residues are 
shown to either interact with the ligand or to be positioned to far away from the bound-ligand 
depending on the shape of the ligand binding pocket (36).  As with other nuclear receptor 
LBDs, the AF-2 region of PXR is responsible for binding LxxLL motifs found in 
transcriptional coactivators, or the I/LxxI/VI motifs in corepressors (37).  The LxxLL motif 
of the SRC-1 peptide forms an α-helix motif binding the AF-2 region of PXR’s LBD through 
hydrophobic interactions (Figure 5.3).  Upon coactivator binding, the malleability of the 
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ligand binding pocket of PXR is believed to become more restricted, stabilizing ligand 
binding into a single conformation (36). 
 
NUCLEAR RECEPTOR CROSS-TALK AND PXR/RXRα TERTIARY COMPLEX 
 
Functionality Overlap with CAR 
 Both PXR and CAR have been classified as xenobiotics receptors through a number 
of previous studies (38). These two nuclear receptors overlap functionally in terms of ligand 
binding and gene activation.  Previous studies have shown that certain ligands, for example, 
phenobarbital, lead to distinct modes in CYP2B and CYP3A expression (39). In addition, it 
was shown that PXR and CAR could both be activated by this ligand to affect CYP450 
expression (14).  There has been divergence between the two nuclear receptors, as PXR was 
found to mainly regulate CYP3A genes (11, 13, 14) and CAR the CYP2B genes (40); 
however, both nuclear receptors are activated by the same ligand, phenobarbital. Further 
similarities in ligand activation have been determined with both xenobiotics and endobiotic 
compounds.  This includes rifampicin, which has been shown to activate both nuclear 
receptors in previous studies (41). 
 This overlap in functionality between CAR and PXR also extends to DNA binding. 
Studies show that PXR can utilize CAR’s response element along the CYP2B gene promoter 
region, and vice versa in the CYP3A gene (21).  It is evident that these two closely related 
nuclear receptors work in tandem to control target gene expression through similar ligand 
binding and DNA response element sequences. 
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RXRα is a Binding Partner for PXR 
 As with many nuclear receptors, PXR forms a higher order oligomer with RXRα.  In 
complex with RXRα, many nuclear receptors are found to bind to a number of response 
elements including direct repeats (DR) and everted repeats (ER) and PXR is no exception.  
PXR is known to bind to several response elements, several of which are listed in Table 5.2. 
Crystal structures of various RXRα/NR heterodimeric complexes have been solved to date 
(42, 43), including the PPARγ/RXRα and the RARα/RXRα LBD structures. However, only 
one full-length RXRα complex with PPARγ bound to DNA has been solved (44). 
 Of interest is how the RXRα/PXR complex is formed on duplex DNA containing 
response elements.  As PXR forms a strong homodimer, it is a possibility that the 
biologically relevant complex of these two nuclear receptors could take the form of a 
heterotetramer, which would prove to be unique in comparison to the other NR/RXRα 
complexes. 
 
EXPRESSION AND PURIFICATION OF PXR.1/RXRα 
 
Codon Optimization, Cloning, and Expression of PXR.1 and RXRα 
 Prior knowledge in the Redinbo lab of PXR-LBD expression suggests that the full-
length receptor would be far more difficult to express in a soluble, well-folded form and in 
suitable quantities for DNA binding and crystallization experiments.  Initial attempts to 
express the full-length genes of both PXR.1 and RXRα resulted in ~0.3 mg/L of PXR and ~5 
mg/L of RXRα (Table 5.3). Sequence analysis of both the human PXR.1 and RXRα gene 
showed that over 12% of the codons are rare.  In addition, the SRC-1 peptide fragment has 
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previously been shown to facilitate PXR-LBD expression (30, 45), and so co-expression of 
the SRC-1 fragment was crucial for protein expression.  However, instead of co-expression 
of the SRC-1 peptide as was previously done in the Redinbo lab (30, 35, 46-49), a tethered 
version was constructed by fusing a glycine-serine linker at the end of the protein followed 
by the SRC-1 fragment.  Literature has demonstrated that this technique is successful at 
producing soluble, stable protein, permanently linked to the SRC-1 coactivator (45). To 
increase protein expression, codon optimization using the services of GenScript was utilized 
to construct each gene, with the addition of the tethered SRC-1 fragment. 
Both genes were cloned in the MBP-LIC pMCSG vector, as the MBP-fusion would 
help the stability and solubility of the proteins as they are being expressed.  The following 
cloning primers were used for PXR.1: Forward, 5’-
TACTTCCAATCCAATGCGATGACCGTGACGCGTACCCAT-3’; Reverse, 5’-
TTATCCACTTCCAATGCGCTATTAAGACGGGCTACCTTCCTGCAG-3’.  RXRα was 
also PCR amplified and inserted using the following primers: Forward, 5’-
TACTTCCAATCCAATGCGATGGATACCAAACATTTCCTGCCGCTG-3’; Reverse, 5’-
TTATCCACTTCCAATGCGCTATTAACTCGGAGAGCCTTCCTGCAG-3’.  E. coli BL21 
(DE3) AI cells were transformed with either the PXR.1 or RXRα plasmid for protein 
expression.   
Terrific broth media was inoculated with a saturated culture of BL21 AI cells 
transformed with the MBP-PXR.1 plasmid and allowed to shake at 37 °C.  When the cells 
reach and OD600 of ~1.4-1.6 the temperature was turned down to 15 °C.  At ~17 °C L-
arabinose was added to each flask up to a final concentration of 0.1%.  When the temperature 
achieved 15 °C, IPTG was added (final concentration of 1 mM) to induce protein expression.  
106 
 
After shaking overnight, cells were collected by centrifugation at 4,500xg for 20 min and 
stored at -80 °C.  These growths yielded on average 2-3 mg/L of PXR.1 protein (Table 5.3). 
The growth and expression of RXRα was carried out in a similar manner as PXR.1 
described above.  When the RXRα growth achieved an OD600 of ~1.4-1.6, the temperature 
was reduced to 17 °C.  A final concentration of 0.1% L-arabinose was added when 
temperature reached ~19 °C, and expression was induced at 17 °C with a final concentration 
of 1 mM IPTG.  With this protocol, ~10 mg/L of RXRα is produced on average (Table 5.3). 
 
Purification of PXR.1 and RXRα 
 PXR.1 and RXRα were each purified similarly but individually prior to complex 
formation. Cell pellets were resuspended in Buffer A (50 mM HEPES pH 7.5, 50 mM 
imidazole, 500 mM NaCl, 10% glycerol) supplemented with a protease inhibitor tablet 
(Roche), DNase, and lysozyme.  After sonication, the cell lysate was clarified by high-speed 
centrifugation at 14,500xg for 50 mins.  The supernatant was removed and syringe filtered 
through a 0.22 um filter.  For PXR.1 purifications, an excess amount of ligand was added to 
the lysate to help stabilize the protein throughout the purification process.  Clarified lysate 
was loaded onto the Äktaxpress FPLC system (Amersham Biosciences) for a step-
purification, up to 500 mM imidazole, on Ni His-Trap (GE Healthcare) columns.  Purest 
fractions (determined by SDS-PAGE, Figure 5.4.A) were combined and concentrated as 
much as possible without destabilizing the protein.  While concentrating PXR.1, additional 
ligand was added periodically to compensate for any ligand washed away during Ni-column 
purification.  Concentrated samples were loaded on the FPLC system for sizing purification 
using a HiLoad™ 16/60 Superdex™ 200 gel filtration column.  Each protein was eluted into 
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20 mM Tris-HCl pH 7.5, 250 mM NaCl, 1 mM TCEP, and 5% glycerol.  Purity of each 
fraction was assessed by SDS-PAGE and fractions of >95% purity were combined (Figure 
5.4.B). 
 After each protein was individually purified, 5 mL reactions were prepared to form 
the PXR.1/RXRα complex for a final round of gel filtration.  One reaction consisted of 30 
μM each of PXR.1 and RXRα, 5-times excess of PXR ligand, 2-times excess of the RXRα 
ligand 9-cis-retinoic acid.  TEV protease was also added to the reaction to cleave the MBP-
fusion tag from each protein.  The complex formation reactions were directly injected onto 
the S200 gel filtration column after a >8 h incubation at 4 °C to allow complete cleavage to 
occur. Two peaks eluted from the sizing column (Figure 5.5.A), the first being the 
PXR.1/RXRα complex and the second the now cleaved MBP-fusion tag.  This reaction 
protocol for complex formation yielded the purified hetero-complex, without DNA, as 
assessed by SDS-PAGE (Figure 5.5.B) showing two protein bands representing PXR.1 and 
RXRα.  Alternate reactions were also prepared that included 1.5-times excess duplex DNA 
containing various HREs, of which the PXR.1/RXRα has been shown to bind (50, 51).  
 
 
 
Table 5.1 List of three major xenobiotics ligands that PXR has been shown to bind 
with high affinity.  This small subset of ligands describes the type of 
variety of compound that PXR binds, further supporting the 
promiscuous nature of this nuclear receptor. In addition, there are many 
similar interacting residues shared with each ligand. 
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Table 5.2 Subsection of the hormone response elements that PXR is known to bind 
(50).  Each sequence is composed of two 6-base response element half-
sites, divided by spacer DNA bases.  Each type of sequence leads to the 
upregulation of a different type of CYP. 
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Table 5.3 Optimization of expression of PXR and RXRα.  Both gene sequences 
were optimized for codon usage using the services at GenScript.  In 
addition, protein growth was further optimized by using TB media 
instead of LB media.  The fusion protein MBP was also utilized to 
improve stability and solubility to increase yield of well-folded, soluble 
protein. 
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FIGURE LEGENDS 
 
Figure 5.1 (A) PXR LBD monomer, with secondary structural elements label, and unique 
structural features colored (36). The coactivator peptide fragment SRC-1 is 
colored in cyan, and structural features unique to the nuclear receptor PXR are 
colored magenta. The ligand binding site is occupied with the SR12813 ligand 
(red). (B) The PXR LBD homodimer seen in many of the crystal structures 
solved of the LBD in complex with the SRC-1 peptide fragment.  This 
homodimeric form of PXR is also unique to this nuclear receptor, as other 
similar proteins (CAR, for example) are only monomeric receptors. 
 
Figure 5.2 (A) Overlay of the SR12813-bound PXR LBD structure (cyan, PDB ID 
1NRL) and the Rifampicin-bound structure (magenta, PDB ID 1SKX), with 
residues 193-209 highlighted in the SR12813-bound structure, but missing in 
the Rifampicin-structure. The LBD of PXR must swing residues 193-209 out 
of the pocket to accommodate the larger Rifampicin compound, and, in doing 
so, these residues become disordered and are not resolved in the electron 
density. (B) Close-up view of the Rifampicin-bound structure, with three 
regions (yellow) that become disordered to accommodate Rifampicin (36). Of 
the 193-209 stretch of residues ordered in a α-helical fashion in the SR12813 
structure (see Figure 5.2.A) only the 200-209 range is ordered. 
 
Figure 5.3 The SRC-1 peptide LxxLL motif (orange, residues 682-696) bound to the AF-
2 region of the LDB of PXR; highlighted are hydrophobic interactions (cyan) 
and electrostatic interactions (magenta). Lys259 and Glu427 form electrostatic 
interactions with various main chain elements along the SRC-1 fragment.  The 
three Leucines in the LxxLL motif constitute the main hydrophobic 
interactions between the coactivator fragment and the AF-2 region of PXR. 
 
Figure 5.4 (A) SDS-PAGE gels from Ni-column purifications of MBP-PXR (left) and 
MBP-RXRα (right). Eluted samples were collected and concentrated in 
preparation for the following gel filtration purification. (B) SDS-PAGE gels 
from S200 gel filtrations purification of MBP-PXR (left) and MBP-RXRα 
(right) showing >95% purity for each protein.  Both proteins were purified 
separately prior to ternary complex formation to ensure complete removal of 
any degraded protein. 
 
Figure 5.5 (A) Chromatogram from a S200 gel purification of the full-length complex 
reaction of PXR.1 and RXRα after TEV protease cleavage of the MBP-fusion 
tag. The first eluted peak at ~67 mL represents the PXR/RXRα protein 
complex, calculated as being the heterotetramer form of the complex. The 
second eluted peak at ~92 mL is the TEV-cleaved MBP-fusion tag now 
removed from PXR and RXRα. (B) SDS-PAGE denaturing gel analysis of the 
peak fractions from S200 purification of the PXR/RXRα complex showing the 
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presence of both proteins.  The complex was assessed to be >95% pure after 
the final round of gel filtration purification and TEV cleavage. 
 
 
 
 
 
 
 
 
Figure 5.1 (A) PXR LBD monomer, with secondary structural elements labeled, and 
unique structural features colored (36). (B) The PXR LBD homodimer 
seen in many of the crystal structures solved of the LBD in complex with 
the SRC-1 peptide fragment. 
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Figure 5.2 (A) Overlay of the SR12813-bound PXR LBD structure (cyan, PDB ID 
1NRL) and the Rifampicin-bound structure (magenta, PDB ID 1SKX), 
with residues 193-209 highlighted in the SR12813-bound structure, but 
missing in the Rifampicin-structure. (B) Close-up view of the Rifampicin-
bound structure, with three regions (yellow) that become disordered to 
accommodate Rifampicin (36). 
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Figure 5.3 The SRC-1 peptide LxxLL motif (orange, residues 682-696) bound to the 
AF-2 region of the LBD of PXR; highlighted are hydrophobic 
interactions (cyan) and electrostatic interactions (magenta). 
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Figure 5.4 (A) SDS-PAGE gels from Ni-column purifications of MBP-PXR (left) and 
MBP-RXRα (right). (B) SDS-PAGE gels from S200 gel filtration 
purification of MBP-PXR (left) and MBP-RXRα (right) showing >95% 
purity for each protein. 
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Figure 5.5 (A) Chromatogram from a S200 gel purification of the full-length 
complex reaction of PXR.1 and RXRα after TEV protease cleavage of the 
MBP-fusion tag. (B) SDS-PAGE denaturing gel analysis of the peak 
fractions from the S200 purification of the PXR/RXRα complex showing 
the presence of both proteins. 
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CHAPTER 6. 
PXR/RXRα DNA Binding and Crystallization Trials 
 
INTRODUCTION 
 To date, a number of LBD crystal structures have been solved of the nuclear receptor 
PXR bound with a number of distinct ligands. Crystal structures of RXRα LBD in complex 
with other nuclear receptor LBD’s have been successfully crystallized.  However, only one 
crystal structure of a full-length, intact nuclear receptor complex (PPARγ/RXRα) has been 
determined (1).  The 3-dimensional structural determination of PXR has been limited to the 
LBD and only of the homodimer. Further understanding how PXR regulates xenobiotic 
metabolism requires a more in-depth knowledge of the interactions made between PXR and 
its binding partner RXRα, and how this nuclear receptor complex interacts with various 
hormone response elements through their DBD. 
 To our knowledge, we are the first lab to successful purify appreciable quantities of 
the full-length PXR.1, with high purity, to be suitable for biochemical and structural analysis.  
Furthermore, we have successfully purified the PXR/RXRα complex to be analyzed for its 
DNA binding properties in the presence of a number of different PXR ligands, as well as for 
crystallization trials. The PXR/RXRα LBD complex has been elucidated recently in the 
Redinbo Lab, revealing a novel oligomeric state in the nuclear receptor field.  A 
 
heterotetramer complex was formed, with a PXR LBD homodimer bound by two RXRα 
LBD monomers. Attempts to crystallize the full-length complex has proved unsuccessful, 
however, further methods are being utilized to overcome this obstacle.  Presented in this 
chapter are the first in vitro DNA binding assays for the full-length PXR/RXRα complex, as 
well as methods for the crystallization of the LBD nuclear receptor complex. 
 
DNA BINDING ASSAYS 
 
Fluorescence Anisotropy Binding Assays 
With the full-length PXR.1/RXRα complex purified, we were able to begin testing 
how well the complex binds to various hormone response elements (HREs) in the presence of 
two known PXR ligands, SR12813 and rifampicin. In addition, the SRC-1 co-activator 
fragment was tethered to the end of each nuclear receptor.  Several different types of duplex 
DNA containing HREs were procured to test the binding affinity for each type of HRE as 
well as to assess the necessity of flanking bases on each side of the HRE repeats.  The 
sequences of each duplex DNA tested are listed in Table 6.1. 
 Two DNA binding assays were utilized to measure binding of the nuclear receptor 
complex to HREs.  The first assay used fluorescein-labeled duplex DNA (Table 6.1) to 
measure the dissociation constant, Kd, for a DR3 and ER6 type DNA from the CYP3A4 
promoter region.  These pieces of DNA contained the minimum number of bases to create 
the repeat.  This DNA binding assay consisted of 16 different concentrations of the complex, 
starting at a maximum of 5 μM with 3 dilutions at a 0.6 dilution factor, 7 at a 0.8 dilution 
factor, and 5 additional dilutions at a 0.6 dilution factor.  The 16th concentration was a zero-
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protein control.  Twenty-five microliters of the total assay volume consisted of the nuclear 
receptor complex and the assay buffer, which was configured to create a final NaCl 
concentration of 100 mM.  Another 25 μL of a DNA probe solution (50 nM), for a final 
concentration of 50 nM, was added, making the final reaction volume 50 μL.  Fluorescence 
anisotropy was detected using a PHERAstar Plus microplate reader (BMG Labtech).  Data 
acquired was analyzed using Microsoft Excel and Sigmaplot 11.0.  
 Shown in Table 6.2 are the calculated Kd, dissociation constant, values for the 
fluorescein-labeled CYP3A4, DR3 and ER6 piece of DNA.  These pieces of DNA contain 
the minimum hormone response element (labeled in red, Table 6.2) as well as the 3-base 
spacer in between the direct repeat.  The CYP3A4 DR3 piece of DNA was found to have a kd 
of 206 ± 53.2 nM and the CYP3A4 ER6 DNA has a kd of 215 ± 36.1 nM (Figure 6.1). These 
values were utilized in the following experiments to calculate the Ki values for each 
competitor DNA substrate.   
 
Competition DNA Binding Assays 
 The second DNA binding assay is competition-based to measure the binding of 
several pieces of duplex DNA with different lengths of flanking bases (Table 6.1) in addition 
to the minimum HRE repeats.  This assay was composed of a constant protein concentration 
(200 nM) and a constant concentration of fluorescein-labeled duplex DNA (50 nM).  A range 
of DNA competitor concentrations was used in each assay, with a max concentration of 10 
μM and 15 dilutions at a factor of 2.  Total reaction volume is 50 μL and the final NaCl 
concentration is 100 mM.  Data was collected and analyzed as with the first DNA binding 
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assay described above.  For each competitor the Ki values were calculated using the Cheng-
Prusoff equation (2). 
 Inhibition constants, Ki, were calculated for each competitor using the Kd values for 
the DR3 and ER6 minimum duplex DNA as the substrate affinity.  Table 6.3 lists the Ki 
values with standard error for the competitors.  With several flanking bases added to both the 
5’ and 3’ end of these competitors, the binding affinities for these pieces of DNA were strong, 
with values in the 80-130 nM range (Table 6.3).  Previous studies have suggested that the 
strength of the nuclear receptor complex binding to DNA is improved upon the addition of 
these flanking bases found in the CYP3A4 promoter region (1, 3-5).  A detailed examination 
of the only known full-length nuclear receptor-DNA complex crystal structure 
(RXRα/PPARγ/DR1) (1) reveals that there are key electrostatic interactions made between 
the hinge-region of both nuclear receptors and the DNA bases just outside of the response 
element region (Figure 6.2). 
 It should also be noted that cutting into the response element repeat regions on one 
side or the other does slightly deter the formation of the complex, as evidenced by the 
weakening of the inhibition constants of these competitors, DR3 -2/+9, DR3 +9/-2, DR3 -2/-
2, ER6 -2/+9, ER6 +9/-2, ER6 -2/-2 (Table 6.3).  Furthermore, removing bases on both ends 
of the direct or everted repeat response regions completely abolishes DNA binding (Table 
6.3). 
 
FULL-LENGTH PXR.1/RXRα/DNA CRYSTALLIZATION TRIALS 
 
Full-length PXR.1/RXRα/DNA Crystal Trials 
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 Several crystallization trials were conducted in an attempt to elucidate the full-length 
crystal structure of the PXR/RXRα complex bound to DNA. Complexes were purified with 
various forms of DNA (Table 6.4) containing the DR3 and ER6 response elements from the 
CYP3A4 promoter region.  The final round of gel filtration purification with the inclusion of 
DNA was performed to increase homogeneity of the complex samples and to remove any 
excess DNA and extraneous PXR or RXRα protein that may have been in excess. A wide 
range of commercially available crystallization screens were setup from Qiagen (Nucleix, 
PEGs I, PEGs II, Classics Lite, PACT, pH Clear, ComPAS, and JCSG+) and Hampton 
Research (PEGRx, PEG/Ion, Index, Crystal Screen).  Various complex concentrations were 
tested, ranging from 2 to 10 mg/mL, as well as three different incubation temperatures, 4 °C, 
16 °C, and 20 °C. 
 A number of forms of duplex DNA were tested to encourage strong packing and thus, 
crystallization (Table 6.4). Sticky-ended, duplex DNA was constructed to facilitate the 
ordering of complexes in a relatively linear fashion, which has been done successfully in 
previous crystallization experiments (6, 7). Both 1- and 2-base sticky ends were purchased 
(Integrated DNA Technologies) for the DR3 and ER6 response element. Theoretically, after 
the nuclear receptor complex, binds the DNA and is subjected to various precipitants and 
crystallization conditions, the sticky ends of the DNA would anneal to adjacent sticky ends, 
encouraging a linear-order of packing. 
 In addition to purification in the presence of DNA, the complex was purified without 
any DNA.  The PXR/RXRα complex was successfully stabilized and purified without DNA.  
This allowed testing of multiple DNA substrates simultaneously with only one round 
complex preparation, whereas purifying with DNA would only allow a single or possibly two 
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types of DNA.  However, purification without DNA did lead to a lower purity of the final 
complex, as the lack of stabilizing DNA-binding, eventually would lead to protein 
degradation over time.  DNA-free complex was also subjected to similar commercial crystal 
screens, with similar variances in testing, including temperature, protein concentration, and 
DNA sequence and form. 
 The results from the vast amount of crystal screening proved unsuccessful with no 
crystal growth.  However, many of the conditions in the 4 °C and 16 °C temperatures 
generally yielded phase separation, with occasional nucleation.  Observations of the drop 
setups revealed most of the protein complex would precipitate immediately upon addition to 
the crystal condition.  Most likely, this resulted in the dissociation of the two proteins and 
DNA from each, and may have been unable to re-associate after drop equilibration, resulting 
in no nucleation or crystal growth.  
 
New Crystallization Constructs of PXR.1 and RXRα 
 Secondary structure analysis using Phyre (Figure 6.3, (8)) revealed a majority of the 
N-terminus of both PXR and RXRα to be highly disordered up to the first cysteine in the first 
Zinc-finger domain of both proteins. In addition, further investigation of the full-length 
RXRα/PPARγ crystal structure shows that this N-terminal region is indeed disordered, and 
was unable to be placed into any electron density (Figure 6.4).  As such new constructs for 
both PXR and RXRα were generated to remove portions of the disordered N-terminus, and 
potential obstacles to crystal packing. 
 Two new RXRα protein constructs and one new PXR construct were generated, listed 
in Table 6.5.  The following primers were used to mutate the full-length genes to create the 
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new protein constructs: RXRα11, Fwd 5’-
CCTGTACTTCCAATCCAATGCGTTTAGCACGCAGGTGAACAGCTCTC-3’, Rev 5’-
GAGAGCTGTTCACCTGCGTGCTAAACGCATTGGATTGGAAGTACAGG-3’; 
RXRα129, Fwd 5’-TACTTCCAATCCAATGCGAGTTTCACCAAACACATTTGCGC-3’, 
Rev 5’-TTATCCACTTCCAATGCGCTATTAACTCGGAGAGCCTTCCTG-3’; PXR28, 
Fwd 5’-
TACTTCCAATCCAATGCGAGTGTTAATGCCGATGAAGAAGTGGGCGGTCCGCAG-
3’, Rev 5’-
CTGCGGACCGCCCACTTCTTCATCGGCATTAACACTCGCATTGGATTGGAAGTA-
3’. A number of new complexes were produced using the new crystallization constructs 
(Table 6.5), purified without DNA and put through various crystallization trials. Of all the 
new crystallization constructs tested, only the PXR/RXRα11 revealed potential crystal hits. 
Microcrystals were observed to grow in a condition from the Nucleix screen (4 M lithium 
chloride, 0.01 M magnesium chloride, 0.05 M HEPES pH 7.0) and small needle clusters 
from a conditions in the Classics Lite screen (0.1 M magnesium formate) (Figure 6.5.A-B). 
 Attempts to optimize these initial crystal hits have proved unsuccessful.  Both hits, 
from the Nucleix and Classics Lite screen, were never reproduced or optimized after grid 
screening with varying precipitant and salt concentrations.  In addition, several different 
protein concentrations and drop ratios were tried, but all proved fruitless.  
 
CRYSTALLIZATION OF PXR/RXRα LBD COMPLEX 
 
Expression of the PXR/RXRα LBD Complex 
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 The PXR LBD (residues 130-434) was PCR amplified from the full-length, codon-
optimized PXR.1 gene fused to a 5-residue glycine-serine linker and the SRC-1 coactivator 
fragment by Dr. Laurie Betts, currently a staff scientist in the Redinbo Lab. This construct 
was previously used in successful crystallization studies for the PXR LBD (9). The PXR 
LBD construct was cloned into the HIS-LIC pMCSG vector for protein expression. RXRα 
LBD (residues 227-462) was PCR amplified from the full-length, codon-optimized RXRα 
gene fused to the same glycine-serine linker with the SRC-1 coactivator fragment. The 
RXRα LBD was transformed into a pET-30b expression vector, without a His-tag fused to 
the protein. 
Terrific broth media was inoculated with a saturated culture of BL21 AI cells 
transformed with the HIS-LIC plasmid containing the PXR LBD construct and allowed to 
shake at 37 °C.  When the cells reach and OD600 of ~1.0 the temperature was turned down 
to 16 °C.  At ~16 °C L-arabinose was added to each flask up to a final concentration of 0.1%.  
When the temperature achieved 16 °C, IPTG was added (final concentration of 0.2 mM) to 
induce protein expression.  After shaking overnight, cells were collected by centrifugation at 
4,500xg for 20 mins and stored at -80 °C.  
The growth and expression of RXRα LBD was carried out in a similar manner as the 
PXR LBD described above.  When the RXRα LBD growth achieved an OD600 of ~1.0, the 
temperature was reduced to 16 °C.  A final concentration of 0.1% L-arabinose was added 
when temperature reached ~16 °C, and expression was induced at 16 °C with a final 
concentration of 0.2 mM IPTG. 
 
Purification of the PXR/RXRα LBD Complex 
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 PXR LBD and RXRα LBD protein was co-purified to encourage complex formation.  
In an approximate 3:1 PXR to RXRα cell ratio, cell pellets were resuspended in Buffer A (50 
mM HEPES pH 7.5, 30 mM Imidazole, 250 mM NaCl, 5% glycerol) supplemented with a 
protease inhibitor tablet (Roche), DNase, and lysozyme.  After sonication, the cell lysate was 
clarified by high-speed centrifugation at 14,500xg for 50 min.  The supernatant was removed 
and syringe filtered through a 0.22 um filter.  PXR and RXRα LBD cell lysates were 
combined prior to further purification. Excess amount of PXR ligand was added to the lysate 
to help stabilize the protein throughout the purification process.  Clarified lysate was loaded 
onto the Äktaxpress FPLC system (Amersham Biosciences) for a gradient-elution using 
Buffer B (50 mM HEPES pH 7.5, 300 mM imidazole, 250 mM NaCl, 5% glycerol) on Ni 
His-Trap (GE Healthcare) columns.  Excess RXRα LBD protein was washed away at low 
concentrations of Buffer B during the gradient elution as this protein was untagged.  Purest 
fractions (determined by SDS-PAGE, Figure 6.6.A) were combined and concentrated as 
much as possible without destabilizing the protein.  While concentrating the PXR/RXRα 
LBD complex, additional ligand was added periodically to compensate for any ligand 
washed away during Ni-column purification.   
LBD complex was dialyzed overnight into a TEV cleavage/Gel filtration buffer (25 
mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT, and 5% glycerol) in the presence of TEV 
protease to cleave the His-fusion tag from the PXR LBD.  Samples were concentrated and 
loaded on the FPLC system for sizing purification using a HiLoad™ 16/60 Superdex™ 200 
gel filtration column.  Each protein was eluted into 25 mM HEPES pH 7.5, 150 mM NaCl, 1 
mM DTT, and 5% glycerol.  Purity of each fraction was assessed by SDS-PAGE and >95% 
pure fractions were combined (Figure 6.6.B). 
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Crystallization and Structural Determination of the PXR/RXRα LBD Complex 
 Purified PXR/RXRα LBD complex was shipped to the Hauptman-Woodward 
Medical Research Institute in Buffalo, NY to screen several crystallization conditions using 
their automated crystallization setup.  An initial crystal hit was found in 20% (w/v) PEG 
8000, 0.1 M magnesium chloride, and 0.1 M bis-tris propane pH 7.0 at 4 °C.  Crystallization 
optimization was carried out in-house, by setting up grid optimization screens around the 
original hit condition.  Varying precipitant concentration, salt concentration, and protein to 
crystallant drop ratio was successful in reproducing these crystals (Figure 6.7). 
 Additional crystallization optimization experiments were performed to improve 
crystal growth, as these crystals grew as 2D plates, with only a few crystals growing 
successfully in the 3rd dimension.  Decoupling experiments (10) as well as alternating the salt 
anion (MgX, where X= acetate, formate, sulfate).  Optimized crystals were harvested and 
streaked through mother liquor supplemented with 20% (v/v) glycerol to cryo-protect the 
crystals for X-ray data collection. 
 Crystals were shipped to GM/CA-CAT at APS for X-ray data collection.  Test shots 
indicated that the crystals were highly mosaic, and only certain angles diffracted well. As 
such, data was collected in 0.2° oscillations for each crystal.  Multiple data sets were 
collected on a single crystal, picking out the best diffracting areas and angles of the crystal.  
Data was indexed in the space group P212121, with cell constants of a= 70.09, b= 120.3, c= 
175.8, α/β/γ= 90°.  Data was processed using HKL2000 (11) and XDS (12) to ensure that 
proper data reduction was performed.  Phases were calculated using Phaser (13), and a PXR 
LBD monomer derived from PDB ID 1NRL and RXRα LBD monomer from PDB ID 3PCU.  
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The first round of molecular replacement successful placed the PXR LBD homodimer, seen 
in nearly all PXR LBD crystal structures.  Two consecutive rounds of molecular replacement 
were necessary to find each RXRα LBD monomer. The overall structure of the SR12813-
bound PXR/RXRα LBD heterotetramer complex is shown in Figure 6.8. 
 
 
 
Table 6.1 List of DR3 CYP3A4 and ER6 CYP3A4 duplex DNA sequences used for 
DNA binding and competition assays with an abbreviated label. 
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Table 6.2 Calculated kd values for the binding of labeled DR3 and ER6 CYP3A4 to 
the PXR/RXRα complex. Binding curves for the fluorescence anisotropy 
experiments can be viewed in Figure 6.1. 
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Table 6.3 Ki values calculated for various DNA competitors with the DR3 and ER6 
CYP3A4 response elements (N.B.= No Binding). 
 
 
136 
 
Table 6.4 List of all the DNA sequences (one strand of the duplex DNA shown) used 
in crystal trials.  A number of flanking bases were added onto the 5’ and 
3’ end of DR3 and ER6 response element repeats, both with blunt and 
sticky ends.  
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Table 6.5 New crystallization constructs generated for both RXRα (new start at 11, 
and 129) and PXR (new start at 28).  These constructs cut out portions of 
the predicted disordered regions in the N-terminal regions (see Figure 
6.3).  New PXR/RXRα crystallization complexes were purified and 
subjected to crystal trials. 
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FIGURE LEGENDS 
 
Figure 6.1 Fluorescence anisotropy DNA binding curves for the fluorescently-labeled 
DR3 CYP3A4 and the ER6 CYP3A4 (Table 6.1 and Table 6.2) bound by the 
PXR.1/RXRα nuclear receptor complex.  The calculated Kd value for the 
minimum DR3 sequence is 206 ± 53.2 nM and for the minimum ER6, 215 ± 
36.1 nM. 
 
Figure 6.2 Overall structure of the full-length RXRα/PPARγ/DR1 crystal structure; 
close-up view of the hinge-region of PPARγ binding in the groove of the DR1 
duplex DNA, with several residues in position to form DNA base interactions. 
There are multiple main-chain, as well as electrostatic, interactions formed 
between the residues contained within this hinge region and the DNA bases in 
the groove flanking the response element sequence.  These interactions not 
only stabilize the flexible hinge-region, but most likely create a tight complex 
formation. 
 
Figure 6.3 Secondary structure prediction results from Phyre (8). The N-terminal region 
for PXR.1 (residues 1-38) and RXRα (residues 1-132) are predicted to be 
disordered; as such, new crystallization constructs were pursued. Listed in 
Table 6.5 are new protein constructs generated, and the various complexes 
formed with each.  Each construct removes portions of the disordered regions 
in the N-terminal region, hopefully facilitating proper crystal packing. 
 
Figure 6.4 Diagram of the domains within a nuclear receptor, and the crystallization 
construct that was used to solve the full-length RXRα/PPARγ complex (1) as 
well as the actual ordered residues refined in the crystal structure.  For both 
PPARγ and RXRα, a large portion of the N-terminal A/B region was found to 
be disordered as well as a portion of the DBD.  The actual ordered regions 
found in the crystal structure started just before the first cysteine in zinc-finger 
domains.  This evidence led us to create new crystallization constructs that 
removed the superfluous residues in the N-terminal region, and started just 
before the first zinc-finger domain. 
 
Figure 6.5 (A) Initial hit using the Nucleix suite #29 condition showing possible 
microcrystals of the PXR/RXRα complex.  This condition contained 4 M 
lithium chloride, 0.01 M magnesium chloride, and 0.05 M HEPES pH 7.0. 
Attempts to reproduce these crystals, however, proved unsuccessful. (B) 
Another possible hit using the Classics Lite #61 condition showing needle 
clusters of the nuclear receptor complex.  This condition contained 0.1 M 
magnesium formate.  Crystallization trials are still ongoing to reproduce this 
hit. 
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Figure 6.6 (A) SDS-PAGE gel of the Ni-column purification of the PXR/RXRα LBD 
complex; excess RXRα is washed away at low Buffer B concentrations, and 
the complex is eluted at high Buffer B concentrations. The lysates were 
combined in an approximate 3:1 (PXR/RXRα) ratio; the excess RXRα, 
untagged, most likely was forming dimeric, and tetrameric oligomers with 
itself, leading to some of the RXRα sticking non-specifically, to the column, 
however, this was washed away with a gradient elution, with the complex 
eluting at the highest concentrations of Buffer B shown on the gel as two 
distinct bands.  (B) S200 gel filtration purification of the LBD complex 
reveals >95% purity of the two proteins in complex.  Although not shown on 
the gel, there was still some residual, free RXRα LBD; however, this was 
easily separated from the higher MW LBD complex via sizing purification. 
 
Figure 6.7 Crystals of the PXR/RXRα LBD complex. Most of these crystals grew in the 
form of 2D plates, with only a few growing in the third dimension 
successfully.  Various methods were utilized to entice 3D growth of these 
plates, outlined in this chapter. Courtesy of Dr. Laurie Betts. 
 
Figure 6.8 Crystal structure of the PXR/RXRα LBD heterotetramer complex.  Each 
monomer has the fused SRC-1 peptide fragment, and both PXR monomers 
contain the SR12813 compound.  Although heterotetramers have been seen in 
previous crystal structures with similar nuclear receptors (CAR, for example), 
this heterotetramer is unique in that it is biologically relevant.  The PXR 
homodimer, seen in many PXR LBD structures, is conserved in this structure, 
with each PXR monomer bound with a single RXRα LBD. 
 
 
 
 
 
Figure 6.1 Fluorescence anisotropy DNA binding curves for the fluorescently-
labeled DR3 CYP3A4 and the ER6 CYP3A4 (Table 6.1 and Table 6.2) 
bound by the PXR.1/RXRα nuclear receptor complex. 
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Figure 6.2 Overall structure of the full-length RXRα/PPARγ/DR1 crystal structure; 
close-up view of the hinge-region of PPARγ binding in the groove of the 
DR1 duplex DNA, with several residues in position to form DNA base 
interactions. 
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Figure 6.3 Secondary structure prediction results from Phyre (8).  The N-terminal 
region for PXR.1 (residues 1-38) and RXRα (residues 1-132) are 
predicted to be disordered; as such, new crystallization constructs were 
pursued. 
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Figure 6.4 Diagram of the domains within a nuclear receptor, and the crystallization 
construct that was used to solve the full-length RXRα/PPARγ complex (1) 
as well as the actual ordered residues refined in the crystal structure. 
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Figure 6.5 (A) Initial hit using the Nucleix suite #29 condition showing possible 
microcrystals of the PXR/RXRα complex. (B) Another possible hit using 
the Classics Lite #61 condition showing needle clusters of the nuclear 
receptor complex. 
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Figure 6.6 (A) SDS-PAGE gel of the Ni-column purification of the PXR/RXRα LBD 
complex; excess RXRα is washed away at low Buffer B concentrations, 
and the complex is eluted at high Buffer B concentrations. (B) S200 gel 
filtration purification of the LBD complex reveals >95% purity of the two 
proteins in complex. 
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Figure 6.7 Crystals of the PXR/RXRα LBD complex.  Most of these crystals grew in 
the form of 2D plates, with only a few growing in the third dimension 
successfully. Courtesy of Dr. Laurie Betts. 
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Figure 6.8 Crystal structure of the PXR/RXRα LBD heterotetramer complex.  Each 
monomer has the fused SRC-1 peptide fragment, and both PXR 
monomers contain the SR12813 compound. 
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ABSTRACT 
Bacillithiol (Cys-GlcN-malate, BSH) has recently been identified as a novel low-
molecular-weight thiol in Bacillus anthracis, Staphylococcus aureus, and several other 
Gram-positive bacteria lacking glutathione and mycothiol.  We have now characterized the 
first two enzymes for the BSH biosynthetic pathway in B. anthracis, which combine to 
produce α-D-glucosaminyl L-malate (GlcN-malate) from UDP-GlcNAc and L-malate.  The 
structure of the GlcNAc-malate intermediate has been determined, as have the kinetic 
parameters for the BaBshA glycosyltransferase (→GlcNAc-malate) and the BaBshB 
deacetylase (→GlcN-malate).  BSH is one of only two natural products reported to contain a 
malyl glycoside, and the crystal structure of the BaBshA-UDP-malate ternary complex, 
determined in this work at 3.3 Å resolution, identifies several active-site interactions 
important for the specific recognition of L-malate, but not other α-hydroxyacids, as acceptor 
substrate.  In sharp contrast to the structures reported for the GlcNAc—1-D-myo-inositol-3-
phosphate synthase (MshA) apo and ternary complex forms, there is no major 
conformational change observed in the structures of the corresponding BaBshA forms.  A 
mutant strain of B. anthracis deficient in the BshA glycosyltransferase fails to produce BSH, 
as predicted.  This B. anthracis bshA locus (BA1558) has been identified in a transposon site 
hybridization study as required for growth, sporulation, or germination (1), suggesting that 
the biosynthesis of BSH could represent a target for development of novel antimicrobials 
with broad spectrum activity against Gram-positive pathogens like B. anthracis.  The 
metabolites that function in thiol redox buffering and homeostasis in Bacillus are not well 
understood, and we present a composite picture based on this and other recent work.   
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INTRODUCTION 
In his recent review on the management of oxidative stress in Bacillus, Zuber (2) 
concludes that the metabolites that function in redox buffering and thiol homeostasis, and 
their influence on the oxidative stress response, are not well understood.  Earlier work from 
this laboratory (3) demonstrated that CoASH provided the major low-molecular weight thiol 
redox buffer in Bacillus anthracis, replacing GSH as had previously been demonstrated for 
Staphylococcus aureus (4).  The likelihood that CoASH plays an important functional role in 
redox buffering and thiol homeostasis is strengthened by the demonstration that both B. 
anthracis (5) and S. aureus (4, 6-8) have NAD(P)H-dependent coenzyme A-disulfide 
reductases (CoADRs).1  We have also shown that the type III pantothenate kinase, which is 
unusual in its insensitivity to feedback inhibition by CoASH (3), is essential for growth of B. 
anthracis (9).  CoADR, the chimeric CoADR-RHD protein (10), and the type III 
pantothenate kinase represent three well-characterized adaptations to the CoASH-based 
redox buffer system for this Gram-positive pathogen. 
  A new unknown thiol, originally referred to as U12, was also identified in the B. 
anthracis extract (3); a mass of 398 Da was reported for U12-SH.  By combining analytical 
chemical approaches with mass spectrometry and NMR, the structure of U12 has been 
determined to be N-cysteinyl-α-D-glucosaminyl L-malate, and U12 has been renamed 
bacillithiol [BSH (11)].  BSH is present at intracellular concentrations of 0.1-0.35 mM 2 in a 
number of Bacillus species, including B. anthracis, Bacillus subtilis, and Bacillus 
megaterium, as well as in S. aureus.  While none of the four B. subtilis strains represented in 
the NCBI database have orthologs of CoADR or any of its isoforms (10), B. anthracis, B. 
megaterium (12), and S. aureus (4) maintain both CoASH and BSH redox buffer systems, in 
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the absence of GSH.  Pöther et al. (13), in a recent study with S. aureus demonstrating that 
the majority of reversible protein thiol oxidations observed during treatment of cells with 
diamide are based on S-thiolations with Cys rather than protein disulfide formation, have 
concluded that Cys also functions as an important thiol redox buffer in S. aureus. 
 In an initial study of the biosynthesis and functions of BSH (14), we have 
demonstrated that the B. subtilis YpjH protein (BsuBshA), the enzyme orthologous to B. 
anthracis ORF BA1558, catalyzes the synthesis of N-acetyl-α-D-glucosaminyl L-malate 
(GlcNAc-malate) from UDP-GlcNAc and L-malate; the product structure has been 
confirmed by mass spectrometry (11, 14).  We have also demonstrated that the BA1557 gene 
product (BaBshB) catalyzes the deacetylation of GlcNAc-malate (14), providing the free 2-
amino group of the GlcN moiety required for the Cys ligation step that is proposed to 
complete the synthesis.  Deletion of the B. subtilis yllA locus, predicted to be involved in the 
biosynthetic pathway and initially suggested to encode this putative ligase, does eliminate 
BSH production; the recombinant protein, however, does not catalyze ATP-dependent BSH 
formation from Cys and GlcN-malate, as assayed in vitro.   
 In the absence of functional information, Ruane et al. (15) have reported the structure 
of the ORF BA1558 (identified in this work as BaBshA) apoenzyme, refined at a resolution 
of 3.1 Å.  Although this enzyme, like the MshA glycosyltransferase that produces GlcNAc-
Ins-P in the first step of mycothiol (MSH) biosynthesis (16, 17), is a member of the GT-B 
and GT4 fold (18) and Carbohydrate-Active enZymes (19) families, respectively, structural 
homology searches using the MshA apoenzyme structure were unsuccessful in identification 
of other GT-B family members, including ORF BA1558.  This indicates a major 
conformational difference between the two apoenzymes, despite the similarity in reactions 
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catalyzed.  Fadouloglou et al. (20) reported the crystal structure of the Zn2+-binding BcZBP 
protein from Bacillus cereus, as refined at a resolution of 1.8 Å.  BcZBP is the enzyme 
orthologous to BaBshB, the GlcNAc-malate deacetylase, with 97% sequence identity.  A 
recent kinetic analysis (21) with GlcNAc and several GlcNAc oligomers indicated that, 
although the biological function and natural substrate for BcZBP were unknown, the enzyme 
had optimal activity with (GlcNAc)2 (kcat/Km = 3.3 x 107 M-1s-1 at 37ºC).  The enzyme is a 
member of the PIG-L superfamily represented by GlcNAc-phosphatidylinositol deacetylase 
(22), the MshB deacetylase (23) of the MSH biosynthetic pathway, and the mycothiol S-
conjugate amidase (24).  The active-site Zn2+ of BcZBP is buried at the bottom of a ca. 12 Å 
deep cavity on the hexamer surface, and Arg140 is prominently positioned at the entry of the 
cavity.  Both R140A and R140E mutants exhibit kcat/Km values 0.2-0.3% that of wild-type 
enzyme (21).  His12, Asp15, and His113 provide the protein ligands to the Zn2+, and Asp14 
has been proposed as an acid-base catalyst in the hydrolase reaction.  A model of a BcZBP-
GlcNAc complex reveals that this substrate is considerably smaller than the volume of the 
cavity; a hydrophilic patch consisting of the side chains of Asp108, Asn150, and Tyr194 
marks an unoccupied region proximal to the Zn2+.  The Y194F mutant specificity constant, 
which is <0.1% that of wild-type (21), reflects a dominant effect on Km.  In particular, the 
anomeric C1-OH of GlcNAc also appears to be accommodated by a relatively large space 
within the cavity.  For the BcZBP apoenzyme structure, three very mobile loops have 
recently been implicated in determining active-site accessibility and regulating substrate 
specificity (25).   
 Given the goal of better defining the thiol redox buffer in B. anthracis and 
characterizing potential new targets for the development of antimicrobial agents that are 
154 
 
selective against B. anthracis, S. aureus, and other Gram-positive pathogens that rely on the 
BSH-based redox buffer system, we report here detailed kinetic analyses of the BaBshA 
glycosyltransferase and BaBshB deacetylase.  The kinetic studies are interpreted in view of 
the ORF BA1558 and BcZBP crystal structures, and we also provide the structure of the 
BaBshA-UDP-malate complex, refined at a resolution of 3.3 Å, which demonstrates the 
absence of any major conformational change on ligand binding.  In addition we show that 
deletion of the BAS1445 locus encoding BshA in B. anthracis Sterne generates a BSH-
deficient strain appropriate for testing in a murine model of inhalational anthrax.   
 
EXPERIMENTAL PROCEDURES 
 
Bacterial Strains and Antibiotics   
 The B. anthracis Sterne 34F2 strain (pXO1+ pXO2-) used in these studies was 
obtained from Dr. Philip Hanna, University of Michigan Medical School.  Cultures were 
grown and maintained in BHI broth (Difco) and on solid media containing 15 g/L of agar.  
For preparation of parental and mutant endospores, cultures were grown at 37°C on BHI 
plates containing antibiotics as appropriate.  A single colony was inoculated into 3 mL of 
BHI broth containing antibiotics as required, and this culture was taken as the inoculum (5%, 
v/v) into 75 mL of fresh modified G (sporulation) medium (26) without antibiotic, after 8-12 
h of growth.  After 4 days' growth at the appropriate temperature endospores were collected 
by centrifugation, and residual vegetative cells were killed by a 30-min incubation at 65°C.  
Pellets were washed 3-4 times in deionized water, and endospores were stored (in deionized 
water) at ambient temperature.  The purity of the spore preparations was confirmed by phase-
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contrast microscopy, and spore titers were determined by serial dilution.  Escherichia coli 
strains DB3.1 (27) and GM272 were used for the cloning and propagation of pBKJ236 and 
pBKJ223 (28), respectively.  DB3.1(pBKJ236) was cultured and maintained in LB broth or 
on solid media supplemented with 250-400 μg/mL erythromycin.  GM272(pBKJ223) was 
cultured and maintained in LB broth or on solid media supplemented with 15 μg/mL 
tetracycline. 
 
Construction of B. anthracis Sterne Deletion Strains 
 In-frame deletion mutants of the genes encoding BaBshA (bshA, loci BA1558 and 
BAS1445 in Ames and Sterne strains, respectively), BaBshB (bshB, loci BA1557 and 
BAS1444, respectively), BaCoADR [cdr, loci BA1263 (5) and BAS1170, respectively] and 
BaCoADR-RHD [cdr2, loci BA0774 (10) and BAS0736, respectively] were constructed 
following the markerless gene replacement protocol (28), using the pBKJ236 and pBKJ223 
plasmids.  The procedure followed in this work is described in detail for the BASΔ1445 
mutant.  A modified chromosomal segment containing the BAS1445 deletion was 
constructed by first amplifying the flanking upstream and downstream regions (>500 bp 
each) using primer sets BAS1445up (FWD/REV) and BAS1445dwn (FWD/REV), 
respectively (Table S1).  The two amplified products were then ligated using overlap PCR 
with BAS1445up FWD/BAS1445dwn REV, and the resulting deletion fragment was TA 
cloned into pCR2.1 (Invitrogen) before subcloning into pBKJ236 digested with NotI.  This 
plasmid, pBKJ236::BAS1445′ was electroporated into methylation-deficient (dam- dcm-) E. 
coli GM272.  E. coli GM272(pBKJ236::BAS1445′) (LB plus 250 μg/mL erythromycin), E. 
coli helper strain 459 (LB plus 100 μg/mL ampicillin), and B. anthracis Sterne were grown 
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overnight, and aliquots (75 μL) from washed samples of each culture were mixed and spotted 
onto BHI agar before incubating for 48 h at room temperature.  The accumulated growth was 
resuspended in fresh LB broth, and 150 μL of the suspension was dispensed in a “straight 
line” on one quadrant of a BHI agar plate supplemented with 5 μg/mL erythromycin and 80 
U/mL polymyxin B.  After the line was allowed to dry, cells were streaked to isolation and 
incubated at room temperature for 48 h.  Isolated EryR colonies were cultured overnight, 
again at room temperature, before diluting 1:1000 in fresh BHI broth plus erythromycin and 
shifting to 37°C, a nonpermissive temperature for plasmid replication.  Following this 
overnight incubation, integrants were isolated using the "straight line" procedure described 
above, but with incubation at 37°C on BHI agar plus erythromycin.  A single EryR colony 
was grown out, to A600 ca. 0.2, in 25 mL of LB plus glucose (29) at 37°C, with shaking at 
100 rpm; cells were harvested by centrifugation at 4°C, resuspended and washed in ice-cold 
electrotransformation buffer (30), and transferred (400 μL) to a chilled 0.4-cm electrode-gap 
cuvette.  After 10 min incubation on ice, with 5 μL of unmethylated pBKJ223 [isolated from 
E. coli GM272(pBKJ223)], cells were electroporated at 2.4 kV, 200 Ω, and 25 μF.  After 
pulsing, cells were placed back on ice, and 700 μL of ice-cold LB plus glucose was added; 
the mixture was transferred to a microcentrifuge tube, and cells were allowed to recover for 3 
h at 30°C before plating on BHI agar plus 10 μg/mL tetracycline and incubating overnight at 
37°C.  Several single TetR colonies selected after repeatedly mixing and streaking to isolation 
were patched onto BHI agar plus erythromycin and BHI agar plus tetracycline and incubated 
overnight at 37°C.  Clones with the desired TetR EryS (loss of pBKJ236) phenotype were 
validated by colony PCR, repurified by streaking, and patched onto BHI agar with and 
without tetracycline.  Clones cured of TetR (loss of pBKJ223) were again validated by colony 
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PCR to confirm the BAS1445 deletion.  ΔbshB, Δcdr, and Δcdr2 mutants were constructed 
following the same protocol; the ΔcdrΔcdr2 double mutant utilized the Δcdr strain in the 
initial conjugation step. 
 
Fosfomycin Sensitivity of Wild-Type and Δbsh Strains 
An active culture grown to A600 of 0.5 (mid-log) was used to inoculate (1% v/v) 5 mL 
aliquots of fresh BHI broth containing fosfomycin at incremental concentrations.  The wild-
type Sterne strain showed robust growth (static conditions in 17 x 100 mm polystyrene tubes) 
at all fosfomycin concentrations (0-1,000 μg/mL).  The ΔbshA mutant grew only in the 
control (no fosfomycin) culture and at the lowest fosfomycin concentration tested (200 
μg/mL), but not at concentrations ≥400 μg/mL.  The ΔbshB mutant was sensitive to 
fosfomycin at 800 μg/mL, but not at  ≤400 μg/mL.         
 
Expression and Purification of B. anthracis BshA, BshB, and CysS   
The codon-optimized BA1558 and BA1557 genes, encoding BaBshA and BaBshB, 
respectively, were synthesized by GenScript (Piscataway, NJ) and subcloned into pET28a(+) 
(Novagen).  Both genes were expressed in E. coli BL21(DE3) cells using auto-induction 
media at 37°C (31); BshA was expressed with an N-terminal His-tag (see "Results"), while 
BshB had a C-terminal His-tag (-LEH6).  All steps of both purifications were carried out at 
4°C.  Harvested cells were disrupted using an Avestin EmulsiFlex-C5 homogenizer, and 
nucleic acids were removed by addition of 2% streptomycin sulfate and centrifugation 
(27,000g for 20 min).  For BshA, the clarified extract was loaded onto a 25-mL Ni Sepharose 
High Performance column (GE Healthcare, Piscataway, NJ) in 50 mM sodium phosphate, pH 
158 
 
8.0, containing 0.3 M NaCl and 20 mM imidazole; the protein was eluted with a stepwise 
increase of imidazole, to 250 mM.  Peak fractions were pooled and loaded onto a Q-
Sepharose HP column after dialysis against 20 mM HEPES, pH 7.5, containing 50 mM NaCl.  
The protein was eluted with a linear 375-mL gradient of 0.05 → 1 M NaCl, and the BaBshA 
pool was dialyzed against the Q-Sepharose loading buffer before concentrating and storing in 
aliquots at -80°C.  For BaBshB, the immobilized metal-ion affinity chromatography column 
was first converted to the Zn2+ form (32); the clarified extract was loaded onto the 25-mL Zn 
Sepharose column in 50 mM sodium phosphate, pH 8.0, containing 0.3 M NaCl and 20 mM 
imidazole. The protein was eluted with a stepwise increase of imidazole, to 250 mM.  Peak 
fractions were pooled and loaded onto a Q-Sepharose HP column after dialysis against 25 
mM potassium phosphate, pH 7.0. The protein was eluted with a linear 375-mL gradient of 0 
→ 1 M NaCl, and the purified BaBshB protein was dialysed against 25 mM Tris-HCl, pH 8.0, 
containing 50 mM NaCl, concentrated by ultrafiltration, and brought to a final concentration 
of 20% (v/v) glycerol before being frozen in aliquots at -80°C.   
The cysteinyl-tRNA synthetase gene (cysS, BA0089) was amplified from genomic B. 
anthracis DNA using primers designed with NcoI and XhoI linkers that allowed cloning into 
pET28a.  The recombinant C-terminal His-tagged CysS protein was expressed in E. coli 
BL21(DE3); cultures grown to mid-log phase in LB plus kanamycin at 37°C were induced 
with lactose for 3 h.  Harvested cells were resuspended in 1.5 volumes of degassed 50 mM 
Tris-HCl, pH 8.0, containing 0.5 M NaCl, and were lysed with a French press.  The extract 
was clarified by centrifugation and applied to a Ni2+-charged metal-ion affinity column (GE 
Healthcare) equilibrated with the lysis buffer; the column was washed with this buffer 
containing 20 mM imidazole before the recombinant CysS protein was eluted with 100 mM 
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imidazole.  Pooled fractions were diluted with 5 volumes of lysis buffer and loaded onto a 
HiTrap Q XL column (GE Healthcare); the column was washed with the lysis buffer before 
eluting the protein with a linear 50-mL gradient of 0 → 1 M NaCl.  The cysteine adenylation 
activity of B. anthracis CysS was assayed using the ATP-32PPi exchange reaction in the 
presence of 50 μM Cys (33).   
 
Enzymatic Synthesis of GlcNAc-malate 
GlcNAc-malate required for kinetic analysis of BaBshB was produced on a 
preparative scale by incubating 0.5 mg BaBshA at 37°C with 50 μmol each of UDP-GlcNAc 
and L-malate (substrates purchased from Sigma) in 5 mL of 25 mM HEPES, pH 7.5, 
containing 100 mM NaCl, 10 mM MgCl2, and 1 mM 2-mercaptoethanol.  The reaction was 
sampled at indicated times; samples were processed as described by Newton et al. (16) for 
identification of the MshA-catalyzed reaction products (using unlabeled substrates) and were 
analyzed by HPLC with A260 detection for UDP-GlcNAc and UDP.  The conversion of UDP-
GlcNAc → UDP was complete in 2 h.  The GlcNAc-malate product (50 μmol, ca. 15 mg) 
was processed for preparative HPLC purification by 1) adding 1 volume of acetonitrile to the 
reaction mixture and incubating at 60°C for 15 min, 2) clarifying by centrifugation, and 3) 
adjusting the supernatant pH→3 with trifluoroacetic acid after reducing the volume to 2 mL 
in a SpeedVac.  A Vydac 218TP1022 (1 x 25 cm) reversed-phase preparative column was 
used with a linear gradient from 0→20% methanol in 0.1% trifluoroacetic acid, over 40 min 
(flow rate of 5 mL/min), with online detection by mass spectrometry.  Fractions containing 
GlcNAc-malate (ESP-, m/z 336) were combined, and the separation was repeated to obtain 
the purified product, which was adjusted to pH 6 with NaOH and lyophilized. 
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 Synthetic GlcNAc-malate was maintained at -70°C in H2O at a concentration of 80 
mM and contained ca. 1 equiv sodium trifluoroacetate from the HPLC solvent.  The sodium 
trifluoroacetate content was determined in the quantitative pH titration described above.  In 
addition, the disodium GlcNAc-malate content determined by the BaBshB—Accu-Tag 
method (see below) accounts for ca. 50% of the total mass of the lyophilized material.  1H- 
and gCOSY NMR spectra were recorded on a Jeol ECA500 at 500 MHz and were referenced 
to residual solvent (HDO) at 4.8 ppm.  The 1H NMR of GlcNAc-malate in D2O 
(trifluoroacetate is not observable) confirmed the absence of other organic impurities.  13C 
spectra were collected on a Varian X500 (125 MHz) equipped with an XSens cold probe.  
All spectra were collected at 23°C.  High resolution mass spectrometry analysis was 
provided by the UCSD Chemistry and Biochemistry Mass Spectrometry Facility using a 
Thermo Scientific LTQ Orbitrap XL mass spectrometer operating in positive ion mode ESP 
ionization.      
 
BaBshA and BaBshB Kinetic Parameters   
The kinetic properties of BaBshA were first analyzed from initial rates of UDP-
GlcNAc → UDP conversion, using the A260-based HPLC assay described above (16) for 
monitoring GlcNAc-malate synthesis.  Initial rates were determined over a range of UDP-
GlcNAc concentrations (0→25 mM) at a fixed concentration of 2 mM L-malate (ca. 15 x Km, 
see "Results"); for each individual assay at 37°C [in 25 mM HEPES, pH 7.5, containing 100 
mM NaCl, 10 mM MgCl2, and 1 mM 2-mercaptoethanol], the reaction was sampled four 
times in order to establish the observed rate of UDP formation.  Similarly, initial rates were 
measured over a series of L-malate concentrations (0→3.2 mM) at a fixed concentration of 3 
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mM UDP-GlcNAc (ca. 5 x Km).  Results representing the mean of triplicate determinations 
were fit to the Michaelis-Menten equation [equation 1 (34)] where Vmax is the apparent 
maximal velocity, A is the concentration of the varied substrate, and KA is the Michaelis 
constant (apparent) for substrate A.   
v = Vmax·A/(KA + A)        (Eq. 1) 
Data described with this single variable equation were analyzed using KaleidaGraph. 
 In order to analyze the steady-state kinetic mechanism with several fixed 
concentrations of UDP-GlcNAc and L-malate, respectively, the continuous 
spectrophotometric assay for glycosyltransferases (35) was adapted, using a 96-well format 
with a POLARstar OPTIMA (BMG LABTECH) microplate reader.  For each assay at 37°C, 
30 ng of BaBshA was incubated in 25 mM HEPES, pH 7.5, containing 50 mM KCl, 10 mM 
MgCl2, 7.5 U pyruvate kinase and 15 U lactate dehydrogenase (both enzymes purchased 
from Sigma), 0.8 mM phosphoenolpyruvate, and 0.15 mM NADH in a final volume of 200 
μL.  The concentration of L-malate was varied over the range 0.08-1.2 mM at fixed 
concentrations of 0.1-1.5 mM UDP-GlcNAc.  Reactions were initiated by addition of enzyme 
and were performed in duplicate.  These results (for varying [L-malate]) were fit to the 
reciprocal form of the velocity equation for a rapid equilibrium random system [equation 2 
(34)], using GraFit version 5. 
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 where Don = UDP-GlcNAc and Acc = L-malate.  α is a factor representing the effect each 
substrate has on the binding of the second substrate.  Controls showed that the omission of 2-
mercaptoethanol and substitution of 50 mM KCl for 100 mM NaCl in the coupled assay had 
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no effect on initial velocity.  In addition, any competitive UDP-GlcNAc hydrolysis reaction 
(measured in the absence of L-malate) was negligible.   
The kinetic parameters for BaBshB were determined from initial rates of GlcNAc-
malate → GlcN-malate conversion, using an HPLC assay for the AccQ-Tag derivative of the 
GlcN-malate product, as monitored by fluorescence (14, 32, 36).  Initial rates were 
determined over a series of GlcNAc-malate concentrations (0→2 mM); for each assay at 
37°C [in 50 mM HEPES, pH 7.5, containing 50 mM NaCl and 1 equiv of sodium 
trifluoroacetate per mol GlcNAc-malate], the reaction was sampled at intervals in order to 
establish the rate of GlcN-malate formation.  Results representing the mean of triplicate 
determinations were fit to equation 1 as described above.  Bacillithiol S-conjugate amidase 
activity was measured using the methylbimane derivative of BSH (BSmB) purified as 
described (11).  The reaction was sampled at intervals; aliquots were processed for analysis, 
using an adaptation of the fluorescence-based HPLC assay for CySmB (+ GlcN-malate) 
product formation described previously (24).  The initial rate of CySmB formation was 
determined by sampling the reaction four times in the presence of 320 μM BSmB.   
 
Crystallographic Methods 
After purification BaBshA was buffer-exchanged into 20 mM HEPES, pH 7.5, 
containing 150 mM NaCl plus 5 mM dithiothreitol, and concentrated to 16 mg/mL for 
crystallization.  Crystals were obtained in 0.2 M Mg(HCO2-)2 containing 15% PEG3350 with 
1 mM each of UDP and L-malate.  Crystals were cryoprotected with mother liquor 
supplemented with 25% glycerol and flash-frozen in liquid nitrogen.  BaBshA crystals, 
which appeared after 4-5 days, diffracted to 3.3 Å.  Data sets were collected at SER-CAT 
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beamline 22-BM (Advanced Photon Source, Argonne National Laboratory).  Data were 
indexed and scaled using HKL2000 (37).  Molecular replacement was performed using 
PHASER (38), and model refinement was carried out using the PHENIX software suite  (39).  
The model was adjusted manually using COOT (40) as well as 2Fo-Fc and Fo-Fc electron 
density maps.  The UDP and L-malate model and definition files were generated with 
PHENIX. 
 
Analysis of Thiols from Wild-Type and Mutant Strains of B. anthracis   
All manipulations of B. anthracis Sterne strains were carried out under Biosafety 
Level 2 conditions at Wake Forest University School of Medicine and at University of 
California, San Diego.  The detailed methods for culture growth, sample preparation, and 
analysis, including the determination of thiol redox status, are given in Nicely et al. (3) and 
Newton et al. (11). 
 
Bioinformatics   
Sequence analyses were performed with the NCBI and PDB databases using 
BLASTP, and the resources of the Carbohydrate-Active enZymes database (19) were also 
utilized in this work.  Structure superpositions and sequence alignments were performed 
using DALILITE (41), PyMOL (42) , CLUSTALW (43), and ESPript (44), respectively.  
Figures of protein molecules and residues were prepared using PyMOL. 
 
RESULTS 
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Proposed BSH Biosynthetic Pathway in B. anthracis   
Given the structural similarity between bacillithiol and mycothiol (Figure 7.1) and 
the well-defined pathway for MSH biosynthesis in Mycobacterium tuberculosis and other 
Actinobacteria (45, 46), three distinct enzymatic steps have been considered in the pathway 
for BSH biosynthesis (Figure 7.2).  The first reaction produces GlcNAc-malate from UDP-
GlcNAc and L-malate, as indicated: 
UDP-GlcNAc  +  L-malate  →  GlcNAc-malate  +  UDP     (1) 
We have demonstrated (14) that the B. subtilis YpjH gene product catalyzes the synthesis of 
GlcNAc-malate as given in reaction (1).  In B. anthracis the BA1558 locus is the ortholog of 
B. subtilis ypjH; as shown in the preparative scale assay (Figure S1), ORF BA1558 catalyzes 
the production of UDP and GlcNAc-malate when incubated with UDP-GlcNAc and L-malate.  
Isolation of the GlcNAc-malate product from this preparative scale reaction allowed its 
confirmation by 1H and 13C NMR (Figure S2) and high resolution mass spectrometry.  The 
proton NMR spectra (Figure S2A) indicated that the GlcNAc-malate was pure (see 
"EXPERIMENTAL PROCEDURES") and contained the L-malate and D-glucosamine 
resonances found in bacillithiol (11).  The glucosamine N-acetyl group is validated by the 
acetyl protons (singlet, 2.04 ppm) and the carbon resonances at 174.3 and 21.9 ppm (Figure 
S2B).  The carbon 2 proton (3.9 ppm) of glucosamine (nitrogen bonded carbon) is identified 
in the gCOSY spectra (Figure S2A) by correlation to the anomeric proton.  The anomeric 
proton (4.89 ppm) coupling constant (3.8 Hz) indicated this was the α-anomer of the malyl 
glycoside as predicted by the structure of bacillithiol.  The high-resolution mass spectra of 
this compound gave a mass of 360.0902 for the sodium ion of GlcNAc-malate (360.0901, δ 
0.3 ppm) corresponding to a formula of C12H19NO10Na, consistent with the product of 
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BaBshA.  Confirmation of the novel D-glucosaminyl L-(α)-malate moiety validates the 
structure of bacillithiol from Deinococcus radiodurans (11) and shows that it is identical to 
bacillithiol produced in B. anthracis.  ORF BA1558 is the BshA glycosyltransferase in B. 
anthracis and is therefore designated BaBshA (Figure 7.2).  
 When the structure of the M. tuberculosis GlcNAc-Ins deacetylase MshB [PDB entry 
1Q74 (23)] was used to query the Protein Data Bank with DALILITE, the highest score (Z = 
21.6) was observed with the Zn2+-binding BcZBP protein [PDB entry 2IXD; rmsd = 2.3 Å, 
24% identity (20)] from B. cereus.  This deacetylase is 97% identical in sequence to the B. 
anthracis ortholog, ORF BA1557.  We have recently demonstrated (14) that recombinant 
ORF BA1557 catalyzes the efficient deacetylation of GlcNAc-malate → GlcN-malate, as 
given in reaction (2): 
GlcNAc-malate  +  H2O  →  GlcN-malate  +  OAc-  + H+     (2) 
The preparative scale reaction, using GlcNAc-malate prepared by enzymatic synthesis with 
BaBshA and purified by HPLC (see "EXPERIMENTAL PROCEDURES"), allowed 
isolation of the GlcN-malate product, and deacetylation of the substrate was confirmed by 
ESP mass spectrometry.  ORF BA1557 is the BshB GlcNAc-malate deacetylase in B. 
anthracis and is therefore designated BaBshB.  We have now identified the enzymatic 
activities, in vitro, for the BaBshA glycosyltransferase and the BaBshB deacetylase.  Thus, 
from UDP-GlcNAc and L-malate precursors, these enzymes combine to produce GlcN-
malate, UDP, and acetate; GlcN-malate has also been identified by HPLC analysis of cell-
free extracts from B. subtilis (14), confirming this aspect of the BSH biosynthetic pathway as 
presented in Figure 7.2 for B. anthracis.  While we have not attempted to identify GlcNAc-
malate in vivo, these combined results provide very strong evidence that the biosynthetic 
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scheme presented in Figure 7.2 for BshA and BshB represents the intracellular process in B. 
anthracis.  
 These functional assignments, as confirmed experimentally, leave the enzyme(s) 
responsible for the proposed ATP-dependent Cys:GlcN-malate ligase reaction (Figure 7.2) 
unidentified.  The mshC gene product in M. tuberculosis is a second cysteinyl-tRNA 
synthetase isoform that differs from the functional CysS enzyme primarily through the 
absence of a 76-residue C-terminal extension that is responsible for recognition and specific 
binding of the tRNACys anticodon (47, 48); the Cys:GlcN-Ins ligase catalyzes the ATP-
dependent formation of the amide linkage in the ultimate MSH product (+ AMP + PPi).  
BLASTP analysis of the B. anthracis genome, however, fails to identify any second CysS 
isoform, and the ORF BA0089 (annotated as cysteinyl-tRNA synthetase) protein as 
expressed is active in the standard tRNA synthetase assay.  Although deletion of the B. 
subtilis yllA locus eliminates BSH production with a concomitant increase in intracellular 
GlcN-malate (the BshB product), the recombinant B. subtilis YllA and S. aureus CysS 
proteins both fail to catalyze ATP-dependent production of BSH from Cys and GlcN-malate 
in an in vitro assay (14). 
 
Genetic Analysis of bshA and bshB Functions in B. anthracis   
Passalacqua et al. (49) have recently demonstrated that the seven genes corresponding 
to BA1554-BA1560 (Ames strain) are transcribed as a single mRNA unit in B. anthracis 
Sterne (BAS1441-BAS1447); this experimental result is consistent with results obtained 
earlier with the operon prediction algorithm developed by Bergman et al. (50).  Given the 
involvement of both BSH and CoASH in the B. anthracis thiol redox buffer (3, 11), we note 
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that the BA1562-BA1564 loci (panBCD) encoding three key enzymes in the synthesis of the 
CoASH precursor pantothenate (51) are separated by a single ORF from the bsh operon and 
have been demonstrated to be cotranscribed together with BA1565 in a second tetracistronic 
operon (49).  In the event that candidate bshC loci might be clustered within the bsh operon, 
we analyzed the seven protein products for structural homologs of known function, using the 
PDB and NCBI databases.  Table 7.1 summarizes details of the structural and functional 
annotations for each of the ORFs in the bsh and pan operons.  Although there may be a 
functional linkage between BSH production and methylglyoxal synthase [ORF BA1556 (52)] 
activity (see "DISCUSSION"), we find no evidence for candidate bshC loci in either bsh or 
pan operons in B. anthracis.   
 In contrast to the soil bacterium B. subtilis, which lacks the CoASH thiol redox buffer 
(10), the redundancy provided by the CoASH and BSH redox buffers in B. anthracis and S. 
aureus may provide these two pathogens with some advantage in virulence and/or survival, 
given the hostile environment posed by host defense mechanisms (53, 54).  The results 
described above predict that individual deletions of the bshA and bshB genes in B. anthracis 
Sterne (loci BAS1445 and BAS1444, respectively) will disrupt the BSH biosynthetic 
pathway at the points of GlcNAc-malate and GlcN-malate precursor production, respectively.  
The two mutants were prepared using the markerless deletion method developed by Janes 
and Stibitz (28) and were analyzed for low-molecular-weight thiol content in parallel with 
wild-type B. anthracis Sterne and deletion mutants lacking the cdr and cdr2 genes that 
encode BaCoADR (5) and the chimeric CoADR-RHD protein (10).  The major conclusions 
from the analytical data presented in Table 7.2 are as follows: 1) deletion of the bshA locus 
eliminates BSH production, 2) deletion of the bshB locus does not eliminate BSH production 
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but reduces it by 30% relative to wild-type, 3) BSH redox status (BSH/BSSB) strongly 
favors the reduced thiol in vegetative B. anthracis cells, and this is not affected by deletions 
of the cdr and/or cdr2 loci, 4) the value for CoASH is higher (1.9±0.4 μmol/g dry residual 
weight) than that reported previously [0.87±0.11 μmol/g (3)]; this is attributed to the different 
wild-type strains used in the two analyses, 5) Cys is a major low-molecular weight thiol, 
consistent with the recent report of Pöther et al. (13), for S. aureus, and 6) thiosulfate 
(S=SO32-), a principal source of sulfur for aerobic bacteria (55) and donor substrate for the 
sulfurtransferase rhodanese (56), is a major inorganic sulfur compound in B. anthracis. 
 In B. subtilis the primary fosfomycin resistance determinant FosB functions as a 
thiol-dependent S-transferase that produces a thioether conjugate from the thiol and the 
antibiotic; until very recently, however, the enzyme had only been demonstrated to work 
quite poorly in vitro (57), with Cys as thiol substrate.  Using a zone of inhibition assay we 
have recently demonstrated (14) that a B. subtilis mutant deficient in BSH is as sensitive to 
fosfomycin as a fosB mutant, leading to the conclusion that FosB is a BSH S-transferase.  We 
tested the sensitivity of wild-type and ΔbshA mutant strains of B. anthracis to fosfomycin in 
liquid culture.  While the wild-type strain grew well at 1,000 μg/mL fosfomycin, the ΔbshA 
mutant did not grow at fosfomycin concentrations ≥400 μg/mL.  B. anthracis ORF BA4109 
is annotated as the FosB protein, and we propose that this enzyme requires BSH as a cofactor 
for conjugation in the detoxification of fosfomycin (Scheme 7.1). 
 Our results with the ΔbshB mutant clearly indicate that other protein(s) capable of 
recognizing and deacetylating GlcNAc-malate are expressed in B. anthracis.  Fadouloglou et 
al., in their earlier structural analysis of BcZBP (20), had identified ORF Bc3461 as a BcZBP 
paralog; more recently, this analysis was extended (25) with the identification of the BA630 
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(BaBshB), BA425 (ORF BA3524), and BA758 (ORF BA3888) orthologs in the B. anthracis 
genome (Figure 7.3).  ORF Bc3461 has now been expressed and characterized (21); when 
assayed in parallel with BcZBP, the enzyme shows a preference for (GlcNAc)2 and 
(GlcNAc)3 as deacetylase substrates.  kcat/Km(GlcNAc)2 = 5.6 x 106 M-1s-1, or ca. 20% that of 
BcZBP.  While its biological role is unclear, ORF Bc3461 has potent deacetylase activity.  
Figure 7.3 gives a structure-based sequence alignment for BcZBP, BaBshB, ORF BA3888, 
ORF BA3524, and ORF Bc3461.  While BA3888 and BA3524 have limited sequence 
similarity to BcZBP (26-28% identity), the latter protein is 95% identical in sequence to 
Bc3461; all three conserve the three Zn2+ protein ligands identified in BcZBP as well as the 
proposed active-site base and charge-relay dyad (His110/Asp112).  These conserved features 
identify these as Zn2+-dependent hydrolases3; Figure 7.3 also identifies a series of conserved 
insertions and deletions that distinguish the true BshB deacetylases BcZBP and BaBshB from 
the three paralogs.  These include a 10-residue insert I1 (relative to BcZBP) after Ser45, two 
small inserts (1-2 residues) following BcZBP Lys82 and Asp108, and two deletions D1 and 
D2 of 4-6 residues following Ile129 and Phe205, respectively.  The I1 insert falls within the 
hypermobile BcZBP active-site loop L46, and the D1 deletion falls within the L135 loop 
identified in the molecular dynamics study (25).  Fadouloglou et al. have implicated these 
loops (plus loop L185) in active-site accessibility and substrate specificity.  Further 
consideration of proposed ORF BA3524 and BA3888 catalytic functions is presented in a 
following section.  
 
Enzymatic Characterization of BaBshA and BaBshB   
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Using a coupled assay, Vetting et al. (17) reported that the dimeric CgMshA catalyzes 
the formation of GlcNAc-Ins-P via a sequential (ternary complex) kinetic mechanism in 
which the donor substrate UDP-GlcNAc almost certainly binds first.  The steady-state kinetic 
parameters determined at pH 7.8, 25°C, yield Km(UDP-GlcNAc) = 0.21 mM, Km(Ins-1-P) = 
0.24 mM, and kcat = 12.5 s-1.  Structural analyses of the apoenzyme and the binary UDP 
complex demonstrate that nucleotide binding leads to a major rotation of the C-terminal 
domain relative to the N-terminal domain.  kcat/Km(UDP-GlcNAc) is 6 x 104 M-1s-1, and a 
superposition of the CgMshA apoenzyme and UDP complex structures gives an rmsd of ca. 
11 Å, underscoring the magnitude of the conformational change in the UDP complex.   
 Using an HPLC assay for the UDP product, we demonstrated that the BaBshA 
reaction was saturable with respect to both donor and acceptor substrates (Figure 7.4).  At 
pH 7.5 and 37°C, in the presence of 100 mM NaCl, the apparent kinetic parameters (at 2 mM 
L-malate) for UDP-GlcNAc are Km = 0.37 mM, kcat = 28 s-1, and kcat/Km = 7.6 x 104 M-1s-1.  
D-Malate, other α-hydroxyacids such as glycolate and D-lactate, and Ins-1-P gave no more 
than 0.5% of the activity with L-malate when assayed at 0.1 mM (Table S2).  The coupled 
spectrophotometric assay was then employed in an analysis of the steady-state kinetic 
mechanism for BaBshA.  As given in Figure S3, the family of reciprocal plots obtained with 
varying [L-malate] at different fixed [UDP-GlcNAc] intersects below the x-axis.  This 
suggests that 1) the kinetic mechanism conforms to a rapid equilibrium random bireactant 
system (34), as contrasted with an ordered system, and 2) the binding of either substrate to 
free enzyme increases Kapp for the second substrate.  From the primary plot and secondary 
slope and intercept replots, we have determined the kinetic parameters: Km(UDP-GlcNAc) = 
171 
 
0.22 mM, Km(L-malate) = 58 μM, kcat = 15 s-1, and α = 2.6.  kcat/Km(UDP-GlcNAc) = 6.8 x 
104 M-1s-1, similar to that reported for CgMshA at 25ºC.   
 Figure 7.5 gives a structure-based sequence alignment for CgMshA and the three 
known functional BshA enzymes.  An initial description of the BaBshA donor substrate 
binding environment, based on an overlay of the apoenzyme structure with those of the 
UDP—2-deoxy-2-fluoroglucose complex of the GT4 glucosyltransferase WaaG and the 
PimA—GDP-mannose complex, identified BaBshA His120, Lys211, Glu282, and Glu290 
within the active site (15).  Figure 7.5 demonstrates that His120 is conserved in the 
functional BshA enzymes; the equivalent of this His (His118) is essential for PimA activity 
(58).  Lys211, interacting with the distal phosphate oxygens of UDP, and the two Glu 
residues, which recognize the sugar 4-OH and the ribose-2′-OH and 3′-OH, respectively, in 
the PimA complex (58), are conserved in all four sequences.  Guerin et al. demonstrated that 
other residues within the PimA Glu274-Ile278 signature motif, notably Ser275, Phe276, and 
Ile278, provide main chain hydrogen bonds to the bound mannose sugar moiety, and this 
motif (BaBshA Glu282-Leu286, with Leu replacing Ile) is conserved in the BshA and MshA 
enzymes.  Vetting et al. (17) have identified four CgMshA residues (Lys78, Tyr110, Thr134, 
and Arg154) that coordinate the phosphate of bound Ins-1-P in the ternary complex.  As 
represented in Figure 7.5, CgMshA Tyr110, Thr134, and Arg154 are conserved in all three 
known functional BshAs, with the single exception of a conservative Arg→Lys substitution 
in SaBshA; CgMshA Lys78 is replaced by Val in the sequence alignment.  When the 
BaBshA apoenzyme is used to query the PDB database with DALILITE, the closed UDP 
(and UDP + Ins-1-P complex) structures for CgMshA give the highest Z-scores [ca. 37; rmsd 
= 2.4-2.5 Å (respective A-chains)].  Without adjustments, the superposition represented in 
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Figure 7.6 gives a clear view of the donor substrate binding environment in BaBshA, as 
described above.  In addition, the overlay demonstrates that CgMshA-UDP His133 is the 
structural equivalent of BaBshA His120 and identifies BaBshA Ile204 (main chain), Asn206, 
Asp263, and Glu282 as likely recognition elements for the UDP pyrophosphate and for the 
ribose-2′-OH and uracil oxygens, respectively.  There is no evidence for any conformational 
change on binding of UDP to BaBshA, based on the model deduced from this overlay.   
 The kinetic parameters for BaBshB were determined using an HPLC assay for the 
AccQ-Tag derivative of the GlcN-malate product, as monitored by fluorescence (14, 32); 
Figure 7.7 gives the resulting initial velocity plot and the fit to the Michaelis-Menten 
equation.  At pH 7.5 and 37°C, in the presence of 50 mM NaCl, the kinetic parameters are 
Km(GlcNAc-malate) = 0.16 mM, kcat =  42 s-1, and kcat/Km(GlcNAc-malate) = 2.6 x 105 M-1s-
1.  We also analyzed the deacetylase activity of BaBshB with GlcNAc, at a fixed 
concentration of 0.15 mM.  The observed rate of GlcN production is ca. 10-5 that measured 
with GlcNAc-malate at the same concentration; the L-malate moiety of GlcNAc-malate is 
therefore a major determinant of substrate recognition and/or transition state stabilization 
with BaBshB. When BaBshB was assayed for amidase activity with BSmB (→ CySmB + 
GlcN-malate), the observed rate at 0.15 mM substrate is only ca. 2 x 10-5 that for GlcNAc-
malate deacetylation.     
 
Structural Analysis of the BaBshA-UDP-Malate Complex   
In order to test the model for the enzyme-UDP complex described above, and in an 
attempt to identify the binding determinants for L-malate, we undertook a crystallographic 
study with the N-terminal His-tagged BaBshA protein.  This His-tag 
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(MGSH6SSGLVPRGSHMASMTGGQQMGRGS-) differs from that for the ORF BA1558 
construct (MGSSH6-) analyzed by Ruane et al. (15), which crystallized in space group P21; 
there were 12 monomers organized into three tetramers within that asymmetric unit.  
BaBshA crystals belonging to space group P41 were obtained in 0.2 M Mg(HCO2-)2 
containing 15% PEG3350 with 1 mM each of UDP and L-malate.  The structure determined 
by molecular replacement using the ORF BA1558 apoenzyme coordinates has eight 
monomers arranged as a dimer of tetramers within the asymmetric unit (Figure 7.8); gel 
filtration analysis of the apoenzyme, in the presence of dithiothreitol, suggests that the 
biological unit for BaBshA is the dimer.  Refinement at 3.3 Å resolution led to a final model 
with reasonable statistics (Table 7.3).  The final refined structure is missing the residues of 
the N-terminal His-tag and Met1, as well as residues 11-13, 42-47, and 60-63; the short 
internal segments correspond closely to three of the four exposed regions in the final ORF 
BA1558 model (15).  Within the BaBshA asymmetric unit, the final model includes two 
UDP, two malate, and one Mg2+ per tetramer; Vetting et al. (17) reported that Ins-1-P soaks 
of CgMshA-UDP crystals resulted in a complex with two UDP, two Mg2+, and only one Ins-
1-P per dimeric asymmetric unit.  The dimeric (substrate-bound) unit of the BaBshA-UDP-
malate complex gives an overall Cα rmsd of 1.1 Å for 371 atoms when compared with the 
corresponding dimeric unit of the ORF BA1558 apoenzyme (Figure 7.9).  In addition, the 
two subunits per tetramer that are complexed with UDP and malate are covalently linked via 
an intersubunit Cys241-Cys241′ disulfide (Figure 7.8); this disulfide is not observed with the 
complementary unbound subunits within that tetramer, which appear to reflect crystal 
packing.  Focusing on one of the subunits containing bound UDP and malate, Figure 7.10 
gives a final composite omit Fo-Fc map in the vicinity of the substrates, together with the 
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refined model.  Considering the 3.3 Å resolution of the BaBshA complex, we have also 
worked with the possibility of modeling glycerol in two conformations as an alternative to 
malate.  Two conformations of glycerol could be modeled into the density; however, after 
refinement, additional positive density appears.  Upon placing malate in the electron density, 
no additional Fo-Fc density appears.   
           Bacillithiol is only the second malyl glycoside reported in the literature to date (11, 
59), and the interactions and specificity determinants for L-malate recognition are of 
significant interest, particularly given the recent report that L-malate is a second preferred 
carbon source in B. subtilis (60), strongly contributing to repression of the uptake of alternate 
substrates.  An overlay of the CgMshA—UDP-Ins-1-P and BaBshA-UDP-malate complexes 
(not shown) demonstrates that the positioning and geometry of the Ins-1-P 3-OH and malate 
2-OH, relative to the distal phosphates of the respective UDPs, are similar.  Neither malate 
carboxylate is close to the position of the Ins-1-P phosphate, however.  Although this 
interpretation is limited by the 3.3 Å resolution of the BaBshA complex, it is consistent with 
a chemical mechanism [Scheme 7.2 (17, 61)] involving nucleophilic attack by the malate 2-
OH on the anomeric carbon of UDP-GlcNAc.   
 The superposition of the two complexes also demonstrates that two residues in the 
CgMshA phosphate coordination site, Tyr110 and Thr134 (see Figure 7.5), are structurally 
conserved in BaBshA.  BshA Val64 does occupy the same approximate position as MshA 
Lys78, but the respective Arg138 and Arg154 residues are not equivalent.  Figure 7.11 gives 
a stereo representation of the BaBshA-UDP-malate active site, focusing on important polar 
interactions with both malate and UDP.  In particular, this analysis identifies Thr122-OH, 
Asn206-Nδ2 and -Oδ1, and a distal phosphate oxygen (O1B) of UDP as ligands to the malate 
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C1-carboxylate.  The substrate C2-OH interacts with Gly15-N and with both O1B and O2B 
oxygens of the uridine-pyrophosphate, and Ser16-O stabilizes the C4-carboxylate.  All four 
BaBshA residues are conserved in the other known functional BshA enzymes (Figure 7.5).  
It has previously been proposed (62) that an active-site His functions in glycogen 
phosphorylase and related glycosyltransferases to stabilize an oxocarbenium transition state 
(e.g., via interaction with His377-O in glycogen phosphorylase) such as that considered for 
CgMshA.  This is thought to be especially important for those GT enzymes operating with 
negatively-charged (e.g., malate, Ins-1-P) acceptor substrates (62), and the conservation of 
His120 in the BaBshA catalytic center appears to be an important factor in this regard.   
 With regard to UDP binding, the structure of the BaBshA ternary complex confirms 
several aspects of the model deduced from the overlay described in Figure 7.6.  The very 
favorable comparison of apoenzyme and ternary complex structures (Figure 7.9) 
demonstrates that there is no major conformational change on substrate binding to BaBshA. 
 
DISCUSSION 
 
BaBshA Structure and Kinetics   
In this work we have defined the functions of ORF BA1558, previously annotated as 
a glycosyltransferase, group 1 family protein, and ORF BA1557, previously annotated as a 
hypothetical protein, as the N-acetyl-α-D-glucosaminyl L-malate synthase (BaBshA) and 
deacetylase (BaBshB), respectively.  The GlcNAc-malate product of BaBshA has been 
confirmed by 1H and 13C NMR and by high resolution mass spectrometry; deacetylation by 
BaBshB gives GlcN-malate, as confirmed by ESP mass spectrometry.  The kinetic 
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parameters have been determined for both enzymes.  BaBshA is specific for L-malate and 
does not recognize either D-malate or other α-hydroxyacids as acceptor substrates.  BaBshA 
appears to follow a rapid equilibrium random bireactant mechanism in which the binding of 
either substrate increases Kapp for the second substrate (34).  Vetting et al. (17) reported that 
CgMshA followed a sequential mechanism in which UDP-GlcNAc was proposed to bind 
first, i.e., as in a rapid equilibrium ordered bireactant scheme.  However, Segel has shown 
that the family of reciprocal plots (1/ν versus 1/[Acc], at several fixed [Don]) for such an 
ordered sequential mechanism intersects on the y-axis, in the case where substrate A (e.g., 
UDP-GlcNAc) binds first (34).  An examination of the data (17) indicates, in contrast, that 
reciprocal plots of 1/ν versus 1/[Ins-1-P] for CgMshA intersect in the second quadrant, very 
close to the x-axis.  We suggest that BaBshA and CgMshA both follow rapid equilibrium 
random bireactant mechanisms; they differ primarily in the fact that α ~1 for CgMshA.  
While binding of either substrate to BaBshA has the effect of increasing Kapp for the second 
substrate (α = 2.6), this interpretation does not apply to CgMshA. 
 The respective kcat/Km(UDP-GlcNAc) values of 6.8 x 104 M-1s-1 (37ºC) and 6 x 104 
M-1s-1 (25ºC) correspond to free energies of activation [ΔGT‡ (63)] of 11.3 kcal/mol and 10.9 
kcal/mol.  This quantitative similarity is significant, in that Vetting et al. (17) have reported a 
large conformational change between the CgMshA apoenzyme and UDP complex.  
Apoenzyme crystals were prepared with an N-terminal His-tagged protein and were of space 
group P31, while crystals of the complex were prepared with a C-terminal His-tagged protein 
and were of space group I422.  While a crystallographic argument has been presented against 
the possibility that the apoenzyme conformation does not represent the functional enzyme, 
this remains an open question.  In particular, searches using the CgMshA apoenzyme with 
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the SSM server yielded no significant structural homologs among the GT-B fold family.  
There is no major conformational change on UDP binding to BaBshA; the possibility of a 
conformationally distinct BaBshA—UDP-GlcNAc complex also appears unlikely, as the 
superposition of the BaBshA apoenzyme with the monomeric PimA—GDP-mannose 
structure reveals similar conformational states (Z = 33.6, rmsd = 3.0 Å).  In view of the 
Km(UDP-GlcNAc) value of 0.22 mM for BaBshA, the intracellular concentration of ca. 2.4 
mM reported for B. megaterium (64) predicts that ca. 8% of the enzyme is present in the apo 
form in the in vivo steady state.  With respect to the BaBshA complex, crystal packing 
stabilizes a closed tetrameric protein form (two UDP and two malate per tetramer; Figure 
7.8) in which bound UDP is solvent inaccessible.  Similarly, Vetting et al. showed that 
crystals of the dimeric CgMshA-UDP complex, when soaked with high concentrations of 
UDP-GlcNAc, do not exchange bound UDP (17). 
 
Bioinformatics of the B. anthracis bsh and pan Operons   
Using a transposon site hybridization assay protocol, Day et al. (1) concluded 
(without the benefit of the functional assignments presented in this work) that the bshA and 
panC genes, as well as BA1559 (pcnB, Table 7.1), were individually required for optimal 
growth, sporulation, or germination in B. anthracis strain ΔAmes.  As we have demonstrated 
that deletion of the bshA locus in B. anthracis Sterne eliminates BSH production, this 
suggests that BSH is important for one or more of these aspects of the life cycle.  In this 
context, we have recently demonstrated that the B. subtilis bshA mutant sporulates with an 
efficiency ca. 1% that of the wild-type strain (14).  In their transcriptional profiling of the B. 
anthracis life cycle, in which five distinct temporal waves of gene expression were identified 
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from germination through sporulation, Bergman et al. (65) showed that the bshA and bshB 
genes encoding the first two enzymes in the BSH biosynthetic pathway are upregulated 
together in waves II and III; the panBCD genes are upregulated in wave V of the 
germination→sporulation cycle.  panB and panC are also upregulated between 1 and 2 h 
postinfection within host macrophages (53).     
 We have described the gene products for all seven loci in the bsh operon, which is 
upregulated during that part of the life cycle corresponding to early outgrowth → rapid 
growth (65).  Aside from the GlcNAc-malate synthase and deacetylase enzymes, we find no 
evidence for coding sequences that provide for the enzymatic conversion of GlcN-malate → 
BSH.  In connection with the demonstration that BSH is important for fosfomycin resistance 
in B. anthracis, the coexpression of the mgsA gene encoding methylglyoxal synthase is of 
interest.  Methylglyoxal is cytotoxic in millimolar concentrations and is also mutagenic (52).  
Still, many bacteria produce methylglyoxal synthase, with a functional implication as a 
bypass of glycolysis active under conditions of Pi starvation.  In most microorganisms, 
methylglyoxal is detoxified via GSH-dependent conversion to D-lactate; however, we have 
demonstrated that GSH is absent in B. anthracis (3).  Both methylglyoxal (52) and 
fosfomycin (66) are potent C3-electrophiles known to react with GSH, and our evidence 
strongly suggests that BSH is the cofactor for FosB in B. anthracis.  We have recently 
demonstrated, using a zone of inhibition assay, that a B. subtilis bshA mutant has a 
significantly increased sensitivity to methylglyoxal (14).  We conclude that BSH may also be 
the cofactor for an S-transferase reaction converting methylglyoxal to lactoyl-bacillithiol 
[CH3CHOHCO-SCH2CH(NH3+)CO-NGlc-malate].  A possible fate of these BSH conjugates 
is discussed below. 
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 BaBshB Structure, Function, and Genetics   
As indicated previously, BshB is both a structural and functional homolog of M. 
tuberculosis MshB; when assayed in parallel with synthetic GlcNAc-Ins, however, MshB 
gives kcat of only 0.49 s-1 (32), with kcat/Km(GlcNAc-Ins) = 1.44 x 103 M-1s-1.  Both values are 
ca. 1% of the respective parameters with BaBshB (acting on GlcNAc-malate as substrate).  
The difference in BshB and MshB catalytic efficiencies is approximately that required by 
rapidly dividing cells to maintain stable levels of BSH or MSH, respectively, given the 50-
fold difference in generation times for B. anthracis and M. tuberculosis (0.5 and 24 h).  We 
have shown that the B. anthracis ΔbshB mutant produces BSH at ca. 70% of the wild-type 
level, and this has been attributed to an overlapping substrate specificity for two BaBshB 
paralogs, ORFs BA3524 and BA3888.  In the closely related B. cereus 14579, the ORF 
Bc3461 ortholog of BA3524 has been demonstrated (21) to catalyze deacetylation of both 
(GlcNAc)2 and (GlcNAc)3, and we propose that this enzyme and BcZBP similarly have 
overlapping specificities for GlcNAc-malate deacetylation in B. cereus.  A BcZBP-deficient 
mutant would still be expected to produce significant BSH, through the action of ORF 
Bc3461.   
 The substrate specificity of the MshB deacetylase overlaps that of the M. tuberculosis 
mycothiol S-conjugate amidase (Mca), which functions in the MSH-dependent detoxification 
of thiol-reactive drugs and metabolites by cleaving the Cys-GlcN amide bond of the S-
conjugate to give AcCySR plus GlcN-Ins.  The optimal amidase substrate for Mca is MSmB, 
yielding AcCySmB +  GlcN-Ins; kcat/Km = 9 x 104 M-1s-1 at 37°C (24), and MshB catalyzes 
amide cleavage with this substrate, though with kcat/Km = 460 M-1s-1 (32), less than 1% of the 
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value observed with Mca.  The M. tuberculosis Rv1170 mutant deficient in MshB continues 
to produce MSH at ca. 20% of the wild-type level (67), and this has been attributed to the 
weak deacetylase activity observed with purified Mca in vitro for GlcNAc-Ins [kcat/Km = 0.3 
M-1s-1 (24)], ca. 10-4 that of MshB (see above).  In addition to providing for GlcNAc-malate 
deacetylation in the absence of BshB (see above), ORFs Bc3461, BA3524, and BA3888 may 
function primarily as paralogs of Mca that catalyze bacillithiol S-conjugate amidase reactions 
related to xenobiotic detoxification.  The S-conjugates of fosfomycin and methylglyoxal 
described above represent two potential substrates (Scheme 7.3).  The charged GlcN-malate 
product of the amidase reaction can be recycled for BSH synthesis, and a number of AcCySR 
products from the analogous amidase reactions with mycothiol S-conjugates are known to be 
lost from the cell (45, 46).  Rukmana et al. (68) have recently reported that the Spx regulon is 
induced in B. subtilis cells challenged by the antibiotics enduracin and bacitracin, suggesting 
that disulfide stress is occurring under these conditions, but the Spx regulatory system 
appears to be independent of BSH (14).   
 
The Nature and Influence of Low-Molecular-Weight Thiols as Redox Buffers in B. 
anthracis   
Bacterial growth and proliferation, especially during infection of the host, often 
involves a hostile environment (53, 54) that challenges the defensive mechanisms of the 
pathogen (e.g., B. anthracis or S. aureus).  Among the physiological mechanisms for 
maintaining thiol-disulfide redox homeostasis are the important functions of thiols such as 
GSH (69, 70) and MSH (45, 46).  B. anthracis (3), S. aureus (4), and B. megaterium (12) are 
among a number of Gram-positive bacteria that lack both of these thiols.  It is clear from 
several studies, perhaps most closely associated with the Beckwith laboratory (69, 70), that 
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redundancy in these systems is the rule, particularly in E. coli; mutants lacking either TrxR or 
glutathione reductase grow normally (70, 71).   
 Figure 7.12 gives the present working scheme for cytoplasmic disulfide reducing and 
oxidizing pathways in our model Gram-positive pathogen, B. anthracis; the same or very 
similar system applies in S. aureus and in the soil bacterium B. megaterium.  The three 
branches include CoASH/CoADR, Trx/TrxR, and bacillithiol (BSH).  The recent work of 
Pöther et al. (13) indicates that cysteine (CySH) represents a fourth branch in S. aureus, 
accounting for most protein (mixed) disulfide formation during diamide stress.  While a 
specific bacillithiol disulfide reductase has not been identified, the BSH/BSSB redox status is 
very reduced (redox ratio of 84 versus 2.8 for CySH/CySSR) in vegetative B. anthracis cells 
(Table 7.2); this ratio is unchanged in the Δcdr and Δcdr2 mutants, and neither CoADR nor 
CoADR-RHD is a reductant of oxidized bacillithiol (BSSB).  There is, however, no direct 
evidence as to whether the B. anthracis Trx/TrxR system might reduce BSSB.  In both 
Arabidopsis (72) and Drosophila (73), for example, the Trx/TrxR system either constitutes a 
functional backup or substitutes for glutathione reductase.  In E. coli, the Grx-SSG reductase 
activity of AhpC* maintains the reduced GSH pool at essentially wild-type levels in 
ΔgorΔtrxB strains (70).   
 We recently demonstrated (9) that the B. anthracis cysK-1 locus encoding cysteine 
synthase A is part of the tricistronic coaX operon that also encodes the type III pantothenate 
kinase.  The B. anthracis pathway from pantothenate → CoASH (Figure 7.13), as well as the 
components of the de novo pantothenate biosynthetic pathway (including the panBCD genes 
of the pan operon; Table 7.1), have now been established (3, 74).  In this work we describe 
the first two steps in BSH biosynthesis for B. anthracis and the effects of deleting the 
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respective genes on BSH production.  While the identification of the proposed Cys:GlcN-
malate ligase, the biological functions of the B. subtilis YllA and ORF BA3524 proteins, and 
the description of the reductase(s) that maintain the reduced status of BSH in vegetative B. 
anthracis cells remain as priority goals, the materials necessary for genetic analysis of the 
relative roles of the CoASH/CoADR and BSH systems in both intracellular thiol-disulfide 
redox homeostasis and in virulence are presently being exploited. 
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 Table 7.1 Bioinformatics of the B. anthracis bsh and pan Operons 
Functional homolog/PDB entrya Gene Comparison 
Putative pyrophosphatase YpjD/2GTA (B. subtilis) 74% identity; E value 4e-45 BA1554 
Dihydrodipicolinate reductase/1YL6 (M. tuberculosis) 44% identity; E value 3e-48 BA1555 
(dapB) 
Methylglyoxal synthase/1B93 (E. coli) 50% identity; E value 2e-32 BA1556 
(mgsA) 
GlcNAc-malate deacetylase/2IXD (B. cereus) 96% identity; E value 6e-133 BA1557 
(bshB) 
BA1558 GlcNAc-malate synthase/2JJM identical 
(bshA) 
49% identity; E value 4e-106 tRNA CCA-adding enzyme/1MIY (Bacillus stearothermophilus)BA1559 
(pcnB) 
32% identity; E value 7e-36 Biotin:CoASAc carboxylase ligase/1WNL (Pyrococcus 
horikoshii) 
BA1560 
(birA) 184    
Ketopantoate hydroxymethyltransferase/1M3U (E. coli) 46% identity; E value 1e-63 BA1562 
(panB) 
Pantothenate synthetase/2X3F (S. aureus) 53% identity; E value 2e-87 BA1563 
(panC) 
Aspartate decarboxylase proenzyme/2C45 (M. tuberculosis) 55% identity; E value 1e-33 BA1564 
(panD) 
34% identity; E value 1e-16 BA1565 Putative PolC-type DNA polymerase III, exonuclease domain/ 
2P1J (Thermotoga maritima) 
aObtained with BLASTP using the PDB proteins database. 
 
 
 Table 7.2 Low-Molecular-Weight Thiol Contents and Redox Ratios for B. anthracis Sterne Wild-Type and Mutant Strains       
Strain            Thiol and Disulfide Contents (μmol per g dry weighta) and Redox Ratiosb 
   Redox 
ratio 
  Redox 
ratio 
  
CoASHc S=SO32- BSH BSSR/0.5 CySH CySSR/0.5 
Wild-type 1.1±0.1 0.027±0.004 84 0.40±0.04 0.29±0.04 2.8 1.9±0.4 2.2±0.4 
ΔbshA <0.03 <0.002 — 0.22±0.06 0.43±0.09 1.0 1.8±0.4 2.0±0.4 
ΔbshB 0.79±0.02 0.013±0.002 122 0.39±0.02 0.47±0.056 1.7 3.0±0.7 2.4±0.4 
Δcdr 0.95±0.12 0.022±0.003 86 0.39±0.04 0.43±0.054 1.8 1.4±0.3 2.2±0.2 
Δcdr2 1.2±0.06 0.03±0.01 80 0.41±0.02 0.40±0.12 2.1 1.6±0.3 2.2±0.2 
ΔcdrΔcdr2 0.88±0.03 0.015±0.002 118 0.46±0.02 0.28±0.02 3.2 1.8±0.1 2.5±0.3 
185 
aMean of triplicate determinations (10).  bExpressed as thiol/disulfide (RSH/RSSR), where disulfide is estimated as half the thiol 
content released by dithiothreitol from an N-ethylmaleimide-blocked sample (10).  cIncludes 3′-dephospho-CoASH; redox ratio cannot 
be determined with confidence due to contribution from cleavage of acyl-CoAs by the dithiothreitol reagent (2, 10). 
 
 
Table 7.3 Data Collectiona and Refinement Statistics for the BaBshA Complex with 
UDP and Malate   
BaBshA-UDP-malate  
 Data collection 
P41     Space group  
   Cell dimensions  
     a, b, c (Å)  226.3, 226.3, 75.4  
     α, β, γ (°)  90, 90, 90  
   Wavelength (Å)  1.000  
226-3.31 (3.39-3.31)b    Resolution (Å)  
   I/σ  12.3 (1.3)  
   Completeness (%)  99.2 (93.9)  
   Redundancy  5.7 (2.7)  
Refinement statistics  
   Resolution (Å)  226-3.31  
   No. reflections  54419  
   Rwork  0.229  
   Rfree  0.259  
   Molecules per asymmetric unit (AU)  8  
   No. of amino acid residues per AU  2961  
   No. of waters per AU  288  
   Average B-factors  69.7  
   Stereochemical ideality  
      Bond length rmsd (Å)  0.009  
      Bond angle rmsd (°)  1.97  
      Φ,ψ preferred (%) 93.7  
      Φ,ψ allowed (%)  5.90  
      Φ,ψ outliers (%)  0.40  
   PDB entry 3MBO 
aCollected at SER-CAT beamline BM-22 of the Advanced Photon Source.   
 
bNumbers in parentheses represent data for the highest resolution shell.   
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 Scheme 7.1 Catalytic addition of bacillithiol (BSH) to fosfomycin, as proposed for 
FosB. 
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 Scheme 7.2 Possible oxocarbenium-ion like transition state for the glycosyltransferase 
reaction of BaBshA (adapted from Refs 16 and 60).      
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 Scheme 7.3:  Bacillithiol S-conjugate amidase (Bca) reaction proposed for ORFs Bc3461, 
BA3524, and BA3888.  The S-conjugate of fosfomycin (Scheme 7.1) is taken as the 
substrate.
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EGENDS 
 
Figure 7.1 Low-molecular-weight thiol redox buffers. 
Figure 7.2 Mycothiol biosynthetic pathway (upper), and proposed bacillithiol 
biosynthetic pathway (lower). 
 
Figure 7.3 Structure-based sequence alignment for BcZBP, BaBshB, and ORFs BA3888, 
BA3524, and Bc3461.  Secondary structure assignments correspond to BcZBP; 
red boxes represent conserved residues, and yellow boxes represent 
conservative substitutions.  Active-site loops L46, L135, and L185 as defined for 
BcZBP (24) are indicated, as are the insert I1 and deletions D1 and D2 
described in the text.  Green and blue triangles represent ligands to the BcZBP 
active-site Zn2+ and the proposed acid-base catalyst (Asp14) and charge-relay 
dyad (His110/Asp112), respectively. 
 
Figure 7.4 (A) UDP-GlcNAc dependence for BaBshA with 2 mM L-malate.  (B) L-
Malate dependence with 3 mM UDP-GlcNAc.  
Figure 7.5 Structure-based sequence alignment for CgMshA and the three known                         
functional BshAs.  Secondary structure assignments (color-coded by domain) 
correspond to the CgMshA—UDP-Ins-1-P complex.  BshA sequences 
correspond to B. subtilis [BsuBshA (YpjH, Ref 13)], S. aureus JH9 
(YP_001246887), and B. anthracis.  CgMshA and BaBshA residue numbering 
are shown above and below the alignment, respectively.  Green and blue 
triangles denote residues from CgMshA that interact with the modeled UDP-
GlcNAc substrate and with the phosphate of Ins-1-P, respectively.  Blue boxes 
represent active-site residues conserved in BshA and thought to be important 
for L-malate binding and catalysis.  Other details are as in Figure 7.3. 
Figure 7.6 Monomer (left) and active-site (right) overlay for the ORF BA1558 
apoenzyme and the CgMshA-UDP complex.  The superposition was 
performed using PyMOL with the respective A-chains for PDB entries 2JJM 
(ORF BA1558) and 3C4Q (CgMshA-UDP), as described in the text.  ORF 
BA1558 and CgMshA side chains (stick diagram) are color-coded by atom 
type, with carbon atoms colored green and yellow, respectively.  Bound UDP 
(CgMshA, with space-filling overlay rendered as 50% transparent) is included 
and is color-coded by atom type, with carbon atoms colored magenta.  Active-
site overlay depicts the bound UDP and all residues within 4 Å, as well as the 
BaBshA His120/CgMshA His133 pair. 
Figure 7.7 GlcNAc-malate dependence for BaBshB. 
Figure 7.8 Asymmetric unit for the BaBshA ternary complex.  The asymmetric unit 
consists of a dimer of tetramers; the polypeptides of one tetramer (left) are 
FIGURE L
 color-coded by domains.  The two polypeptides that do not contain bound 
substrate (cyan, N-terminal domain; salmon, C-terminal domain) are 
distinguished from the substrate-bound monomers (blue, N-terminal domain; 
red, C-terminal domain).  The substrate-bound monomers are linked by the 
econd tetramer (right) within the 
asymmetric unit is colored green.  For both tetramers, bound UDP molecules 
 magnesium ions in the respective active sites 
(one per substrate-bound dimer) are colored red.  Stereoviews of the BaBshA 
Figure 7.9 
igure 7.10 te complex, focusing on the active site.  
2+
7, and Glu290.  A composite 
Figure 7.11 
Figure 7.12 
X gene 
Figure 7.13 
racis pantothenate kinase active-site 
f 2. 
Cys241-Cys241′ disulfide (yellow).  The s
are color-coded as in Figure 7.6, malate is color-coded by atom type, with 
carbon atoms colored blue, and
ternary complex, focusing on important active-site interactions, are given in 
Figures 7.10 and 7.11.  
Superposition of the BaBshA-UDP-malate complex (chain A, cyan) with an 
apoenzyme (PDB entry 2JJM) monomer (green).  An overlay with the 
respective dimers gives rmsd = 1.1 Å for 371 Cα atoms.  Bound UDP, malate, 
and magnesium ion are color-coded as in Figure 8.      
Stereoview of the BaBshA-UDP-malaF
The refined model includes bound UDP and malate, Mg , one water 
molecule (Water 295), and protein segments corresponding to His120, 
Ser205-Asn206, Val210-Lys211, Glu282-Val28
omit Fo-Fc map is shown contoured at 1.2σ.  All atoms are color-coded as in 
Figure 7.8 except for BaBshA Cα and side chain carbon atoms, which are 
colored green. 
Stereo representation of the BaBshA ternary complex, focusing on important 
polar interactions with UDP and malate.  Hydrogen-bonding interactions, 
shown as black dotted lines, are shown for bound UDP, malate, Mg2+, and 
Water 295.  All atoms are color-coded as in Figure 7.10.   
Cytoplasmic thiol redox pathways in B. anthracis.  Structural genes are 
identified in parentheses beneath the respective proteins; the coa
encodes the type III pantothenate kinase that catalyzes the first step in CoASH 
biosynthesis.  Results with the Δcdr mutant are described in Table 7.2 and in 
the text.  TrxA appears to reduce ribonucleotide reductase in B. subtilis, but 
this is still under investigation.  The thumbnail representation of the B. 
anthracis CoADR active-site structure is adapted from Figure 7.5 of Ref 4. 
CoASH and BSH biosynthetic pathways in B. anthracis.  Structural genes are 
identified in parentheses beneath the respective proteins; the properties of the 
ΔbshA and ΔbshB mutants are described in Table 7.2 and in the text.  The 
properties of a conditional coaX mutant have been reported (8).  The 
thumbnail representation of the B. anth
structure is adapted from Figure 7.7 of Re
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Figure 7.3 Structure-based sequence alignment for BcZBP, BaBshB, and ORFs BA3888, BA3524, and Bc3461.  
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Figure 7.4 UDP-GlcNAc (A) and L-malate (B) substrate dependence for enzymatic 
activity. 
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Figure 7.6 Monomer (left) and active-site (right) overlay for the ORF BA1558 apoenzyme and the CgMshA-UDP complex.
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Figure 7.7 Glc-NAc-malate dependence for BaBshB.
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Figure 7.8 Asymmetric unit for the BaBshA ternary complex. 
 Figure 7.9 Superposition of the BaBshA-UDP-malate complex (chain A, cyan) with 
  an apoenzyme (PDB entry 2JJM) monomer (green).
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 Figure 7.10 Stereoview of the BaBshA-UDP-malate complex, focusing on the active 
site. 
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 Figure 7.11  Stereo representation of the BaBshA ternary complex, focusing on 
important polar interactions with UDP and malate. 
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Figure 7.12 Cytoplasmic thiol redox pathways in B. anthracis. 
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Figure 7.13 CoASH and BSH biosynthetic pathways in B. anth
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